Xxxxxxxx Komise 2000/32/ES
ze xxx 19. května 2000,
xxxxxx se xx xxxxxxx xxxxx xxxxxxxxxxxx xxxxxxxxxxx pokroku směrnice Xxxx 67/548/EHS x xxxxxxxxxx xxxxxxxx x xxxxxxxxx xxxxxxxx xxxxxxxxxx xx klasifikace, xxxxxx x xxxxxxxxxx xxxxxxxxxxxx xxxxx [1]
(Xxxx x xxxxxxxx xxx XXX)
XXXXXX XXXXXXXXXX XXXXXXXXXXXX,
x xxxxxxx xx Xxxxxxx x xxxxxxxx Xxxxxxxxxx xxxxxxxxxxxx,
x xxxxxxx na xxxxxxxx Xxxx 67/548/XXX xx xxx 27. xxxxxx 1967 x xxxxxxxxxx xxxxxxxx a xxxxxxxxx xxxxxxxx xxxxxxxxxx xx xxxxxxxxxxx, xxxxxx x xxxxxxxxxx nebezpečných xxxxx [2], xxxxxxxxx pozměněnou xxxxxxxx Evropského xxxxxxxxxx x Xxxx 1999/33/XX [3], a xxxxxxx xx xxxxxx 28 xxxxxxx xxxxxxxx,
xxxxxxxx k xxxxx xxxxxxx:
(1) Příloha X směrnice 67/548/XXX xxxxxxxx seznam xxxxxxxxxxxx xxxxx xxxxxxxx x xxxxxxxxxx xxxxx x xxxxxxxxxxx x označování xxxxx xxxxx. Xxxxxxxx xxxxxxx x xxxxxxxxx xxxxxxxx xxxxxxx, xx xx xxx xxx xxxxxx xxxxxxxxxxxx látek x xxxxxxx příloze xxxxxxxxxxx. Xxxxxxx xxxxxxxx xxxxx xxxxxxxx vyžadují xxxxxx xxxxxxxx xxxxxx xxxxxxxxx x xxxxxxx X x xxxxxxx X.
(2) Xxxxxxx XXX xxxxxxxx 67/548/XXX xxxxxxxx xxxxxx xxx udávajících xxxxxx zvláštních xxxxx xxxxxxxxx x nebezpečnými xxxxxxx x xxxxxxxxx. Xxxxxxx XX xxxxxxxx 67/548/XXX obsahuje xxxxxx xxx x bezpečnostními xxxxxx xxxxxxxxxx xx xxxxxxxxxxxx látek a xxxxxxxxx. Příloha VI xxxxxxxx 67/548/XXX obsahuje xxxxx xx klasifikaci x x xxxxxxxxxx xxxxxxxxxxxx xxxxx x xxxxxxxxx. Některé xxxxxxxx xxxxx xxxxxxxx xxxxxxxx xxxxxx xxxxxxxx oddílů xxxxxx III, IV x VI.
(3) V xxxxxxx V xxxxxxxx 67/548/XXX xx stanoví xxxxxx pro stanovení xxxxxxxxx-xxxxxxxxxx vlastností, xxxxxxxx x xxxxxxxxxxx xxxxx x xxxxxxxxx. Xx xxxxxxxx xxxxxxxxxxx tuto xxxxxxx xxxxxxxxxxx xxxxxxx.
(4) Xxxxxxx XX xxxxxxxx 67/548/XXX xxxxxxxx xxxxxxxx xxxxxxxx xx uzávěrů xxxxxxxx xxxxx xxxxxxxx xxxxx. Tyto xxxxxxxx xx xxxx být xxxxxxxxxxxx x xxxxxxxxxxxxx. Xx xxxxxxxx rozšířit xxxxxx, xxx xx xxxxxxx xxxxxx xxxxx xxxxxxxx dětmi xxxxxxxxx.
(5) Xxxxxxxx xxxx xxxxxxxx xxxx x xxxxxxx xx xxxxxxxxxxx Xxxxxx xxx xxxxxxxxxxxx xxxxxxxxxxx xxxxxxx xxxxxxx xxx xxxxxxxxxx xxxxxxxxxxx překážek xxxxxxx xx xxxxx xxxxxxxxxxxx xxxxx a xxxxxxxxx,
XXXXXXX TUTO SMĚRNICI:
Xxxxxx 1
Xxxxxxxx 67/548/EHS xx mění xxxxx:
1. Xxxxxxx I xx xxxx xxxxx:
x) xxxxxxxxxxxx xxxxxxxx x xxxxxxxxx xx nahrazuje poznámkou X x příloze 1X xxxx xxxxxxxx;
x) xxxxxxxxxxxx xxxxx v xxxxxxx X xx xxxxxxxxx řádky x xxxxxxx 1X této xxxxxxxx;
x) odpovídající položky xx xxxxxxxxx položkami x příloze 1X xxxx směrnice;
d) xxxxxxxx xx položky v xxxxxxx 1D xxxx xxxxxxxx.
2. Xxxxxxxxxxxx xxxx x xxxxxxx XXX xx nahrazuje standardní xxxxx xxxxxxxxxx xxxxxxxxxxx xxxxxxxxxx x xxxxxxx 2 této xxxxxxxx.
3. Xxxxxxx XX xx xxxx xxxxx:
x) odpovídající xxxxxx x příloze XX xx nahrazují xxxxxxxxxxxx xxxxxx xxx xxxxxxxx xxxxxxxxx x xxxxxxx 3X xxxx xxxxxxxx;
x) xxxxxxxxxxxx pokyny x příloze XX xx xxxxxxxxx kombinovanými xxxxxxxxxxxx xxxxxx xxx xxxxxxxx xxxxxxxxx x xxxxxxx 3X této xxxxxxxx.
4. Xxxx X xxxxxxx X se xxxx xxxxx:
x) kapitola X.10 xx xxxxxxxxx xxxxxx v příloze 4X této xxxxxxxx;
x) xxxxxxxx B.11 se xxxxxxxxx textem x xxxxxxx 4X xxxx xxxxxxxx;
x) kapitola X.12 xx xxxxxxxxx xxxxxx x xxxxxxx 4X xxxx směrnice;
d) xxxxxxxx X.13 x X.14 xx nahrazují xxxxxx x xxxxxxx 4D xxxx xxxxxxxx;
x) xxxxxxxx X.17 se xxxxxxxxx xxxxxx x xxxxxxx 4X této směrnice;
f) xxxxxxxx B.23 xx xxxxxxxxx xxxxxx v xxxxxxx 4X této xxxxxxxx. Xxxxx xxxxxxxx X.23 ve xxxxxxxxxxx xx mění xxxxxxxxxxxxx xxxxxxxx;
x) vkládá se xxxx x xxxxxxx 4X xxxx xxxxxxxx.
5. Xxxxxxx se čtvrtá xxxxxxx xxxxxxxx xxxxx x xxxxx X xxxxxxx V.
6. Odpovídající xxxxx v xxxxxxx XX se xxxxxxxxx xxxxx x xxxxxxx 5 xxxx směrnice.
7. Xxxxxxx XX xx xxxx způsobem uvedeným x xxxxxxx 6 xxxx xxxxxxxx.
Xxxxxx 2
1. Členské xxxxx xxxxxx x xxxxxxxx právní a xxxxxxx xxxxxxxx xxxxxxxx xxx xxxxxxxx souladu x xxxxx xxxxxxxx xxxxxxxxxx xx 1. xxxxxx 2001. Xxxxxxxxxx x xxxx xxxxxxx Xxxxxx.
Xxxx xxxxxxxx xxxxxxx xxxxxxxxx xxxxx xxxx xxxxxxxxx odkaz na xxxx xxxxxxxx nebo xxxx xxxxxx odkaz xxx učiněn xxx xxxxxx xxxxxxx xxxxxxxxx. Xxxxxx odkazu xx xxxxxxx členské státy.
2. Xxxxxxx xxxxx xxxxx Xxxxxx xxxxx xxxxxxxx xxxxxxxxxx vnitrostátních xxxxxxxx xxxxxxxx, které xxxxxxx x xxxxxxx xxxxxxxxxx xxxx xxxxxxxx, x xxxxxxxxxx xxxxxxx xxxx xxxxxxxx x xxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxxxxx.
Xxxxxx 3
Xxxx směrnice xxxxxxxx x xxxxxxxx xxxxxx xxxx po xxxxxxxxx x Xxxxxxx xxxxxxxx Xxxxxxxxxx společenství.
Xxxxxx 4
Tato xxxxxxxx xx určena členským xxxxxx.
X Xxxxxxx dne 19. xxxxxx 2000.
Za Xxxxxx
Xxxxxx Xxxxxxxöx
xxxxxx Xxxxxx
[1] Přijato xx xxxxxxxxxxxx xx xxxxxxx xxxxx.
[2] Xx. xxxx. 196, 16.8.1967, x. 1.
[3] Xx. xxxx. X 199, 30.7.1999, x. 57.
XXXXXXX 1A
PŘEDMLUVA X XXXXXXX X
Xxxxxxxxxx xxxxxxxx xxxxxxxxxx xx xxxxxxxxxxxx, xxxxxxxxxxx a xxxxxxxxxx xxxxx
(Xxxxxx xx českého xxxxx)
PŘÍLOHA 1B
"TABULKA X
X |
Xxxxxx |
XX |
XX |
XX |
XX |
XX |
XX |
XX |
XX |
XX |
XX |
XX |
18 |
Xx |
Xxxxx |
Xxxxx |
Xxxxx |
Αργό |
Xxxxx |
Xxxxx |
Xxxxx |
Xxxxx |
Xxxxx |
Xxxxx |
Xxxxx |
64 |
Xx |
Xxxxxxxxx |
Xxxxxxxxxx |
Xxxxxxxxxx |
Γαδολίνιο |
Xxxxxxxxxx |
Xxxxxxxxxx |
Xxxxxxxxxx |
Xxxxxxxxx |
Xxxxxxxxxx |
Xxxxxxxxx |
Xxxxxxxxxx" |
XXXXXXX 1X
Xxxxxxxx xxxxx |
Xxxxxxxx xxxxx |
Xxxxxxxx x xxxxxx |
Xxxxx XX |
Xxxxx CAS |
Klasifikace |
Označení |
Koncentrační xxxxxx |
Xxxxxxxx x xxxxxxxxxx |
006–011–00–7 |
xxxxxxxx (ISO) 1-xxxxxx-X-xxxxxxxxxxxxxx |
200–555–0 |
63–25–2 |
Xxxx. xxx. 3; X40 Xx; X22 X; X50 |
Xx; X X: 22–40–50 X: (2-)22–24–36/37–46–61 |
|||
006–013–00–8 |
xxxxxx-xxxxxxx (XXX) xxxxxxx-X-xxxxxxxxxxxxxxxxxxxx |
205–293–0 |
137–42–8 |
Xx; X22 X31 X; X34 R43 X; X50–53 |
X; X X: 22–31–34–43–50/53 X: (1/2-)26–36/37/39–45–60–61 |
|||
006–015–00–9 |
xxxxxx (XXX) 3-(3,4-dichlorfenyl)-1,1-dimethylmočovina |
206–354–4 |
330–54–1 |
Karc. xxx. 3; R40 Muta. xxx. 3; X40 Xx; X22–48/22 X; X50–53 |
Xx; N X: 22–40–48/22–50/53 S: (2-)13–22–23–37–46–60–61 |
|||
006–016–00–4 |
propoxur (XXX) 2- xxxxxxxxxxxxxxx-X-xxxxxxxxxxxxxx |
204–043–8 |
114–26–1 |
X; X25 X; X50–53 |
X; X R: 25–50/53 X: (1/2-)37–45–60–61 |
|||
006–017–00-X |
aldikarb (XXX) 2-xxxxxx-2-(xxxxxxxxxxxxxx)xxxxxxxx-X-(X-xxxxxxxxxxxxxxx)xxxx |
204–123–2 |
116–06–3 |
X+; X26/28 X; X24 X; R50–53 |
T+; X X: 24–26/28–50/53 X: (1/2-)22–36/37–45–60–61 |
|||
006–018–00–5 |
xxxxxxxxx (XXX) 4-(xxxxxxxxxxxxx)-3-xxxxxxxxxxx-X-xxxxxxxxxxxxxx |
217–990–7 |
2032–59–9 |
X; X24/25 N; X50–53 |
X; N R: 24/25–50/53 X: (1/2-)28–36/37–45–60–61 |
|||
006–019–00–0 |
xx-xxxxx (XXX) X-(2,3-xxxxxxxxxxxx)-X,X-xxxxxxxxxxxxxxxxxxxxxxx |
218–961–1 |
2303–16–4 |
Xxxx. xxx. 3; X40 Xx; X22 X; X50–53 |
Xx; X X: 22–40–50/53 X: (2-)25–36/37–60–61 |
|||
006–020–00–6 |
xxxxxx (ISO) 4-xxxxxxxx-2-xx-1-xx-X -(3-chlorfenyl)karbamát |
202–930–4 |
101–27–9 |
Xn; R22 X43 X; R50–53 |
Xn; X X: 22–43–50/53 X: (2-)24–36/37–60–61 |
|||
006–023–00–2 |
merkaptodimethur (XXX) xxxxxxxxxx 3,5-dimethyl-4-(methylsulfanyl)fenyl-N -xxxxxxxxxxxxxx |
217–991–2 |
2032–65–7 |
X; X25 X; X50–53 |
X; X R: 25–50/53 X: (1/2-)22–37–45–60–61 |
|||
006–024–00–8 |
xxxxxx-xxxxxxx (XXX) xxxxxxx-X-xxxxxxxxx-xxxxxxxxxxxxxx |
205–443–5 |
140–93–2 |
Xx; X22 Xx; X38 N; R51–53 |
Xn; X X: 22–38–51/53 X: (2-)13-61 |
|||
006–026–00–9 |
xxxxxxxxxx (ISO) 2,2-xxxxxxxx-2,3-xxxxxxx-1-xxxxxxxxxx-7-xx-X-xxxxxxxxxxxxxx |
216–353–0 |
1563–66–2 |
X+; R26/28 X; X50–53 |
X+; X X: 26/28–50/53 X: (1/2-)36/37–45–60–61 |
|||
006–028–00-X |
xxxxxxxxx (XXX) 2-(1-xxxxxxxxxxxx)-4,6-xxxxxxxxxxxx-xxxxxxxxx-xxxxxxxx 2-xxx-xxxxx-4,6-xxxxxxxxxxxx-xxxxxxxxx-xxxxxxxx |
213–546–1 |
973–21–7 |
X; X25 X; X50–53 |
X; X X: 25–50/53 X: (1/2-)37–45–60–61 |
|||
006–029–00–5 |
dioxakarb (ISO) 2-(1,3-xxxxxxxx-2-xx)xxxxx-X-xxxxxxxxxxxxxx |
230–253–4 |
6988–21–2 |
X; X25 X; X51–53 |
X; N R: 25–51/53 S: (1/2-)37–45–61 |
|||
006–033–00–7 |
xxxxxxxxx (XXX) 3-(3-xxxxx-4-xxxxxxxxxxxx)-1,1-xxxxxxxxxxxxxxxx |
243–433–2 |
19937–59–8 |
X; X50–53 |
X X: 5 0/ 5 3 X: 60-61 |
|||
006–034–00–2 |
xxxxxxx (ISO) S-propyl-N-butyl-N-ethylthiokarbamát |
214–215–4 |
1114–71–2 |
Xn; X22 X; X51–53 |
Xx; X X: 22–51/53 X: (2-)23-61 |
|||
006–035–00–8 |
xxxxxxxxxx (XXX) 2-(xxxxxxxxxxxxx)- 5,6-xxxxxxxx pyrimidin-4-yl-N,N-dimethylkarbamát |
245–430–1 |
23103–98–2 |
T; X25 X; X50–53 |
X; X X: 25–50/53 X: (1/2)22–37–45–60–61 |
|||
006–037–00–9 |
xxxxxxxxx (ISO) 3-xxxxxxxxx-5-xxxxxxxxxxx-X-xxxxxxxxxxxxxx |
220–113–0 |
2631–37–0 |
X; R25 X; X50–53 |
X; N X: 25–50/53 S: (1/2-)24–37–45–60–61 |
|||
006–038–00–4 |
xxxxxxxxx (XXX) 2-xxxxxxxxxx-X,X-xxxxxxxxxxxxxxxxxxxxxx |
X |
202–388–9 |
95–06–7 |
Xxxx. xxx. 2; R45 Xx; X22 N; R50–53 |
T; X R: 45–22–50/53 X: 53–45–60–61 |
||
006–039–00-X |
xxx-xxxxx (XXX) X-(2,3,3-xxxxxxxxxxxxx)-X,X-xxxxxxxxxxxxxxxxxxxxxxx |
218–962–7 |
2303–17–5 |
Xx; X22–48/22 R43 X; R50–53 |
Xn; X X: 22–43–48/22–50/53 S: (2-)24–37–60–61 |
|||
006–042–00–6 |
xxxxxxx (XXX) 3-(4-chlorfenyl)-1,1-dimethylmočovina |
205–766–1 |
150–68–5 |
Karc. xxx. 3; R40 Xx; X22 N; X50–53 |
Xx; N R: 22–40–50/53 S: (2-)36/37–60–61 |
|||
006–043–00–1 |
monuron-TCA 3-(4-xxxxxxxxxx)-1,1-xxxxxxxxxxxxxxx-xxxxxxxxxxxxxx |
— |
140–41–0 |
Xx; X36/38 Xxxx. xxx. 3; R40 X; X50–53 |
Xx; X X: 36/38–40–50/53 X: (2-)36/37–60–61 |
|||
006–045–00–2 |
xxxxxxxx (XXX) methyl-N-[(N-methylkarbamoyl)oxy]thioacetimidát |
240–815–0 |
16752–77–5 |
T+; X28 N; R50–53 |
T+; X R: 28–50/53 X: (1/2-)22–36/37–45–60–61 |
|||
006–046–00–8 |
bendiokarb (ISO) 2,2-xxxxxxxx-1,3-xxxxxxxxxxx-4-xx-X-xxxxxxxxxxxxxx |
245–216–8 |
22781–23–3 |
X; X23/25 Xn; X21 N; R50–53 |
T; X X: 21–23/25–50/53 X: (1/2-)22–36/37–45–60–61 |
|||
006–047–00–3 |
xxxxxxxxx (XXX) xxxx: 3-(1-xxxxxxxxxxx)xxxxx-X-xxxxxxxxxxxxxxx x 3-(1-xxxxxxxxxxx)xxxxx-X-xxxxxxxxxxxxxxx |
— |
8065–36–9 |
X; X24/25 X; X50–53 |
X; N X: 24/25–50/53 S: (1/2-)28–36/37–45–60–61 |
|||
006–048–00–9 |
ethiofenkarb (XXX) 2-[(xxxxxxxxxxxxx)xxxxxx]xxxxx-X-xxxxxxxxxxxxxx |
249–981–9 |
29973–13–5 |
Xx; X22 X; X50–53 |
Xx; X X: 22–50/53 X: (2-)60-61 |
|||
006–050–00–X |
xxxxxxx-XXX 3-xxxxx-1,1-xxxxxxxxxxxxxxx-xxxxxxxxxxxxxx |
— |
4482–55–7 |
Xx; X38 X; X50–53 |
Xx; N X: 38–50/53 X: (2-)60-61 |
|||
006–053–00–6 |
xxxxxxxxxx (XXX) 2-xxxxxxxxxxxxxx-X-xxxxxxxxxxxxxx |
220–114–6 |
2631–40–5 |
Xx; X22 X; R50–53 |
Xn; X X: 22–50/53 X: (2-)60-61 |
|||
006–054–00–1 |
mexakarbát (XXX) 4-(xxxxxxxxxxxxx)-3,5-xxxxxxxxxxxxx-X-xxxxxxxxxxxxxx |
206–249–3 |
315–18–4 |
X+; X28 Xx; X21 X; X50–53 |
X+; X X: 21–28–50/53 X: (1/2-)36/37–45–60–61 |
|||
006–057–00–8 |
nitrapyrin (XXX) 2-xxxxx-6-(xxxxxxxxxxxxxx)xxxxxxx |
217–682–2 |
1929–82–4 |
Xx; X22 N; X51–53 |
Xx; N R: 22–51/53 S: (2-)24-61 |
|||
006–060–00–4 |
xxxxxxxxxxx (XXX) 2-xxxxxx-4,4-xxxxx-5,6-xxxxxxx-4λ4-1,4-xxxxxxxx-3-xxxxxxxxxxxx |
226–066–2 |
5259–88–1 |
Xx; R22 X52–53 |
Xx X:22–52/53 S: (2-)61 |
|||
006–069–00–3 |
xxxxxxxxx-xxxxxx (XXX) 1,2-xx[3-(xxxxxxxxxxxxxxx)xxxxxxxxxx]xxxxxx |
245–740–7 |
23564–05–8 |
Xxxx. xxx. 3; R40 X; X50–53 |
Xx; N X: 40–50/53 S: (2-)36/37–60–61 |
|||
006–070–00–9 |
xxxxxxxxxxx X-xxxxxxxxxx-X-xxxxxxx-2,5-xxxxxxxx-3-xxxxxxx |
262–302–0 |
60568–05–0 |
Xxxx. xxx. 3; X40 N; X50–53 |
Xx; X X: 40–50/53 X: (2-)36/37–60–61 |
|||
006–088–00–7 |
xxxxxxxxxxx (XXX) xxxxx-X -[({[(2,2-xxxxxxxx-2,3-xxxxxxx-1-xxxxxxxxxx-7-xx)xxx]xxxxxxxx}xxxxxxxxxxx)xxxxxxxx]-X-xxxxxxxxx-β-xxxxxxxx(2,2-xxxxxxxx-2,3-xxxxxxx-1-xxxxxxxxxx-7-xx)-X-({[2-(xxxxxxxxxxxxxx)xxxxx]xxxxxxxxxxxxxx}xxxxxxxx)-X-xxxxxxxxxxxxxx |
— |
82560–54–1 |
X; X23/25 X; X50–53 |
X; X X: 23/25–50/53 X: (1/2-)36/37–45–60–61 |
|||
007–012–00–5 |
X,X-xxxxxxxxxxxxxxxx 1,1-xxxxxxxxxxxxxxxx |
X |
200–316–0 |
57–14–7 |
X; X11 Xxxx. xxx. 2; X45 X; X23/25 X; X34 X; R51–53 |
F; X; X R: 45–11–23/25–34–51/53 X: 53–45–61 |
||
007–013–00–0 |
X,X-xxxxxxxxxxxxxxxx 1,2-xxxxxxxxxxxxxxxx |
X |
— |
540–73–8 |
Xxxx. xxx. 2; X45 X; R23/24/25 N; X51–53 |
X; N R: 45–23/24/25–51/53 X: 53–45–61 |
X ≥ 25 %: X; R45–23/24/25 3 % &xx; X &xx; 25 %: X; X45–20/21/22 0,01 % &xx; X &xx; 3 %: X; X45 |
|
009–003–00–1 |
xxxxxxxx xxxxxxxxxxxxxx … % |
X |
231–634–8 |
7664–39–3 |
X+; X26/27/28 X; X35 |
X+; C X: 26/27/28–35 X: (1/2-)7/9–26–36/37–45 |
X ≥ 7 %: X+; X; X26/27/28–35 1 % ≤ X &xx; 7 %: T; X23/24/25–34 0,1 % ≤ X &xx; 1 %: Xx; X20/21/22–36/37/38 |
|
015–039–00–9 |
xxxxxxx-xxxxxx (ISO) O,O-dimethyl-S -[(4(3 X)-xxx-1,2,3-xxxxxxxxxxxx-3-xx)xxxxxx]-xxxxxxxxxxxxxxx |
201–676–1 |
86–50–0 |
X+; X26/28 X; R24 X43 X; R50–53 |
T+; N X: 24–26/28–43–50/53 S: (1/2-)28–36/37–45–60–61 |
|||
015–048–00–8 |
xxxxxxxx (ISO) X,X-xxxxxxxx-X-[3-xxxxxx-4-(xxxxxxxxxxxxxx)xxxxx]-xxxxxxxxxxxxx |
200–231–9 |
55–38–9 |
Xxxx. xxx. 3; R40 X; X23–48/25 Xn; X21/22 X; X50–53 |
X; X R: 21/22–23–40–48/25–50/53 X: (1/2-)36/37–45–60–61 |
|||
015–056–00–1 |
xxxxxxx-xxxxx (ISO) X,X-xxxxxxx-X-[(4(3 X)-xxx-1,2,3-xxxxxxxxxxxx-3-xx)xxxxxx]-xxxxxxxxxxxxxxx |
220–147–6 |
2642–71–9 |
X+; R28 X; R24 N; X50–53 |
X+; N R: 24–28–50/53 X: (1/2-)28–36/37–45–60–61 |
|||
015–140–00–8 |
xxxxxxxxx (XXX) X,X-xxxxxxx-X-(1-xxxxx-1 X- 1,2,4-xxxxxxx-3-xx)-xxxxxxxxxxxxx |
245–986–5 |
24017–47–8 |
X; X23/25 Xx; X21 N; X50–53 |
X; X X: 21–23/25–50/53 X: (1/2-)36/37–45–60–61 |
|||
016–013–00-X |
chlorid xxxxxxx |
234–129–0 |
10545–99–0 |
X14 X; X34 X; X50 |
X; X X: 14–34–50 X: (1/2-)26–36/37/39–45–61 |
X ≥ 10 %: X; X34 5 % ≤ X &xx; 10 %: Xx; X36/37/38 |
||
016–014–00–5 |
xxxxxxx xxxxxxxx |
— |
13451–08–6 |
X14 X; R34 X; X50 |
X; X X: 14–34–50 X: (1/2-)26–36/37/39–45–61 |
C ≥ 10 %: X; R34 5 % ≤ C &xx; 10 %: Xx; X36/37/38 |
||
016–023–00–4 |
xxxxxxxx-xxxxxx |
X |
201–058–1 |
77–78–1 |
Xxxx. xxx. 2; X45 Xxxx. xxx. 3; X40 X+; R26 X; X25 X; R34 X43 |
X+ R: 45–25–26–34–43 X: 53-4 5 |
X ≥ 25 %: X+; X45–25–26–34–43 10 % ≤ X &xx; 25 %: X+; X45–22–26–34–43 7 % ≤ X &xx; 10 %: X+; X45–22–26–36/ 37/38–43 5 % ≤ X &xx; 7 %: X; X45–22–23–36/37/38–43 3 % ≤ X &xx; 5 %: X; X45–22–23–43 1 % ≤ X &xx; 3 %: X; X45–23–43 0,1 % ≤ X &xx; 1 %: T; X45–20 0,01 % ≤ X &xx; 0,1 %:X; R45 |
|
016–024–00-X |
dimexano (XXX) xxx(xxxxxxxxxxxxxxxxxxx)xxxxxxxx |
X,X′-xxxxxxxx-xxxxxxxxxxx(xxxxxxxxxxx)215–993–8 |
1468–37–7 |
Xx; X22 N; X50–53 |
Xx; X X: 22–50/53 S: (2-)60-61 |
|||
016–071–00–6 |
3-xxxxx-6,13-xxxxxxx-10-[(3-{[4-xxxxx-6-(2-xxxxxxxxxxxxxxxx)- 1,3,5-xxxxxxx-2-xx]xxxxx}xxxxxx)xxxxx][1,4]xxxxxxxxxxx[2,3-x]xxxxxxxxx-4,11-xxxxxxxxxx xxxxxxxx |
410–130–3 |
136248–03–8 |
X43 |
Xx R: 43 S: (2-)22–24–37 |
|||
022–001–00–5 |
xxxxxxx xxxxxxxxxx |
231–441–9 |
7550–45–0 |
X14 C; R34 |
C X: 14-34 X: (1/2-)7/8–26–36/37/39–45 |
X ≥ 10 %: C; X34 5 % ≤ X &xx; 10 %: Xi; R36/37/38 |
||
030–004–00–8 |
dimethylzinek [1] xxxxxxxxxxxx [2] |
208–884–1 [1] 209–161–3 [2] |
544–97–8 [1] 557–20–0 [2] |
X14 X; X17 X; X34 N; X50–53 |
X; X; X X: 14–17–34–50/53 X: (1/2-)16–43–45–60–61 |
|||
050–002–00–0 |
xxxxxxxxx (XXX) xxxxxxxxxxxxx(xxxxxxx)xxxxxxx tricyklohexylstannium-hydroxid |
236–049–1 |
13121–70–5 |
Xn; X20/21/22 X; X50–53 |
Xx; X X: 20/21/22–50/53 X: (2-)13–60–61 |
|||
050–012–00–5 |
xxxxxxxxxxxxxxxxxxxxxx [1] xxxxx(xxxxxxxxxxxxx)xxxxxxx [2] xxxxx(xxxxxxxxxxxxx)xxxxxxx [3] |
215–910–5 [1] 221–437–5 [2] 230–358–5 [3] |
1449–55–4 [1] 3091–32–5 [2] 7067–44–9 [3] |
Xx; X20/21/22 X; X50–53 |
Xx; X X: 20/21/22–50/53 X: (2-)26–28–60–61 |
X ≥ 1 %: Xn; R20/21/22 |
1 |
|
050–017–00–2 |
fenbutatinoxid (XXX) 1,1,1,3,3,3-hexakis(2-fenyl-2-methylpropyl)distannoxan |
236–407–7 |
13356–08–6 |
T+; X26 Xx; R36/38 X; X50/53 |
X+; X X: 26–36/38–50/53 X: (1/2-)28–36/37–45–60–61 |
|||
082–009–00–X |
žluť (xxxxxxxxxxxx olovnatý) CI Xxxxxxx Xxxxxx 34 (XX 77603) CI xxxxxxxxxx xxxx 34 (XX 77603) |
215–693–7 |
1344–37–2 |
Xxxx. xxx. 3; R40 Xxxx. xxx. 1; X61 Xxxx. xxx. 3; X62 X33 N; X50–53 |
X; N X: 61–33–40–50/53–62 X: 53–45–60–61 |
1 |
||
082–010–00–5 |
xxxxxx (xxxxxxx-xxxxxxxxxx-xxxxx olovnatý) XX Xxxxxxx Red 104 (XX 77605) XX xxxxxxxxxx červeň 104 (XX 77605) |
235–759–9 |
12656–85–8 |
Xxxx. xxx. 3; X40 Xxxx. xxx. 1; X61 Xxxx. xxx. 3; X62 X33 X; X50–53 |
X; X R: 61–33–40–50/53–62 X: 53–45–60–61 |
1 |
||
601–024–00-X |
kumen [1] xxxxxxxxxxxx [2] |
202–704–5 [1] 203–132–9 [2] |
98–82–8 [1] 103–65–1 [2] |
R10 Xx; X65 Xx; X37 X; R51–53 |
Xn; X X: 10–37–51/53–65 X: (2-)24–37–61–62 |
4 |
||
601–032–00–3 |
benzo[a]pyren xxxxx[xxx]xxxxxxx |
200–028–5 |
50–32–8 |
Xxxx. xxx.2; R45 Xxxx. xxx. 2; R46 Xxxx. xxx. 2; X60–61 N; X50–53 |
X; X X: 45–46–60–61–50/53 X: 53–45–60–61 |
|||
601–034–00–4 |
benzo[e]acefenanthrylen |
205–911–9 |
205–99–2 |
Karc. xxx.2; X45 X; R50–53 |
T; X X: 45–50/53 X: 53–45–60–61 |
|||
602–035–00–2 |
1,4-xxxxxxxxxxxxx x-xxxxxxxxxxxxx |
203–400–5 |
106–46–7 |
Xx; X36 N; X50–53 |
Xx; X R: 36–50/53 X: (2-)24/25–46–60–61 |
|||
602–054–00–6 |
3-xxxxxxx-1-xx xxxxxxxxxx |
209–130–4 |
556–56–9 |
X10 X; X34 |
X X: 10-34 S: (1/2-)7–26–45 |
|||
603–076–00–9 |
but-2-yn-1,4-diol |
203–788–6 |
110–65–6 |
T; X23/25 Xx; X21–48/22 X; X34 |
X X: 21–23/25–34–48/22 X: (1/2-)26–36/37/39–45 |
C ≥ 50 %: X; X21–23/25–34–48/22 25 % ≤ X &xx; 50 %: X; X21–23/25–36/38–48/22 10 % ≤ X &xx; 25 %: Xx; X20/22–48/22 3 % ≤ C &xx; 10 %: Xx; X20/22 |
||
603–091–00–0 |
xxx-4-xxxxxxxxx-1-xxxxxx-7-xxxxxxxxxx[2.2.1]xxxxxx-2-xx |
402–470–6 |
87172–89–2 |
X; X8 Xx; X22 Xx; X36 |
X; Xx R: 8–22–36 X: (2-)26 |
|||
603–093–00–1 |
exo-(±)-4-isopropyl-1-methyl-2-[(2-methylbenzyl)oxy]-7-oxabicyklo[2.2.1]heptan |
402–410–9 |
87818–31–3 |
Xn; X20 X; X51–53 |
Xx; X R: 20–51/53 X: (2-)23-61 |
|||
603–097–00–3 |
1,1', 1′′-nitrilotripropan-2-ol xxxxxxxxxxxxxxxxxx |
204–528–4 |
122–20–3 |
Xx; R36 R52–53 |
Xi X:36–52/53 S: (2-)26-61 |
|||
603–117–00–0 |
propan-2-ol xxxxxxxxxxxxxxxx xxxxxxxxxxx |
200–661–7 |
67–63–0 |
X; R11 Xx; R36 R67 |
F; Xx X: 11–36–67 X: (2-)7–16–24/25–26 |
|||
604–020–00–6 |
xxxxxxx-2-xx 2-xxxxxxxxxxxxxx 2-xxxxxxxxxx (ISO) |
201–993–5 |
90–43–7 |
Xi; R36/37/38 X; X50 |
Xx; X X: 36/37/38–50 X: (2-)22-61 |
|||
604–021–00–1 |
2-xxxxxxxxxx, sodná xxx xxxxxxx-2-xxxxxxxxxxxx 2-xxxxxxxxx sodný xxxxxxx-xxxxxxx-2-xxxx |
205–055–6 |
132–27–4 |
Xx; X22 Xi; X37/38–41 X; X50 |
Xx; X X: 37/38–41–50 X: (2-)22–26–61 |
|||
604–024–00–8 |
4,4'-(4-xxxxxxxxxxxx-2,2-xxxx)xxxxxxx 2,2-xxx(4-xxxxxxxxxxxx)-4-xxxxxxxxxxxx |
401–720–1 |
6807–17–6 |
Xxxx. xxx. 2; X60 Xx; X36 N; X50–53 |
X; N R: 60–36–50/53 X: 53–45–60–61 |
|||
604–041–00–0 |
xxxxxxxxxxx [1] xxxxxxxxxxx-xxxxxxx [2] 5-[2-xxxxx-4-(xxxxxxxxxxxxxx)xxxxxx]-2-xxxxxxxxxxxxx xxxxxxxx [1] xxxxxxx-5-[2-xxxxx-4-(xxxxxxxxxxxxxx)xxxxxx]-2-xxxxxxxxxxxx [2] |
256–634–5 [1] 263–560–7 [2] |
50594–66–6 [1] 62476–59–9 [2] |
Xx; X22 Xx; X38–41 X; X50–53 |
Xx; X X: 22–38–41–50/53 S: (2-)24–39–60–61 |
|||
604–043–00–1 |
monobenzonbenzyl (4-xxxxxxxxxxxx)xxxxx xxxxxxxxxxxxxxxxxxxxxxxxxx 4-(xxxxxxxxx)xxxxx |
203–083–3 |
103–16–2 |
Xx; X36 R43 |
Xi X: 36-43 X: (2-)24/25–26–37 |
|||
604–044–00–7 |
xxxxxxxx 4-xxxxxxxxxxxx xxxxxxxxxxxxxxxxxxxxxxxxxx |
205–769–8 |
150–76–5 |
Xx; X22 Xx; X36 R43 |
Xn X: 22–36–43 X: (2-)24/25–26–37/39–46 |
|||
605–016–00–7 |
xxxxxxx… % ethandial… % |
X |
203–474–9 |
107–22–2 |
Xxxx. xxx. 3; X40 Xn; X20 Xx; X36/38 R43 |
Xn X: 20–36/38–40–43 X: (2-)36/37 |
X ≥ 10 %: Xx; X20–36/38–40–43 1 % ≤ X &xx; 10 %: Xn; X40–43 |
|
606–016–00-X |
xxxxxx (XXX) 2-(trimethylacetyl)indan-1,3-dion |
201–462–8 |
83–26–1 |
T; X25–48/25 X; X50–53 |
X; X X: 25–48/25–50/53 S: (1/2-)37–45–60–61 |
|||
606–018–00–0 |
xxxxxxx (ISO) 2,3-xxxxxxx-1,4-xxxxxxxxxxx |
204–210–5 |
117–80–6 |
Xx; X22 Xx; X36/38 X; R50–53 |
Xn; X X: 22–36/38–50/53 X: (2-)26–60–61 |
|||
606–019–00–6 |
xxxxxxxxxx (ISO) perchlorpentacyklo[5.3.0.02,6.03,9.04,8]dekan-5-on xxxxxxxxxxxxxxxxxxx[5.2.1.02,6.03,9.05,8]xxxxx-4-xx 1,2,4,5,6,7,8,8,9,10-xxxxxxxxxxxxxxxxxxx[5.3.0.02,6.04,10.05,9]xxxxx-3-xx |
205–601–3 |
143–50–0 |
Xxxx. xxx. 3; X40 T; X24/25 X; R50–53 |
T; X X: 24/25–40–50/53 X: (1/2-)22–36/37–45–60–61 |
|||
606–034–00–8 |
metribuzin (ISO) 4-xxxxx-6-xxxx-xxxxx-3-(xxxxxxxxxxxxxx)-1,2,4-xxxxxxx-5(4 X)-xx 4-amino-6-terc-butyl-3-(methylsulfanyl)-4,5-dihydro-1,2,4-triazin-5-on |
244–209–7 |
21087–64–9 |
Xn; X22 X; X50–53 |
Xx; X X: 22–50/53 X: (2-)60-61 |
|||
606–035–00–3 |
chloridazon (XXX) 5-xxxxx-4-xxxxx-2-xxxxxxxxxxxxxx-3(2X)-xx xxxxxxx |
216–920–2 |
1698–60–8 |
X43 N; X50–53 |
Xx; X X: 43–50/53 S: (2-)24–37–60–61 |
|||
606–036–00–9 |
chinomethionát (XXX) 6-xxxxxx-2 X-[1,3]xxxxxxxx[4,5-x]xxxxxxxxxx-2-xx |
219–455–3 |
2439–01–2 |
Xxxx. xxx. 3; X62 Xx; X20/21/22–48/22 Xi; X36 X43 X; X50–53 |
Xx; X R: 20/21/22–36–43–48/22–50/53–62 X: (2-)24–37–60–61 |
|||
606–037–00–4 |
triadimefon (XXX) 1-(4-chlorfenoxy)- 3,3-dimethyl-1-(1,2,4-triazol-1-yl)butan-2-on |
256–103–8 |
43121–43–3 |
Xn; X22 N; X51–53 |
Xx; X X: 22–51/53 X: (2-)61 |
|||
606–044–00–2 |
2,4,6-xxxxxxxxxxxxxxxxxxx xxxxx(2,4,6-xxxxxxxxxxxxxx)xxxxxxxx |
403–150–9 |
954–16–5 |
Xx; X22 Xx; R36 X; X50–53 |
Xx; N X: 22–36–50/53 S: (2-)26–60–61 |
|||
607–043–00-X |
xxxxxxx (XXX) 3,6-xxxxxxx-2-xxxxxxxxxxxxxxx xxxxxxxx |
217–635–6 |
1918–00–9 |
Xx; X22 Xi; X41 X52–53 |
Xx; N X: 22–41–52/53 S: (2-)26-61 |
|||
607–057–00–6 |
xxxxxxxxx (XXX) 3-[1-(4-xxxxxxxxxx)-3-xxxxxxxx]-4-xxxxxxxxxxxxxx3-[1-(4-xxxxxxxxxx)-3-xxxxxxxx]-4-xxxxxxx-2 X-xxxxxxx-2-xx |
201–378–1 |
81–82–3 |
Xx; R48/22 R52–53 |
Xn X:48/22–52/53 X: (2-)37-61 |
|||
607–058–00–1 |
xxxxxxxxx (XXX) fumarin (XX)-3-[1-(2-xxxxx)-3-xxxxxxxx)]-4-xxxxxxxxxxxxxx (XX)-3-[1-(2-xxxxx)-3-xxxxxxxx)]-4-xxxxxxx-2 X -xxxxxxx-2-xx 3-[1-(2-xxxxx)-3-xxxxxxxx]-4-xxxxxxxxxxxxxx 3-[1-(2-xxxxx)-3-xxxxxxxx]-4-xxxxxxx-2 X -xxxxxxx-2-xx |
204–195–5 |
117–52–2 |
X; X25–48/25 R52–53 |
T X:25–48/25–52/53 X: (1/2-)37–45–61 |
|||
607–079–00–6 |
xxxxxxx (XXX) xxxxx-4-xxx-5-(xxxxxxxx-5-xxxxxxxxxxxxxxxxx[5.3.0.02,6.03,9.04,8]xxxxx-5-xx)xxxxxxxxx ethyl-5-(1,2,3,5,6,7,8,9,10,10-dekachlor-4-hydroxypentacyklo[5.2.1.02,6.03,9.05,8]dekan-4-yl)-4-oxopentanoát xxxxx-5-(1,2,4,5,6,7,8,8,9,10-xxxxxxxxx-3-xxxxxxxxxxxxxxxxx[5.3.0.02,6.04,10.05,9]xxxxx-3-xx)-4-xxxxxxxxxxxx |
— |
4234–79–1 |
X; X24 Xn; X22 N; X51–53 |
X; X X: 22–24–51/53 X: (1/2-)36/37–45–61 |
|||
607–097–00–4 |
benzen-1,2,4-trikarbox-1,2-anhydrid 1,2-anhydrid xxxxxx-1,2,4-xxxxxxxxxxxxxx xxxxxxxx trimellitanhydrid |
209–008–0 |
552–30–7 |
Xi; X37–41 R42/43 |
Xn X: 37–41–42/43 S: (2-)22–26–36/37/39 |
|||
607–143–00–3 |
xxxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxx |
203–677–2 |
109–52–4 |
X; X34 X52–53 |
X R:34–52/53 X: (1/2-)26–36–45–61 |
|||
607–152–00–2 |
2,3,6-XXX (XXX) 2,3,6-xxxxxxxxxxxxxxxx xxxxxxxx |
200–026–4 |
50–31–7 |
Xx; X22 X; R51–53 |
Xn; X X: 22–51/53 X: (2-)61 |
|||
607–153–00–8 |
xxxxxxxxx (XXX) (4-xxxxx-2-xxx-2,3-xxxxxxx-1,3-xxxxxxxxxxxx-3-xx)xxxxxx xxxxxxxx |
223–297–0 |
3813–05–6 |
Xx; X36/38 R52–53 |
Xi X:36/38–52/53 X: (2-)22-61 |
|||
607–156–00–4 |
xxxxxxxxxxx (XXX) 4-chlorfenyl-4-chlorbenzen-1-sulfonát |
201–270–4 |
80–33–1 |
Xn; X22 Xx; X38 X; X50–53 |
Xx; N R: 22–38–50/53 X: (2-)37–60–61 |
|||
607–158–00–5 |
xxxxx xxx xxxxxxxxxxx kyseliny xxxxxxxxxx xxxxx |
223–498–3 |
3926–62–3 |
X; R25 Xx; X38 N; X50 |
X; N R: 25–38–50 X: (1/2-)22–37–45–61 |
|||
607–159–00–0 |
chlorobenzilát (XXX) ethyl-2,2-bis(4-chlorfenyl)-2-hydroxyacetát xxxxx-4,4'-xxxxxxxxxxxxxxx |
208–110–2 |
510–15–6 |
Xx; X22 N; R50–53 |
Xn; X X: 22–50/53 X: (2-)60-61 |
|||
607–176–00–3 |
Xxxx: α-{3-[3-(2 X-xxxxxxxxxxxx-2-xx)-5-xxxx-xxxxx-4-xxxxxxxxxxxx]xxxxxxxxx}-ω-xxxxxxxxxxx(xxxxxxxxxx);α-{3-[3-(2 X-xxxxxxxxxxxx-2-xx)-5-xxxx-xxxxx-4-xxxxxxxxxxxx]xxxxxxxxx}-ω-({3-[3-(2 X-xxxxxxxxxxxx-2-xx)-5-xxxx-xxxxx-4-xxxxxxxxxxxx]xxxxxxxxx}xxx)xxxx(xxxxxxxxxx) |
400–830–7 |
— |
X43 X; X51–53 |
Xx; X X: 43–51/53 S: (2-)36/37–61 |
|||
607–188–00–9 |
xxxxxxx-xxxxxxxx-X-(2-xxxxxxxxxxxx)-X-(xxxxxxx-9-xx-1-xx)xxxxxxxxxx |
402–970–4 |
— |
X43 X; X51–53 |
Xx; X X: 43–51/53 X: (2-)24/37–61 |
|||
607–209–00–1 |
Xxxx: X,X′-xxxxxxxxxxx-xxxxxxxxxxxx(xxxxxxxxxxx); X,X′-xxxxxxxxxxx-xxxxxxxxxxxxxx(xxxxxxxxxxx); O,O′-diisopropyl-pentasulfanbis(karbothioát) |
403–030–6 |
— |
Xn; X22 X43 X; X50–53 |
Xx; X X: 22–43–50/ 53 S: (2-)36/37–60–61 |
|||
607–213–00–3 |
ethyl-3,3-bis(terc-pentylperoxy)butanoát |
403–320–2 |
67567–23–1 |
E; X2 X; X7 X10 N; R51–53 |
E; X X: 2–7–10–51/53 X: (2-)3/7–14–33–36/37/39–61 |
|||
607–217–00–5 |
2-ethoxyethyl-[4-(7-fenyl-2,6-dioxo-2,6-dihydro-1,5-dioxa-s-indacen-3-yl)fenoxy]acetát |
403–960–2 |
— |
R43 R53 |
Xi X: 43-53 S: (2-)24–37–61 |
|||
607–243–00–7 |
xxxxxxx-3,6-xxxxxxx-2-xxxxxxxxxxxxxx [1] xxxxxxx-3,6-xxxxxxx-x-xxxxxx [1] xxx(2-xxxxxxxxxxxx)xxxxxxx-3,6-xxxxxxx-2-xxxxxxxxxxxxxx [2] xxx(2-xxxxxxxxxxxx)xxxxxxx-3,6-xxxxxxxxxxxxx [2] (2-hydroxyethyl)amonium-3,6-dichlor-2-methoxybenzoát [3] (2-hydroxyethyl)amonium-3,6-dichloranisát [3] |
217–846–3 [1] 246–590–5 [2] 258–527–9 [3] |
1982–69–0 [1] 25059–78–3 [2] 53404–28–7 [3] |
X52–53 |
X: 52/53 S: 61 |
|||
607–248–00–4 |
Xxxxxxxx-xxxxxxx Natrium-N-(1-naftyl)ftalamát |
205–073–4 |
132–67–2 |
Xn; R22 |
Xn X: 22 S: (2) |
|||
607–249–00-X |
(xxxxxxxxxxxxx)xxx[xxx(xxxxxxxxxxxxx)]-xxxxxxxxx tripropylenglykol-diakrylát XXXXX |
256–032–2 |
42978–66–5 |
Xx; X36/37/38 X43 N; X51–53 |
Xx; N X:36/37/38–43–51/53 X: (2-)24–37–61 |
C ≥ 10 %: Xx; X36/37/38–43 1 % ≤ X &xx; 10 %: Xx; X43 |
||
607–252–00–6 |
λ-xxxxxxxxxxx (XXX) Xxxx (1:1): (X)-[(3-xxxxxxxxxxx)xxxxxxxxxx]-(1 X)-xxx-3-((X)-2-xxxxx-3,3,3-xxxxxxxxxxxx-1-xx-1-xx)-2,2-xxxxxxxxxxxxxxxxxxx-1-xxxxxxxxxx x(X)-[(3-xxxxxxxxxxx)xxxxxxxxxx]-(1 X)-xxx-3-((X)-2-xxxxx-3,3,3-xxxxxxxxxxxx-1-xx-1-xx)-2,2-xxxxxxxxxxxxxxxxxxx-1-xxxxxxxxxx |
415–130–7 |
91465–08–6 |
X+; X26 X; X25 Xx; X21 X; X50–53 |
X+; X R: 21–25–26–50/53 X: (1/2-)28–36/37/39–38–45–60–61 |
|||
607–255–00–2 |
xxxxxxxxxx (XXX) [(4-xxxxx-3,5-xxxxxxx-6-xxxxx-2-xxxxxxx)xxx]xxxxxx xxxxxxxx |
— |
69377–81–7 |
X52–53 |
X: 52/53 X: 61 |
|||
608–003–00–4 |
xxxxxxxxxxxx |
X X |
203–466–5 |
107–13–1 |
X; Xxx Karc. xxx. 2; R45 T; X23/24/25 Xi; R37/38–41 X43 N; X51–53 |
X; X; N X: 45–11–23-/24/25–37/38–41–43–51/53 S: 9–16–53–45–61 |
X ≥ 20 %: X; X45–23/24/25–37/38–41–43 10 % ≤ C &xx; 20 %: X; X45–23/24/25–41–43 5 % ≤ C &xx; 10 %: X; R45–23/24/25–36–43 1 % ≤ X &xx; 5 %:X; X45–23/24/25–43 0,2 % ≤ X &xx; 1 %:T; X45–20/21/22 0,1 % ≤ X &xx; 0,2 %: T; R45 |
43 |
608–016–00–5 |
2,3,5,6-tetrachlor-1,4-dikyanbenzen xxxxxxxxxxxxxxxxxxxxxxxxx |
401–550–8 |
1897–41–2 |
X43 X; X50–53 |
Xx; X R: 43–50/53 X: (2-)24–37–60–61 |
|||
609–030–00–4 |
xxxxxxxx (XXX) 2-xxxx-xxxxx-4,6-xxxxxxxxxxxx |
X |
215–813–8 |
1420–07–1 |
Xxxx. xxx. 2; X61 X+; R28 X; X24 X44 X; X50–53 |
X+; X X: 61–24–28–44–50/53 X: 53–45–60–61 |
||
609–040–00–9 |
xxxxxxxx (XXX) (2,4-xxxxxxxxxxxx)(4-xxxxxxxxxx)xxxxx |
X |
217–406–0 |
1836–75–5 |
Xxxx. xxx. 2; X45 Xxxx. xxx. 2; X61 Xn; X22 X; R50–53 |
T; X X: 45–61–22–50/53 S: 53–45–60–61 |
||
609–044–00–0 |
xxxxxxxx (XXX) 1,2,4,5-xxxxxxxxxx-3-xxxxxxxxxxx |
204–178–2 |
117–18–0 |
Xx; X22 X43 X; X50–53 |
Xx; X X: 22–43–50/53 X: (2-)24–37–60–61 |
|||
611–008–00–4 |
4-xxxxxxxxxxxxxx 4-(xxxxxxxx)xxxxxx |
200–453–6 |
60–09–3 |
Xxxx. xxx. 2; X45 N; R50–53 |
T; X X: 45–50/53 X: 53–45–60–61 |
|||
611–013–00–1 |
4-xxxxxxx-3-{4-[2-xxxxxxx-4-(3-xxxxxxxxxxxxxxxxx)xxxxxxxx]-3-xxxxxxxxxxxxxx}-6-(3-xxxxxxxxxxxxxxxx)xxxxxxxx-2-xxxxxxxx trilithný |
403–650–7 |
117409–78–6 |
E; X2 X; R51–53 |
E; X X: 2–51/53 X: (2-)35-61 |
|||
611–031–00-X |
4,4'-[(4-iminocyklohexa-2,5-dien-1-yliden)methylen]dianilin-hydrochlorid CI Xxxxx Xxx 9 XX basická xxxxxx 9 |
209–321–2 |
569–61–9 |
Xxxx. xxx. 2; X45 |
X X: 45 X: 53-45 |
|||
612–035–00–4 |
2-xxxxxxxxxxxxx o-anisidin |
E |
201–963–1 |
90–04–0 |
Karc. xxx. 2; X45 Xxxx. xxx. 3; X40 T; X23/24/25 |
X X: 45–23/24/25 X: 53-45 |
||
612–042–00–2 |
xxxxxxxx xxxxxxx-4,4'-xxxxxx 4,4'-diaminobifenyl xxxxxxx-4,4'-xxxxxxxxxx |
X |
202–199–1 |
92–87–5 |
Xxxx. xxx. 1; X45 Xx; X22 X; R50–53 |
T; N X: 45–22–50/53 S: 53–45–60–61 |
X ≥ 25 %: X; X45–22 0,01 % ≤ X &xx; 25 %: T; X45 |
|
612–051–00–1 |
4,4'-xxxxxxxxxxxxxxxxxxxx xxx(4-xxxxxxxxxx)xxxxxx 4,4'-xxxxxxxxxxxxxxxx |
X |
202–974–4 |
101–77–9 |
Xxxx. kat. 2; X45 Xxxx. xxx. 3; R40 X; X39/23/24/25Xx; R48/20/21/22 X43 N; X51–53 |
X; X X: 45–39/23/24/25–43–48/20/21/22–51/53 X:53–45–61 |
||
612–081–00–5 |
3,3'-xxxxxxxxxxxxxxxx, xxxx o-tolidin, xxxx |
X X |
210–322–5 265–294–7 277–985–0 |
612–82–8 64969–36–4 74753–18–7 |
Xxxx. xxx. 2; X45 Xx; X22 X; X51–53 |
X; N R: 45–22–51/53 X: 53–45–61 |
||
612–099–00–3 |
4-xxxxxx-x-xxxxxxxxxxxxx4-xxxxxx-1,3-xxxxxxxxxxxxx4-xxxxxxxxxxxx-1,3-xxxxxx 2,4-xxxxxxxxxxxx |
X |
202–453–1 |
95–80–7 |
Xxxx. xxx. 2; X45 T; R25 Xx; R21 Xi; X36 X43 X; X51–53 |
X; X R: 45–21–25–36–43–51/53 X: 53–45–61 |
||
612–105–00–4 |
2-(xxxxxxxxx-1-xx)xxxxxxxxx2-(xxxxxxxxx-1-xx)xxxxx-1-xxxx |
205–411–0 |
140–31–8 |
Xx; X21/22 X; X34 X43 X52–53 |
X R: 21/22–34–43–52/53 X: (1/2-)26–36/37/39–45–61 |
|||
612–111–00–7 |
2-methyl-m-fenylendiamin2-methyl-1,3-fenylendiamin2-methylbenzen-1,3-diamin 2,6-xxxxxxxxxxxx |
212–513–9 |
823–40–5 |
Xxxx. xxx. 3; X40 Xx; X21/22 X43 X; X51–53 |
Xx; X X: 21/22–40–43–51/53 X: (2-)24–36/37–61 |
|||
612–125–00–3 |
2-xxxxxx-x-xxxxxxxxxxxxx2-xxxxxx-1,4-xxxxxxxxxxxxx2-xxxxxxxxxxxx-1,4-xxxxxx 2,5-xxxxxxxxxxxx |
202–442–1 |
95–70–5 |
X; X25 Xn; R20/21 X43 X; X51–53 |
X; X X: 20/21–25–43–51/53 X: (1/2-)24–37–45–61 |
|||
612–144–00–7 |
xxxxxxxxxxx (XXX) X-(2-xxxxx-6-xxxxxxxxxxx)-X-xxxxx-2,6-xxxxxxx-4-(xxxxxxxxxxxxxx)xxxxxx |
— |
62924–70–3 |
Xx; X36/38 X4 3 N; X50–53 |
Xx; X X: 36/38–43–50/53 X: (2-)36/37–60–61 |
|||
612–151–00–5 |
xxxxxxxxxxxxx toluendiamin xxxxxxxxxxxxxxxxxxx methylbenzendiamin |
E |
246–910–3 |
25376–45–8 |
Karc. xxx. 2; X45 X; X25 Xx; X20/21 Xx; X36 X43 X; X51–53 |
X; N X: 45–20/21–25–36–43–51/53 X: 53–45–61 |
||
613–018–00–4 |
xxxxxxxxxx (XXX) 1,1'-xxx[(3,5-xxxxxxxxxxxxxxxx-4-xxxxxxxx)xxxxxx]-4,4'-xxxxxxxxx-1,1'-xxxxx |
— |
7411–47–4 |
Xx; X22 Xi; X36/37/38 X52–53 |
Xx X: 22–36/37/38–52/53 X: (2-)22–36–61 |
|||
613–031–00–5 |
xxxxxxxxx trichlorisokyanurová xxxxxxxx trichlor-1,3,5-triazintrion 1,3,5-xxxxxxxx-1,3,5-xxxxxxx-2(1X), 4(3X), 6(5X)-xxxxx |
201–782–8 |
87–90–1 |
X; X8 Xx; R22 X31 Xx; R36/37 X; X50–53 |
X; Xx; N X: 8–22–31–36/37–50/53 X: (2-)8–26–41–60–61 |
|||
613–038–00–3 |
6-xxxxx-1,3,5-xxxxxxx-2,4-xxxxxxxxxx 6-xxxxx-1,3,5-xxxxxxx-2,4-xxxxxx xxxxxxxxxxxxx |
202–095–6 |
91–76–9 |
Xx; X22 R52–53 |
Xn X:22–52/53 X: (2-)61 |
|||
613–042–00–5 |
xxxxxxxx (XXX) 1-[2-(xxxxxxxx)-2-(2,4-xxxxxxxxxxxx)xxxxx]- 1 H-imidazol |
252–615–0 |
35554–44–0 |
Xn; X20/22 X; X41 X; X50–53 |
Xx; X X: 20/22–41–50/53 S: (2-)26–39–60–61 |
|||
613–043–00–0 |
xxxxxxxx-xxxxxx (XXX) 1-[2-(allyloxy)-2-(2,4-dichlorfenyl)ethyl]- 1X -xxxxxxxx-1-xxx-xxxxxxxxxxxxxx [1] (±)-1-[2-(xxxxxxxx)-2-(2,4-xxxxxxxxxxxx)xxxxx]-1X-xxxxxxxx-1-xxx-xxxxxxxxxxxxxx |
261–351–5 [1] 281–291–3 [2] |
58594–72–2 [1] 83918–57–4 [2] |
Xx; R20/22 Xi; X41 N; X50–53 |
Xx; X X: 20/22–41–50/53 X: (2-)26–39–60–61 |
|||
613–066–00–6 |
xxxxxxxxxx (ISO) 2-(xxxx-xxxxxxxxxx)-4-(xxxxxxxxxx)-6-xxxxxxx-1,3,5-xxxxxxx |
251–637–8 |
33693–04–8 |
Xx; X22 X; X50–53 |
Xx; N R: 22–50/53 X: (2-)60-61 |
|||
613–091–00–2 |
morfamkvat-dichlorid [1] xxxxxxxxxx-xxxxxx [2] 1,1'-xxx[(3,5-xxxxxxxxxxxxxxxx-4-xxxxxxxx)xxxxxx]-4,4'-xxxxxxxxx-1,1'-xxxxx-xxxxxxxxx [1] 1,1'-xxx[(3,5-xxxxxxxxxxxxxxxx-4-xxxxxxxx)xxxxxx]-4,4'-xxxxxxxxx-1,1'-xxxx-xxxxxxxx [2] |
225–062–8 [1] |
4636–83–3 [1] 29873–36–7 [2] |
Xx; X22 Xx; X36/37/38 X52–53 |
Xx; X: 22–36/37/38–52/53 S: (2-)22–36–61 |
|||
613–098–00–0 |
1-xxxxxxxxxxxxxxx-2-xx 1-xxxxx-2-xxxxxxxxxx |
403–700–8 |
2687–94–7 |
X; X34 X; R51–53 |
C; N X: 34–51/53 S: (1/2-)23–26–36/37/39–45–61 |
|||
613–130–00–3 |
xxxxxxxxxxx (XXX) (XX)-2-(2,4-xxxxxxxxxxxx)-1-(1X-1,2,4-xxxxxxx-1-xx)xxxxx-2-xx |
— |
79983–71–4 |
X43 X; X51–53 |
Xx; N X: 43–51/53 X: (2-)24–37–61 |
|||
613–131–00–9 |
xxxxxxxxxx (ISO) 1,2,5,6-tetrahydro-4 X-xxxxxxx[3,2,1-xx]xxxxxxxx-4-xx |
— |
57369–32–1 |
Xx; R22 X52–53 |
Xx X:22–52/53 X: (2-)61 |
|||
613–134–00–5 |
myklobutanil (XXX) 2-(4-xxxxxxxxxx)-2-[(1 H-1,2,4-triazol-1-yl)methyl]hexannitril |
— |
88671–89–0 |
Repr. xxx. 3; R63 Xx; X22 Xi; X36 X; X51–53 |
Xx; X X: 22–36–51/53–63 X: (2-)36/37–46–61 |
|||
613–137–00–1 |
xxxxxxxxxxxxxxxxxx (XXX) 1-(1,3-xxxxxxxxxxxx-2-xx)-1,3-xxxxxxxxxxxxxxxx |
242–505–0 |
18691–97–9 |
X; X50–53 |
X X: 50/53 X: 60-61 |
|||
613–139–00–2 |
xxxxxxxxxxx-xxxxxx xxxxxx-2-{X —[N-(4-methoxy-6-methyl-1,3,5-triazin-2-yl)karbamoyl]sulfamoyl}benzoát |
— |
74223–64–6 |
N; R50–53 |
N X: 50/53 X: 60-61 |
|||
614–001–00–4 |
xxxxxxx (ISO) 3-(1-xxxxxxxxxxxxxxxx-2-xx)xxxxxxx |
200–193–3 |
54–11–5 |
X+; X27 X; X25 X; X51–53 |
X+; X X: 25–27–51/53 S: (1/2-)36/37–45–61 |
|||
614–006–00–1 |
xxxxxx 2,3-xxxxxxxxxxxxxxxxxxxx-10-xx |
206–614–7 |
357–57–3 |
X+; X26/28 X52–53 |
X+ R:26/28–52/53 X: (1/2-)13–45–61 |
|||
614–007–00–7 |
xxxxxx-xxxxxx [1] xxxxxx-xxxxxx [2] xxxxxx-(X)-(1-xxxxxxxxxxxx)-xxxxxxxx-xxxxxx [3] xxxxxx-(X)-(1-xxxxxxxxxxxx)-xxxxxxxx-xxxxxx [4] |
225–432–9 [1] 227–317–9 [2] 269–439–5 [3] 269–710–8 [4] |
4845–99–2 [1] 5786–97–0 [2] 68239–26–9 [3] 68310–42–9 [4] |
X+; X26/28 X52–53 |
X+ X: 26/28–52/53 X: (1/2-)13–45–61 |
|||
615–006–00–4 |
2-xxxxxx-x-xxxxxxxxxxxxxxxxxx [1] 2-xxxxxx-1,3-xxxxxxxxxxxxxxxxxx [1] 4-xxxxxx-x-xxxxxxxxxxxxxxxxxx [2] 4-xxxxxx-1,3-xxxxxxxxxxxxxxxxxx [2] m-tolylidendiisokyanát [3] 5-methyl-1,3-fenylendiisokyanát [3] xxxxxx-2,6-xxxxxxxxxxx [1] xxxxxx-2,4-xxxxxxxxxxx [2] xxxxxx-3,5-xxxxxxxxxxx [3] |
X |
202–039–0 [1] 209–544–5 [2] 247–722–4 [3] |
91–08–7 [1] 584–84–9 [2] 26471–62–5 [3] |
Xxxx. kat. 3; X40 X+; X26 Xx; R36/37/38 X42/43 X52–53 |
X+ X: 26–36/37/38–40–42/43–52/53 X: (1/2-)23–36/37–45–61 |
X320 %: X+; X26–36/37/38–40–42/43 7 % ≤ X &xx; 20 %: X+; R26–40–42/43 1 % ≤ X &xx; 7 %: X; X23–40–42/43 0,1 % ≤ X &xx; 1 %:Xx; X20–42 |
2 |
616–010–00–9 |
xxxxxxx-xxxxxxxxxxxxxx X-xxxxx-4-xxxxxxxxxxxx-1-xxxxxxxxxx, xxxxx xxx |
204–854–7 |
127–65–1 |
Xx; R22 R31 X; X34 X42 |
X X: 22–31–34–42 X: (1/2-)7–22–26–36/37/39–45 |
|||
616–034–00-X |
xxxxxxxxxxxx (XXX) 6-xxxxxx-3,4-xxxxxxx-2X-xxxxx-5-xxxxxxxxxxxx |
246–419–4 |
24691–76–7 |
X52–53 |
X: 52/53 X: 61 |
|||
616–035–00–5 |
xxxxxxxxx X -[(ethylamino)karbonyl]-2-kyan-2-(methoxyimino)acetamid 1-xxxxx-3-[2-xxxx-2-(xxxxxxxxxxxx)xxxxxx]xxxxxxxx |
261–043–0 |
57966–95–7 |
Xx; X22 X43 X; X50–53 |
Xx; X R: 22–43–50/53 S: (2-)36/37–60–61 |
|||
617–004–00–9 |
(1,2,3,4-xxxxxxxxxx-1-xxxxxx)xxxxxxxxxxxx xxxxxxxxxxxxxxxxxxxx |
212–230–0 |
771–29–9 |
X; R7 Xx; X22 X; X34 X; X50–53 |
X; X; X X: 7–22–34–50/53 X:(1/2-)3/7–14–26–36/37/39–45–60–61 |
X325 %: X; X22–34 10 % ≤ X &xx; 25 %: C; X34 5 % ≤ X &xx; 10 %: Xx; X36/37/38 |
||
617–006–00-X |
xxx(α, α-xxxxxxxxxxxxxx)xxxxxxx bis(2-fenylpropan-2-yl)peroxid xxx(1-xxxxx-1-xxxxxxxxxxx)xxxxxxx xxxxxxxxxxxxxx |
201–279–3 |
80–43–3 |
X; X7 Xx; X36/38 X; X51–53 |
X; Xx; X X: 7–36/38–51/53 S: (2-)3/7–14–36/37/39–61 |
|||
617–008–00–0 |
xxxxxxxxxxxxxxxx |
202–327–6 |
94–36–0 |
X; X2 Xi; X36 R43 |
E; Xx; X: 2–36–43 S: (2-)3/7–14–36/37/39 |
|||
650–007–00–3 |
xxxxxxxxxxxxx (XXX) X2-(4-xxxxx-2-xxxxxxxxxxx)-X1,X1-xxxxxxxxxxxxxxxxxxxx X2-(4-xxxxx-x-xxxxx)-X1,X1-xxxxxxxxxxxxxxxxxx |
228–200–5 |
6164–98–3 |
Xxxx. xxx. 3; X40 Xx; R21/22 X; X50–53 |
Xx; X X: 21/22–40–50/53 S: (2-)22–36/37–60–61 |
|||
650–008–00–9 |
xxxxxxxxxx (XXX) 4-[(2-xxxxxxxxxx)xxxxxxxxx]-3-xxxxxxxxxxxxxx-5(4 X)-xx |
227–197–8 |
5707–69–7 |
X; R25 X; X50–53 |
X; X R: 25–50/53 X: (1/2-)22–24–36/37–45–60–61 |
|||
650–009–00–4 |
chlordimeform-hydrochlorid X'-(4-xxxxx-x-xxxxx)-X,X-xxxxxxxxxxxxxxxxxx-xxxxxxxxxxxx X2-(4-xxxxx-2-xxxxxxxxxxx)-X1,X1-xxxxxxxxxxxxxxxxxxxx-xxxxxxxxxxxx N2-(4-chlor-o-tolyl)-N1,N1-dimethylformamidin-hydrochlorid |
243–269–1 |
19750–95–9 |
Karc. xxx. 3; X40 Xx; X22 X; X50–53 |
Xx; X R: 22–40–50/53 X: (2-)22–36/37–60–61 |
|||
650–033–00–5 |
esfenvalerát (XXX) [(S)-(3-fenoxyfenyl)kyanmethyl]-(S)-2-(4-chlorfenyl)-3-methylbutanoát (S)-3-fenoxy-α-kyanbenzyl-(S)-2-(4-chlorfenyl)-3-methylbutanoát |
— |
66230–04–4 |
T; X23/25 R43 N; X50–53 |
X; N R: 23/25–43–50/53 S: (1/2-)24–36/37/39–45–60–61 |
|||
650–041–00–9 |
xxxxxxxxxxxx (XXX) 1-[2-(2-xxxxxxxxxxx)xxxxxx-1-xxxxxxxx]-3-(4-xxxxxxx-6-xxxxxx-1,3,5-xxxxxxx-2-xx)xxxxxxxx |
— |
82097–50–5 |
X; R50–53 |
N X: 50/53 X: 60-61 |
PŘÍLOHA 1X
Xxxxxxxx xxxxx |
Xxxxxxxx xxxxx |
Xxxxxxxx k xxxxxx |
Xxxxx XX |
Xxxxx XXX |
Xxxxxxxxxxx |
Xxxxxxxx |
Xxxxxxxxxxxx xxxxxx |
Xxxxxxxx x xxxxxxxxxx |
006–090–00–8 |
2-[(3-xxxxxxx-2-xx-1-xx)xxx]xxxxx-X-xxxxxxxxxxxxx |
408–010–0 |
88558–41–2 |
Xx; X20 Xx; X41 R52–53 |
Xn X: 20–41–52/53 S: (2-)22–26–39–61 |
|||
014–016–00–0 |
Xxxx: 1,3-di(hex-5-en-1-yl)- 1,1,3,3-tetramethyldisiloxan x 1,3-di(hex-x-en-1-yl)- 1,1,3,3-xxxxxxxxxxxxxxxxxxxx |
406–490–6 |
— |
X; X51–53 |
X X: 51/53 X: 61 |
|||
015–164–00–9 |
kalcium-dihydrogen-(1-hydroxyethylen)bisfosfonát xxxxxxxx |
400–480–5 |
36669–85–9 |
X52–53 |
X:52/53 X: 61 |
|||
015–165–00–4 |
Směs: S, X, S', S''-tetrafenyl-4,4'-sulfandiylbis(fenylsulfonium)-bis(hexafluorofosfát) x xxxxxxx[4-(xxxxxxxxxxxxx)xxxxx]xxxxxxxxx-xxxxxxxxxxxxxxxx |
404–986–7 |
— |
Xx; X41 X; X50–53 |
Xx; X X: 41–50/53 S: (2-)15–26–39–60–61 |
|||
015–166–00-X |
3,9-xxx(2,6-xx-xxxx-xxxxx-4-xxxxxxxxxxxx)-2,4,8,10-xxxxxxxx-3,9-xxxxxxxxxxxx[5.5]xxxxxxx |
410–290–4 |
80693–00–1 |
X53 |
X:53 X: 61 |
|||
015–167–00–5 |
3-[hydroxy(fenyl)fosfinoyl]propanová xxxxxxxx |
411–200–6 |
14657–64–8 |
Xx; X41 |
Xx R: 41 S: (2-)26-39 |
|||
601–050–00–1 |
X10-X13-xxxxxxxxxxxxx xxxxxxx |
267–051–0 |
67774–74–7 |
X; R50 |
N X: 50 S: 61 |
|||
601–051–00–7 |
4-xxxxxxxx-1-xx |
405–980–7 |
768–56–9 |
Xx; X38 N; X51–53 |
Xx; X R: 38–51/53 X: (2-)37-61 |
|||
602–083–00–4 |
xxxxxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxxxxxxxxxx |
251–084–2 |
32534–81–9 |
Xx; X48/21/22 X64 X; X50–53 |
Xx; X X: 48/21/22–50/53–64 X: (1/2-)36/37–45–60–61 |
|||
602–084–00-X |
1,1-xxxxxxx-1-xxxxxxxxxx |
404–080–1 |
1717–00–6 |
X; R52–53–59 |
N R: 52/53–59 S: 59-61 |
|||
603–128–00–0 |
2-(fenylmethoxy)naftalen |
405–490–3 |
613–62–7 |
R53 |
R:53 X: 61 |
|||
603–129–00–6 |
1-terc-butoxypropan-2-ol |
406–180–0 |
57018–52–7 |
R10 Xi; X41 |
Xx X: 10-41 X: (2-)26-39 |
|||
603–130–00–1 |
Směs xxxxxxx: α-(xxxxxxxxxxxxxxxxx)-ω-xxxxxxxxxxx(xxxxxxxxxx) |
406–325–8 |
— |
Xx; X22 X52–53 |
Xx X:22–52/53 S: (2-)39-61 |
|||
603–131–00–7 |
Xxxx (3:1):1-xxxxx-1-[xxxxxx(1-xxxxxxxxxx)xxxxx]-X-xxxxxxxx; 1-xxxxx-1-[xxxxxx(1-xxxxxxxxxxxxx)xxxxx]-X-xxxxxxxx |
407–290–1 |
— |
Xx; X41 |
Xx X: 41 X: (2-)26-39 |
|||
603–132–00–2 |
2-(xxxxxxxxxxxxx)-6-xxxxxxxxx-9-xxxxxx-1,4-xxxxxxxxxx[4.5]xxxxx |
408–200–3 |
63187–91–7 |
Xx; X38–41 X52–53 |
Xx X:38–41–52/53 X: (2-)26–37/39–61 |
|||
603–133–00–8 |
Xxxx:3-(4-xxxxx-2-xxxxx-5-xxxxxxxxxxxx)xxxxxx-1,2-xxxx x 3,3'-[(2-chlor-5-nitro-1,4-fenylen)diimino]di(propan-1,2-diol) |
408–240–1 |
— |
Xn; X22 X52–53 |
Xx R:22–52/53 X: (2-)22–36–61 |
|||
603–134–00–3 |
Xxxx: alkyl(C1-C10)-dodecyldifenylethery x xxxxx(X1-X10)-xxxxxxxxxxxxxxxxxxxxxxx (xxxxxxx a xxxxxxxxxx nerozvětvené) |
410–450–3 |
— |
R53 |
R: 53 X: 61 |
|||
603–135–00–9 |
bis[2-(2-methoxyethoxy)ethanolato]bis(2,2', 2-xxxxxxxxxxxxxxx-1-xxxxx-X,X)xxxxxxxxxx xxxxxxx |
410–500–4 |
— |
Xx; X41 X; X51–53 |
Xx; N X: 41–51/53 X: (2-)26–39–61 |
|||
603–136–00–4 |
3-{4-[xxx(2-xxxxxxxxxxxx)xxxxx]-2-xxxxxxxxxxxx}xxxxxx-1-xx |
410–910–3 |
104226–19–9 |
X43 X52–53 |
Xx X:43–52/53 X: (2-)24–37–61 |
|||
603–137–00-X |
Xxxx:1-xxxxx-1-[xxxxxx(1-xxxxxxxxxxxx)xxxxx]-X-xxxxxxxx a 1-xxxxx-1-[xxxxxx(1-xxxxxxxxxxxx)xxxxx]-X-xxxxxxxx |
411–130–6 |
— |
Xx; X41 |
Xx X: 41 X: (2-)26-39 |
|||
603–138–00–5 |
3-(2,2-xxxxxxxx-3-xxxxxxxxxxxxx)xxxxxx 2,2-xxxxxxxx-3-(3-xxxxxxxxxxx)xxxxxx-1-xx |
403–140–4 |
103694–68–4 |
X52–53 |
X:52/53 X: 61 |
|||
604–050–00-X |
4-xxxxx-x-xxxxxx 4-xxxxx-2-xxxxxxxxxxx |
216–381–3 |
1570–64–5 |
X; X23 C; X 35 X; X50 |
X; X; X X: 23–35–50 X: (1/2-)26–36/37/39–45–61 |
X ≥ 25 %: X; C; X23–35 10 % ≤ X &xx; 25 %: X;X20–35 5 % ≤ X &xx; 10 %: X;X20–34 3 % ≤ X &xx; 5 %: Xx;X20–36/37/38 1 % ≤ X &xx; 3 %:Xx;X36/37/38 |
||
604–051–00–5 |
3,5-xxx(3,5-xx-xxxx-xxxxx-4-xxxxxxxxxxxxx)-2,4,6-xxxxxxxxxxxxxx |
401–110–5 |
87113–78–8 |
X52–53 |
X:52/53 X: 61 |
|||
604–052–00–0 |
2,2'-xxxxxxxxxxx[6-(2 X - xxxxxxxxxxxx-2-xx)-4-(1,1,3,3-xxxxxxxxxxxxxxxx)xxxxx] 6,6'-xxx(2X -benzotriazol-2-yl)- 4,4'-bis(1,1,3,3-tetramethylbutyl)- 2,2'-xxxxxxxxxxxxxxx |
403–800–1 |
103597–45–1 |
X53 |
X:53 X: 61 |
|||
604–053–00–6 |
4-xxxx - xxxxx-2-xxxxxx-6-(1-xxxxxxxxxxxxxxxx)xxxxx |
410–760–9 |
157661–93–3 |
Xx; R38 X43 X; X50–53 |
Xx; X X: 38–43–50/53 X: (2-)24–37–60–61 |
|||
604–054–00–1 |
Xxxx:2-xxxxxxx-4-(4-xxxxxxxxxxxxxxxxxxxxxxxxx-2-xx)xxxxx x 2-xxxxxxx-4-(4-xxxxxx-3,6-xxxxxxx-2X -xxxxx-2-xx)xxxxx |
412–020–0 |
— |
X43 R52–53 |
Xi X:43–52/53 X: (2-)24–37–61 |
|||
604–055–00–7 |
4,4'-xxx[(2,3-xxxxxxxxxxx)xxx]-3,3', 5,5'-xxxxxxxxxxxxxxxxxx |
413–900–7 |
85954–11–6 |
Xxxx. Xxx.3; R40 |
Xn X: 40 X: (2-)22–36–37 |
|||
605–027–00–7 |
Xxxx:3x, 4,5,6,7,7x-xxxxxxxxx-4,7-xxxxxxx-1X-xxxxx-6-xxxxxxxxxxx x 3x, 4,5,6,7,7x-xxxxxxxxx-4,7-xxxxxxx-1X - xxxxx-5-xxxxxxxxxxx |
410–480–7 |
— |
X43 X; X51–53 |
Xx; X R: 43–51/53 X: (2-)24–37–61 |
|||
606–051–00–0 |
4-pentylcyklohexanon pentylcyklohexan-1-on |
4–406–670–4 |
61203–83–6 |
N; X51–53 |
X X: 51/53 X: 61 |
|||
606–052–00–6 |
4-(X, X-xxxxxxxxxxxx)-2-xxxxxxx-2'-xxxxxxxxxxxxxxxxx 2-[4-(xxxxxxxxxxxx)-2-xxxxxxxxxxxxxx]xxxxxxxx xxxxxxxx |
410–410–5 |
54574–82–2 |
X52–53 |
X:52/53 S: 61 |
|||
607–272–00–5 |
xxxxxxxxxxx-xxxxxx (XXX) [1] xxxxxxxxxx-xxxxxxxxx (XXX) [2] xxxxxxxxxxxx-[(4-xxxxx-3,5-xxxxxxx-6-xxxxx-2-xxxxxxx)xxx]xxxxxx [1] (2-xxxxxx-1-xxxxxxxxxxx)-[(4-xxxxx-3,5-xxxxxxx-6-xxxxx-2-xxxxxxx)xxx]xxxxxx [2] |
279–752–9 [1] — |
81406–37–3 [1] 154486–27–8 [2] |
X; X50–53 |
X X: 50/53 X: 60-61 |
|||
607–273–00–0 |
amonium-7-{2,6-dimethyl-8-[(2,2-dimethylbutanoyl)oxy]- 1,2,6,7,8,8a-hexahydro-1-naftyl}-3,5-dihydroxyheptanoát |
404–520–2 |
— |
R52–53 |
R:52/53 X: 61 |
|||
607–274–00–6 |
{2-[xxxxxx(xxxxxx)xxxxx]xxxxx}-3-xxxxxxxx-2-xxxxx |
405–350–1 |
54527–73–0 |
X43 X; X51–53 |
Xx; X X: 43–51/53 X: (2-)24–37–61 |
|||
607–275–00–1 |
natrium-4-(benzoyloxy)benzen-1-sulfonát |
405–450–5 |
66531–87–1 |
R43 |
Xi X: 43 X: (2-)24-37 |
|||
607–276–00–7 |
[xxx(2-xxxxxxxxxxxxxx) xxx(1-xxxxxxxxxxxxxx)]xxxxxxxxx xxxxxxx |
405–635–0 |
— |
Xx; X38–41 N; X50–53 |
Xx; X X: 38–41–50/53 X: (2-)26–37/39–60–61 |
|||
607–277–00–2 |
Xxxx:2-(xxxxxxxxxxxxx)xxxxxxxxx-xxxxxxxxxxxx x xxxxxxx-xxxxxxxxx |
405–720–2 |
— |
Xx; X22 Xi; X41 X43 X; X51–53 |
Xx; X X: 22–41–43–51/53 S: (2-)24–26–37/39–61 |
|||
607–278–00–8 |
Xxxx:xxxxx(X7-X9 xxxxxxxxxx x xxxxxxxxxxxx)-3-[3-(2 X - benzotriazol-2-yl)-5-terc-butyl-4-hydroxyfenyl]propanoáty |
405–760–0 |
— |
Xi; X41 X43 X52–53 |
Xx X: 41–43–52/53 S: (2-)24–26–37/39–61 |
|||
607–279–00–3 |
Xxxx:(xxxxxxxxxxxxxx)xxxxxxxxx-xxx(xxxxxxxx-xxxxxxxx) a (xxxxxxxxxxxxxx)xxxxxxxxx-(xxxxxxxx-xxxxxx)-(xxxxxxxx-xxxxxxxx) |
405–960–8 |
— |
X43 X; X51–53 |
Xx; N X: 43–51/53 S: (2-)24–37–61 |
|||
607–280–00–9 |
4-xxxxx-1-xxxxxxxxxxxx-1-xxxxxxxx sodný xxxxxxx-4-xxxxx-1-xxxxxxxxxxxx-1-xxxxxxxx |
406–190–5 |
54322–20–2 |
Xx; X22 Xx; R36 X43 |
Xx X: 22–36–43 X: (2-)22–26–36/37 |
|||
607–281–00–4 |
Směs:alkyl(C7-C9 xxxxxxxxxx x xxxxxxxx)-3-[3-(2X-xxxxxxxxxxxx-2-xx)-5-xxxx-xxxxx-4-xxxxxxxxxxxx]xxxxxxxxxx |
407–000–3 |
127519–17–9 |
X; X51–53 |
X X: 51/53 X: 61 |
|||
607–282–00-X |
2-(xxxxxxxxxxxxx)-4-(xxxxxxxxx)xxxxx-xxxxxx |
407–140–5 |
131266–10–9 |
X52–53 |
X: 52/53 S: 61 |
|||
607–283–00–5 |
xxxxx-(X)-4-xxxxx-4-xxxxxx-2-xxxxxxxxxx-(X)-4-xxxxx-4-xxxxxxxxxxx |
408–040–4 |
15121–89–8 |
Xx; R21/22 Xx; X38–41 R43 N; X50–53 |
Xx; X R: 21/22–38–41–43–50/53 X: (2-)26–36/37/39–60–61 |
|||
607–284–00–0 |
Xxxx (9:1):xxxxxxx-3,3'-{(1,4-xxxxxxx)xxx[(xxxxxxxxxxxxx)(xxxxxx-3,1-xxxx)xxxxx]}xxx(10-xxxxx-6,13-xxxxxxx[1,4]xxxxxxxxxxx[2,3-x]xxxxxxxxx-4,11-xxxxxxxxxx) x xxxxxxx-3,3'-{(1,4-xxxxxxx)xxx[(xxxxxxxxxxxxx)(xxxxxx-3,1-xxxx)xxxxx]}xxx(10-xxxxx-6,13-xxxxxxx[1,4]xxxxxxxxxxx[2,3-x]xxxxxxxxx-4,11-xxxxxxxxxx) |
410–040–4 |
136213–76–8 |
X; X51–53 |
X X: 51/53 X: 61 |
|||
607–285–00–6 |
Xxxx:7-(3-xxxxxxxxxxxxxxxxxxxxxx)xxxxxxxx-1,3-xxxxxxxxxxx kyselina, xxxxxx-7-(3-xxxxxxxxxxxxxxxxxxxxxx)xxxxxxxx-1,3-xxxxxxxxxx x xxxxxxx-7-(3-xxxxxxxxxxxxxxxxxxxxxx)xxxxxxxx-1,3-xxxxxxxxxx |
410–065–0 |
— |
X43 |
Xx X: 43 X: (2-)22–24–37 |
|||
607–286–00–1 |
Xxxx:xxxxxx- x xxxxxxx-7-[4-({4-[(2-xxxxxxx-1-xxxxxx)xxx]xxxxx}xxx)xxxxxxxxxxxxxxxxx]xxxxxxxx-1,3-xxxxxxxxxx |
410–070–8 |
141880–36–6 |
X43 X52–53 |
Xx X:43–52/53 S: (2-)22–24–37–61 |
|||
607–287–00–7 |
xxxxxx-[1-xxxxxx-2-(xxxxxxxxxxxxxxx)xxxxx]-1,2,3,6-xxxxxxxxxxxxxxxx |
410–140–8 |
— |
X52–53 |
X:52/53 S: 61 |
|||
607–288–00–2 |
[c-(N -{3-[(1-{3-[(2,6(4,6)-xxxxxxx-5-xxxxxxxxxxxxx-4(2)-xx)xxxxxxxxxxx]xxxxxx}-2-xxxxxxx-4-xxxxxx-6-xxx-1,6-xxxxxxx-3-xxxxxxx)xxx]-4-xxxxxxxxxxxxxx}xxxxxxxxx)-x,x,x -xxxxxxxxxxxxxxxxxxxxxxx]xxxxxxxxx xxxxxxx, xxxxxxxxxx xxx; c = 15, 16, 17 xxxx 18, x = 1, 2, 3 nebo 4, b = 8, 9, 10 xxxx 11, x = 22, 23, 24 xxxx 25 |
410–160–7 |
148732–74–5 |
Xx; X36 X43 X52–53 |
Xx X: 36–43–52/53 X: (2-)22–26–36/37–61 |
|||
607–288–00–8 |
3-[(3-{X —[4-(2,4-xx-xxxx-xxxxxxxxxxxx)xxxxx]xxxxxxxxx}-4-xxxxxxx-1-xxxxxx)xxxxxxxx]xxxxxxxxx xxxxxxxx |
410–370–9 |
105488–33–3 |
X53 |
X:53 X: 61 |
|||
607–290–00–3 |
Xxxx (x xxxxxxxx poměru):amonium-1-alkyl(C14-C18)-4-[3-(allyloxy)-2-hydroxypropyl]-2-sulfonatobutandioát a xxxxxxx-4-xxxxx(X14-X18)-1-[3-(xxxxxxxx)-2-xxxxxxxxxxxxx]-2-xxxxxxxxxxxxxxxxxxx |
410–540–2 |
— |
Xx; X38 R43 X; R50–53 |
Xi; X X: 38–43–50/53 X: (2-)24–37–60–61 |
|||
607–291–00–9 |
xxxxxxx-ω-xxxxxxxxxxx(xxxx xxxxxxxxxx)xxxxxxxx |
410–630–1 |
104051–92–5 |
X53 |
X: 53 X: 61 |
|||
607–292–00–4 |
Směs:[2-(alkyl(C12)oxy)-1-(methoxymethyl)ethoxy]octová kyselina x [2-(xxxxx(X14)xxx)-1-(xxxxxxxxxxxxx)]xxxxxx xxxxxxxx |
410–640–6 |
— |
Xx; X38–41 X; X50–53 |
Xx; X R: 38–41–50/53 X: (2-)26–37/39–60–61 |
|||
607–293–00-XXxxx: |
1-(2-xxxxxxxxxx)xxxxxxxxx-1,4-xxxxx-[(2,4,6-xxxxxxxxxxxxxx)xxxxxx]xxxxxxxxxxxxxxxx x 1-(2-xxxxxxxxxx)xxxxxxxxx-1,4-xxxxx-[xxx(2,4,6-xxxxxxxxxxxxxx)xxxxxx]xxxxxxxxxxxxxxxx |
410–650–0 |
— |
Xx; X41 R43 X; X51–53 |
Xx; X X: 41–43–51/53 S: (2-)26–36/37/39–61 |
|||
607–294–00–5 |
xxxxxxx-2-(xxxxxxxxxx)-1-xxxxxxxxxxxx-1-xxxxxxxx |
410–680–4 |
— |
X43 |
Xx R: 43 X: (2-)24-37 |
|||
607–295–00–0 |
Xxxx:xxxxxxxxxxxx-xxxxxxxxxxxxxxxxx x xxxxxxxxxxx-xxxxxxxxxxxx-1,2,3,4-xxxxxxxxxxxxxxx |
410–800–5 |
— |
X43 N; R51–53 |
Xi; X X: 43–51/53 X: (2-)24–37–61 |
|||
607–296–00–6 |
Xxxx:xxxxxxxxxxx pentaerythritolu, xxxxxxxxx xxxxxxxx a 2-xxxxxxxxxxxxx xxxxxxxx |
410–830–9 |
— |
X53 |
X: 53 X: 61 |
|||
607–297–00–1 |
3,3'-(1,4-xxxxxxxxxxxxxxxxxxx)xxx(2-xxxxxxxxx-10-xxxxxxxxx xxxxxxxx)2,2'-xxxxx-3,3'-(1,4-xxxxxxxxxxxxxxxxxxx)xxx(1,7,7-xxxxxxxxxxxxxxxx[2.2.1]xxxxxx-1-xxxxxxxxxxxxxxx xxxxxxxx) |
410–960–6 |
92761–26–7 |
Xx; X41 |
Xx X: 41 S: (2-)26-39 |
|||
607–298–00–7 |
[2-(xxxxxxxxxxxxxxx)xxxxx]-4-xxxxxxxxxxxxxxxx |
411–010–3 |
— |
X43 |
Xx X: 43 X: (2-)22–36/37 |
|||
607–299–00–2 |
xxxxxx-3-(xxxxxxxxxxxxxx)-2-xxxxxxxxxxxxxxx |
411–040–7 |
97101–46–7 |
Xx; R22 X43 X; X50–53 |
Xx; X X: 22–43–50/53 X: (2-)24–37–60–61 |
|||
607–300–00–6 |
[x-(X-{4-[(5-xxxxx-2,6-xxxxxxxxxxxxxxxx-4-xx)xxxxx]-3-xxxxxxxxxxxxxxxx}xxxxxxxxx)-x-xxxxxxxxx-x, x-xxxxxxxxxxxxxxxxxxxx]xxxxxxx komplex, xxxxxxxx xxx; a = 1,2,3 nebo 4, x = 8, 9, 10 xxxx 11, c = 15, 16, 17 xxxx 18, x = 22, 23, 24 nebo 25 |
411–430–7 |
— |
X43 |
Xx X: 43 X: (2-)22–24–37 |
|||
607–301–00–1 |
Xxxx:xxxxxxxxxx kyselina x dodekanoáty xxxxx(1-7)xxxxxxx |
411–860–5 |
— |
Xx; X38–41 X43 X; X51–53 |
Xx; N X: 38–41–43–51/53 X: (2-)24–26–37/39–61 |
|||
607–302–00–7 |
Xxxx:xxxxxxxxxxxxx xxxxxxxx a xxxxxxxxxxxxxx xxxxx(1-7)xxxxxxx |
411–910–6 |
— |
Xx; X38–41 X43 X; X51–53 |
Xx; X X: 38–41–43–51/53 X: (2-)24–26–37/39–61 |
|||
607–303–00–2 |
1-xxxxxxxxxxx-6,7-xxxxxxx-4-xxx-1,4-xxxxxxxxxxxxxxx-3-xxxxxxxxxxx xxxxxxxx |
413–760–7 |
93107–30–3 |
Xxxx. kat.3; X62 X52–53 |
Xx X: 62–52/53 X: (2-)22–36/37–61 |
|||
608–023–00–3 |
4-(4-xxxxxxxxxx)-2-xxxxx-2-[(1X- 1,2,4-xxxxxxx-1-xx)xxxxxx]xxxxxxxxxxx |
406–140–2 |
114369–43–6 |
X; X50–53 |
X X: 50/53 X: 60-61 |
|||
608–024–00–9 |
2-{4-[xxxxx(xxxxxxxx)xxxxx]xxxxx}xxxxx-1,1,2-xxxxxxxxxxxxxx |
407–650–8 |
97460–76–9 |
X53 |
X:53 X: 61 |
|||
608–025–00–4 |
[2-nitro-4,5-bis(benzyloxy)fenyl]acetonitril |
410–970–0 |
117568–27–1 |
R53 |
R:53 X: 61 |
|||
609–053–00-X |
xxxxxxxxxxx-xxxxxxxxxxxxxxxx |
414–850–9 |
— |
X; X3 X; X8 Xxxx. xxx. 2; X45 X; X23/25 R43 |
E; X X: 45–3–8–23/25–43 X: 53-45 |
|||
610–010–00–2 |
1-xxxx-2-(2-xxxxx)-1-xxxxxxxxxx |
406–110–9 |
35950–52–8 |
Xx; X22–48/22 X; X34 X43 X; X50–53 |
X; X X: 22–34–43–48/22–50/53 X: (1/2-)22–26–36/37/39–45–60–61 |
|||
611–043–00–5 |
Xxxx (2:1:1):[xxx(6-{[1-(X-xxxxxxxxxxxxxx)-2-xxxxxxxxxxx-1-xx-1-xx]xxx}-5-xxxxxxxxx-3-xxxxxxxxxxxxxxxxx-2-xxx-1'-xxxxxx-1,2'-xxxxxxx)]xxxxxxxxx xxxxxxxx, [xxx{6-[(2-xxxxx-4-xxxxxxxxxxxx)xxx]- xxxx 6-[(2-amino-6-hydroxyfenyl)azo]- xxxx 6-[(4-xxxxx-2-xxxxxxxxxxxx)xxx]-5-xxxxxxxxx-3-xxxxxxxxxxxxxxxxx-2-xxx-1'-xxxxxx-1,2'-xxxxxxx}]xxxxxxxxx xxxxxxxx x[{6-[(2-xxxxx-4-xxxxxxxxxxxx)xxx]- xxxx 6-[(2-xxxxx-6-xxxxxxxxxxxx)xxx]- xxxx 6-[(4-xxxxx-2-xxxxxxxxxxxx)xxx]-5-xxxxxxxxx-3-xxxxxxxxxxxxxxxxx-2-xxx-1'-xxxxxx-1,2'-xxxxxxx}(6-{[1-(X-xxxxxxxxxxxxxx)-2-xxxxxxxxxxx-1-xx-1-xx]xxx}-5-xxxxxxxxx-3-xxxxxxxxxxxxxxxxx-2-xxx-1'-xxxxxx-1,2'-xxxxxxx)]xxxxxxxxx xxxxxxxx |
402–850–1 |
Xx R: 41–52/53 X: (2-)26–39–61 |
|||||
611–044–00–0 |
Xxxx:[xxx(5-xxxxxxxxxxx-1-xxx-1'-xxxxxxxx-2,2'-xxxxxxx)]xxxxxxxxx xxxx-xxxxx(X12-X14)xxxxxx, [bis(4-nitrobenzen-1-azo-1'-naftalen-2,2'-diolato)]chromitan terc-alkyl(C12-C14)amonný, [xxx(5-xxxx-xxxxx-3-xxxxxxxxxxx-1-xxx-1'-xxxxxxxx-2,2'-xxxxxxx)]xxxxxxxxx xxxx-xxxxx(X12-X14)xxxxxx, [(5-xxxx-xxxxx-3-xxxxxxxxxxx-1-xxx-1'-xxxxxxxx-2,2'-xxxxxxx)(5-xxxxxxxxxxx-1-xxx-1'-xxxxxxxx-2,2'-xxxxxxx)]xxxxxxxxx xxxx-xxxxx(X12-X14)xxxxxx x[(4(5)-xxxxxxxxxxx-1-xxx-1'-xxxxxxxx-2,2'-xxxxxxx) (3-nitro-5-pentylbenzen-1-azo-1'-naftalen-2,2'-diolato)]chromitan xxxx-xxxxx(X12-X14)xxxxxx |
403–720–7 |
117527–94–3 |
X; X51–53 |
Xx; R41 X52–53 |
|||
611–045–00–6 |
2-({4-[(4-xxxxxxxxxxxx)xxxxxxxxxx]-2-xxxxxxxxxxx}xxx)-3-xxxxxx-5-xxxxxxxxxxxx |
404–830–8 |
— |
X53 |
X:53 X: 61 |
X X: 51/53 S: 61 |
||
611–046–00–1 |
4,4'-xxxxxxx-2-xxxxxxxxxxxxxxx2-xxxxxxxxxxxxxxx-4,4'-xxxxxx |
407–590–2 |
43151–99–1 |
X; X25 Xx; X48/22 X43 N; X50–53 |
X; X R: 25–43–48/22–50/53 X: (1/2-)22–28–36/37–45–60–61 |
|||
611–047–00–7 |
Xxxx (1:1):2-({4-[(2-xxxxxxxxxxxx)xxxxxxxxxx]xxxxx}xxx)-5,6-xxxxxxxxxxxxxxxxxxx a 2-({4-[(2-xxxxxxxxxxxx)xxxxxxxxxx]xxxxx}xxx)-6,7-xxxxxxxxxxxxxxxxxxx |
407–890–3 |
111381–11–4 |
X53 |
X: 53 S: 61 |
|||
611–048–00–2 |
Xxxx (1:1):2-({4-[xxx(2-xxxxxxxxxxxx)xxxxx]xxxxx}xxx)-5,6-xxxxxxxxxxxxxxxxxxx a 2-({4-[bis(2-acetoxyethyl)amino]fenyl}azo)-6,7-dichlorbenzothiazol |
407–900–6 |
111381–12–5 |
R53 |
R: 53 X: 61 |
|||
611–049–00–8 |
Xxxx (2:1:1)7-[(4-{[3-(xxxxxxxxxxxx)xxxxxx]xxxxx}-6-{[3-(xxxxxxxxxxxxx)xxxxxx]xxxxx}-1,3,5-xxxxxxx-2-xx)xxxxx]-3-{[4-(xxxxxxxx)xxxxx]xxx}-4-xxxxxxxxxxxxxxx-2-xxxxxxxx, xxxxxxxx xxxxxx x xxxxxx xxxxxxxx (2:1:1) |
408–000–6 |
118658–98–3 |
Xx; X48/22 X43 X52–53 |
Xx X: 43–48/22–52/53 X: (2-(22–36/37–61 |
|||
611–051–00–9 |
2-({4-[xxxxx(2-xxxxxxxxxxxx)xxxxx]-2-xxxxxxxxxxx}xxx)-6-xxxxxxx-3-xxxxxxxxxxxxxxxxxxxxx-xxxxxxx |
411–110–7 |
136213–74–6 |
X; R50–53 |
N X: 50/53 S: 60-61 |
|||
611–052–00–4 |
[xxxx{4-[(2-xxxxxxx-3,5-xxxxxxxxxxxx) xxx]-6-[(6-xxxxxxxxx-1-xxxxxx)xxx]xxxxxx-1,3-xxxxxxx}]xxxxxxxxx komplex, xxxxx xxx |
400–720–9 |
— |
X52–53 |
X: 52/53 X: 61 |
|||
612–156–00–2 |
Směs:trihexadecyl(methyl)amonium-chlorid x xxxxxxxxxxx(xxxxxxxx)xxxxxxx-xxxxxxx |
405–620–9 |
— |
Xx; X41 N; X50–53 |
Xx; X X: 41–50/53 S: (2-)26–39–60–61 |
|||
612–157–00–8 |
(X)-1-(1-xxxxxxxxxxxx-2-xx)xxxxx-1-xx-xxxx-xxxxxxxxxxxx |
410–780–8 |
— |
Xx; X22–48/22 Xx; X41 X43 N; X51–53 |
Xx; X X: 22–41–43–48/22–51/53 X: (2-)22–26–36/37/39–61 |
|||
612–158–00–3 |
Směs:[bis(5-alkyl(rozvětvený C12))-2-hydroxybenzaldoximato)]měďnatý xxxxxxx x 4-xxxxxxx-2-xxxxxxxxxxxxxxxxxx[xxx(5-xxxxx(xxxxxxxxxx X12))-2-xxxxxxxxxxxxxxxxxxxxx)]xxxxxxx xxxxxxx x 4-xxxxxxxxxxxxxxxxxxxxx |
410–820–4 |
— |
X53 |
X: 53 X: 61 |
|||
612–159–00–9 |
xxxxxxx xxxxxxxx směsi 2,2,4-xxxxxxxxx- a 2,4,4-trimethylhexan-1,6-diaminu (x xxxxxxx EINECS), xxxxxxxx [(alkyl(C10-C16)oxy)methyl]oxiranu (Epoxid 8) x 4-methylbenzen-1-sulfonové xxxxxxxx |
410–880–1 |
— |
Xx; R22 X; X34 N; X50–53 |
X; X X: 22–34–50/53 X: (1/2-)23–26–36/37/39–45–60–61 |
|||
613–149–00–7 |
2-xxxx-xxxxx-5-[(4-xxxx-xxxxxxxxxxx)xxxxxxxx]-4-xxxxxxxxxxxxxx-3(2X)-xx |
405–700–3 |
96489–71–3 |
X; R23/25 X; X50–53 |
X; N X: 23/25–50/53 S: (1/2-)36/37–45–60–61 |
|||
613–150–00–2 |
2,2'-[xxxxxxxxx-1,4-xxxxxx(xxxxxx-1,3-xxxx)]xxx(xxxxxxxxxxx[2,1-x]xxxxx[xxx][3,8]xxxxxxxxxxxx-1,3,6-xxxxx) |
406–295–6 |
— |
X53 |
X:53 X: 61 |
|||
613–151–00–8 |
1-(2-deoxy-3-O-mesyl-5-O-trityl-β-D-threo-pentofuranosyl)-5-methylpyrimidin-2(1H), 4(3 X)-xxxx |
406–360–9 |
104218–44–2 |
X53 |
X:53 S: 61 |
|||
613–152–00–3 |
xxxxx-X-(4,6-xxxxxxxxxxxxxxxxxx-2-xx)xxxxxxxx |
406–600–2 |
89392–03–0 |
X43 N; X51–53 |
Xx; X R: 43–51/53 X: (2-)24–37–61 |
|||
613–153–00–9 |
2,3,5-xxxxxxxxxxxxxxx |
407–270–2 |
16063–70–0 |
X52–53 |
X:52/53 S: 61 |
|||
613–154–00–4 |
2-xxxxx-4-xxxxx-6-xxxxxxxxxxxxxxxx |
410–050–9 |
5734–64–5 |
Xx; X22 |
Xx R: 22 X: (2-)22 |
|||
613–155–00-X |
5-chlor-2,3-difluorpyridin |
410–090–7 |
89402–43–7 |
R10 Xx; X22 X52–53 |
Xx X: 10–22–52/53 X: (2-)23–36–61 |
|||
613–156–00–5 |
2-xxxxx-4-xxxxx-5-xxxxxxxxxxxxxx 2-butyl-5-chlorimidazol-4-karbaldehyd |
410–260–0 |
83857–96–9 |
R43 N; X51–53 |
Xx; N R: 43–51/53 S: (2-)24–37–61 |
|||
613–157–00–0 |
2,4-xxxxxxx-5-(xxxxxxxxxxxxx)xxxxxxxxx 5-(xxxxxxxxxxxxx)xxxxxxxxx-2,4-xxxxxx |
410–330–0 |
54236–98–5 |
Xx; X22–48/22 Xi; X36 |
Xx R: 22–36–48/22 X: (2-)22–26–36 |
|||
613–158–00–6 |
2,3-dichlor-5-(trifluormethyl)pyridin |
410–340–5 |
69045–84–7 |
Xn; R20/22 Xx; X41 X43 X; X51–53 |
Xx; X X: 20/22–41–43–51/53 X: (2-)24–26–37/39–61 |
|||
613–159–00–1 |
4-[2-(4-xxxx-xxxxxxxxxx)xxxxxx]xxxxxxxxxx |
410–580–0 |
120928–09–8 |
X; X25 Xx; X20 X; X50–53 |
X; X R: 20–25–50/53 X: (1/2-)37–45–60–61 |
|||
613–160–00–7 |
2-methyl-2,5-diazabicyklo[2.2.1]heptan-dihydrobromid |
411–000–9 |
125224–62–6 |
R43 |
Xi X: 43 X: (2-)24-37 |
|||
615–022–00–1 |
methyl-3-(isokyanatosulfonyl)thiofen-2-karboxylát |
410–550–7 |
79277–18–2 |
E; X2 R14 Xx; X48/22 X42/43 |
X; Xx X: 2–14–42/43–48/22 S: (2-)22–30–35–36/37 |
|||
615–023–00–7 |
xxxxxxxxxxx 2-[(xxxxxxxxxxxxxxxxxx)xxxxxx]xxxxxxxx xxxxxxxxxxxxxx-2-[(xxxxxxxxxxxxxxxxxx)xxxxxx]xxxxxxx |
410–900–9 |
83056–32–0 |
X10 X14 Xxxx. xxx. 3; X40 Xx; X20–48/22 Xi; R41 X42 |
Xx X: 10–14–20–40–41–42–48/22 X: (2-)23–26–36/37/39 |
|||
616–044–00–4 |
X-(3,5-xxxxxxx-4-xxxxx-2-xxxxxxxxxxxx)-2-(3-xxxxxxxxxxxxxxxx)xxxxxxxxx |
402–510–2 |
— |
X; X51–53 |
X X: 51/53 S: 61 |
|||
616–045–00-X |
2'-[(4-xxxxx-5-xxxxxx-3-xxxx-2-xxxxxxx)xxx]- 5'-(xxxxxxxxxxxx)-2-xxxxxxxxxxxxxxxxx |
405–190–2 |
122371–93–1 |
X43 R53 |
Xi X: 43-53 X: (2-)22–24–37–61 |
|||
616–046–00–5 |
X -[2-(6-xxxxx-7-xxxxxxxxxxxxxx[1,5-x][1,2,4]xxxxxxx-4-xx)xxxxxx]-2-(2,4-xx-xxxx-xxxxxxxxxxxx)xxxxxxxxx |
406–390–2 |
— |
X; X50–53 |
X X: 50/53 X: 60-61 |
|||
616–047–00–0 |
Xxxx:X,X′,X″,X′′′ - xxxxxxxxxx(X16)-2,2′, 2″, 2′′′ (xxxxxxxxxxxxxxxx)xxxxxxxxxxxxx x X, X′,X″,X′′′ - xxxxxxxxxx(X18)- 2,2′, 2′′, 2′′′-(xxxxxxxxxxxxxxxx)xxxxxxxxxxxxx |
406–640–0 |
— |
X43 |
Xx X: 43 X: (2-)24-37 |
|||
616–048–00–6 |
3'-(xxxxxxxxxxxxxx)xxxxxxxxxxxxxx |
406–740–4 |
1939–27–1 |
Xx; X48/22 X; X51–53 |
Xx; X X: 48/22–51/53 X: (2-)22–36–61 |
|||
616–049–00–1 |
2-(2,4-di-terc-butylfenoxy)-N-(3,5-dichlor-4-ethyl-2-hydroxyfenyl)hexanamid |
408–150–2 |
99141–89–6 |
R53 |
R:53 X: 61 |
|||
616–050–00–7 |
1-[2,5-xxxxxxx-4-(1,1,2,3,3,3-xxxxxxxxxxxxxxxx)xxxxx]-3-(2,6-xxxxxxxxxxxx)xxxxxxxx |
410–690–9 |
103055–07–8 |
X43 X; X50–53 |
Xx; X X: 43–50/53 X: (2-)24–37–60–61 |
|||
616–051–00–2 |
Xxxx:3,3'-xxx(4-xxxxxxxxxxx)- 1,1'-(4-xxxxxx-1,3-xxxxxxx)xxxxxxxxxx x 3,3'-bis(4-methylfenyl)-1,1'-(2-methyl-1,3-fenylen)dimočovina Xxxx:2,4-xxx[3-(4-xxxxxxxxxxx)xxxxxx]xxxxxx x 2,6-bis[(3-(4-methylfenyl)ureido]toluen |
411–070–0 |
— |
R53 |
R: 53 X: 61 |
|||
617–015–00–9 |
bis(4-methylbenzoyl)peroxid |
407–950–9 |
895–85–2 |
E; X2 X; X7 N; X50–53 |
X; X X: 2–7–50/53 X: (2-)7–14–36/37/39–47–60–61 |
|||
650–032–00-X |
xxxxxxxxxxxx (XXX) (2X, 3X)-, (2 S, 3 X)-, (2 R, 3 S)-, (2 X, 3 R)-2-(4-chlorfenyl)-3-cyklopropyl-1-(1H- 1,2,4-xxxxxxx-1-xx)xxxxx-2-xx |
— |
94361–06–5 |
Xxxx. xxx. 3; X63 Xx; R22 X; R50–53 |
Xn; N X: 22–50/53–63 S: (2-)36/37–60–61 |
XXXXXXX 2
XXXXXX XXXXXXXXXXXX XXXXX XXXXXXXXX S XXXXXXXXXXXX XXXXXXX A XXXXXXXXX
Xxx xxxxxxxx Xxxxxx 2001/59/XX,
Xx. xxxx. L 332, 28.12.2000, x. 81.
XXXXXXX 3X
XXXXXXXXXX XXXXXX XXX XXXXXXXX XXXXXXXXX X XXXXXXXXXXXX XXXXXXX X XXXXXXXXX
Xxx směrnice Xxxxxx 2001/59/XX,
Xx. xxxx. X 332, 28.12.2000, x. 81.
XXXXXXX 3X
XXXXXXXXXX XXXXXX XXX XXXXXXXX XXXXXXXXX X NEBEZPEČNÝMI XXXXXXX X XXXXXXXXX
Xxx směrnice Xxxxxx 2001/59/XX,
Xx. xxxx. X 332, 28.12.2000, x. 81.
XXXXXXX 4A
"B.10 XXXXXXXXXX — ZKOUŠKA NA XXXXXXXXXXXX XXXXXXX X XXXXX XX XXXXX
1. XXXXXX
Xxxx metoda je xxxxxxxx xxxxxx XXXX XX 473 — Xxxxxxx na xxxxxxxxxxxx xxxxxxx u xxxxx xx xxxxx (1997).
1.1 XXXX
Xxxxxxx na xxxxxxxxxxxx xxxxxxx u xxxxx xx vitro xx xxxxxxxxxxxxx činitele, xxxxx xxxxxxxxx xxxxxxxxxx xxxxxxxxxxxx xxxxxxx v xxxxxxxxxxxxx xxxxxxx xxxxx (1, 2, 3). Rozlišují xx xxx typy xxxxxxxxxxxx aberací: xxxxxxxxxxxx x xxxxxxxxxxxx. X xxxxxxx chemických mutagenů xxxx xxxxxxxxxx xxxxxxx xxxxxxxxxxxxxx xxxx, xxxxx xxxxxxxxxxxx aberace xx xxxxxx xxxxxxxxx. Xxxxxx xxxxxxxxxxx může znamenat, xx xxxxxxxx látka xx xxxxxxxxx xxxxxxxxx xxxxxxxxx xxxxxxx. Xxxx xxxxxx xxxx není xxxxxx xx stanovení xxxxxxxxxxx xxxxxxx a xxxx x xxxxxx xxxxx rutinně xxxxxxxxx. Xxxxxxxxxxxx mutace x xxxxxxx jevy xxxx xxxxxxxx mnoha xxxxxxxxx xxxxxxxxxxx chorob x xxxxxxx x existuje xxxxx xxxxxx o xxx, že xxxxxxxxxxxx xxxxxx a s xxxx xxxxxxxxxxx xxxx xxxxxxxxxxx změny v xxxxxxxxxx x x xxxxxx somatických xxxxx xxxxxxxxx xxxxxx, xxxx xxxxx xx xxxxxxx xxxxxxxx x xxxxxxx x x xxxxxxxxx xxxxxx.
Xx xxxxxxx xx xxxxxxxxxxxx xxxxxxx xx xxxxx xxxxx xxx xxxxxxx xxxxxxxxxxxxx buněčné xxxxx, buněčné xxxxx xxxx xxxxxxxx buněčné xxxxxxx. Xxxxxxx xxxxx xxxx xxxxxxx na xxxxxxx xxxxxxxxxx xxxxx x kultuře, xxxxxxxx xxxxxxxxx, xxxxx xxxxxxxxxx, xxxxxxxxxxxx xxxxxxxxxx x xxxxxxxxx xxxxxxxx xxxxxxxxxxxxxx xxxxxxx.
Xxxxxxx xxxxxxxxx in xxxxx obecně xxxxxxxx xxxxxxx xxxxxxxx xxxxxx xxxxxxxxxxx xxxxxxxx. Xxxxx xxxxxxxxxxx xxxxxxxxx systém xxxxxx zcela xxxxxxxxx xxxxxxxx xx vivo x xxxxx. Xx xxxxx xx xxxxx xxxxxxxxx podmínek, xxxxx xx xxxxx k xxxxxxxxxx výsledkům, jež xxxxxxxxxx xxxxxxx xxxxxxxxxx x xxxx x xxx xxxxx změnou xX, xxxxxxxxxx xxxx xxxxxxxx xxxxxx cytotoxicity (4, 5).
Xxxx xxxxxxx xx xxxxxxx ke xxxxxxxx xxxxxxx mutagenů x xxxxxxxxxxx xxx xxxxx. Mnoho sloučenin, xxx xxx xx xxxx zkouška pozitivní, xxxx xxx savce xxxxxxxxxxx; xxxx xxxxx xxxxxxxx x karcinogenitou xxxx není xxxxxxxxx xxxxxxxx. Korelace xxxxxx xx xxxxxxxx třídě x xxxxxxxxx důkazy x tom, xx xxxxxxxx xxxxxxxxxxx, xxxxx xxxxxx zjištěny xxxxx xxxxxxxx, neboť zřejmě xxxxxx jinými mechanismy xxx přímým poškozením XXX.
Xxx také Xxxxxx xxxx, část X.
1.2 XXXXXXXX
Xxxxxxxxxxxx aberace : xxxxxxxxxx xxxxxxxxx xxxxxxxxxx x podobě xxxxx xxxxxxxxxxxx xxxxxxxxx xxxx xxxxx x xxxxxxxx xxxxxxx xxxxxxxxx.
Xxxxxxxxxxxx xxxxxxx : xxxxxxxxxx xxxxxxxxx xxxxxxxxxx v podobě xxxxx nebo zlomu x xxxxxxx obou xxxxxxxxx x tomtéž xxxxx.
Xxxxxxxxxxxxxxx : proces, xxx xxxxxx v xxxxx po X-xxxx xxxxxxxxx DNA xxxxxxx x xxxxxx, xxxxx xxxxxxxxx xxxxx X-xxxx. Xxxxxxxxx xxxx xxxxxxxxxx xx 4, 8, 16… xxxxxxxxxxxx.
Xxx : xxxxxxxxxxxx xxxx menší xxx xxxxx xxxxx xxxxxxxxxx x s xxxxxxxxx odchylkou xxxxxxxxx.
Xxxxxxxxx xxxxx : xxxxx xxxxx, xxxxx xx xxxxxxxxx x xxxxxxxx, x xxxxxxxxx počtu xxxxx x xxxxxxxx; xxxxx xxxxxx proliferace xxxx xxxxxxxx.
Xxxxxxxxx xxxxxxx : xxxxxxxx xxxxx xxxxxxxxxx od xxxxxxxxxx xxxxx xxxxxxxxx x xxxxxxxxx typu xxxxx.
Xxxxxxxxxxx : násobek haploidního xxxxx xxxxxxxxxxxxxx xxx (x), jiný xxx xxxxxxxxx (xx. 3 x, 4 x xxx.).
Xxxxxxxxxx xxxxxxx : xxxxxxxxxxxxx xxxxxxxxxxxxx změny xxxxxxxxx xxxxxxxxxx xxx xxxxxxxx dělení xx xxxxxx xxxxxxxx; xxxx xx xxxx xxxxxx x fragmenty, xxxxxxxxxxxxxxxxxx xxxx xxxxxxxxxxxxxxxxxx xxxxx.
1.3 XXXXXXXX ZKUŠEBNÍ METODY
Buněčné xxxxxxx jsou vystaveny xxxxxxxx xxxxx, x xx x xxxxxxxxxxxx xxxxxxxx x xxx xx. X xxxxxx xxxxxxxxxxx xxxxxxxxxxx xx xxxxxxxx xxxxx xx xx buněčných kultur xxxxx xxxxx xxxxxxxxxxx xxxxxxxx (xxxx. Xxxxxxxx® xxxx kolchicin), xxxxxxx xx xxxxxx, xxxxxx x přítomnost xxxxxxxxxxxxxx xxxxxxx se xxxxxx xxxxxxxxxxxxxx pozorováním buněk.
1.4 XXXXX XXXXXXXX METODY
1.4.1 Xxxxxxxxx
1.4.1.1 Xxxxx
Xxxxx xxx xxxxxxx xxxxx xxxxxxx xxxxx, xxxxx xxxx xxxxxxxx xxxxxxx xxxxxxx, xxxxxx xxxxxxxx xxxxxxxxx xxxxx (xxxx. xxxxxxxxxxx xxxxxx čínského, xxxxxxxxx xxxxxxxxx xxxx xxxxxxx xxxx jiných savců).
1.4.1.2 Xxxxx x xxxxxxxxxx xxxxxxxx
Xxx udržování xxxxxx xx xxxx xxx xxxxxxx xxxxxx kultivační xxxxx x xxxxxxxxx xxxxxxxx (xxxxxxxxxx nádoby, xxxxxxxxxxx CO2, xxxxxxx x xxxxxxx). U xxxxxxxxxxxxxxx xxxxxxxxx xxxxx x xxxxx xx xxxx xxx rutinně xxxxxxxxxxxx stabilita modální xxxxxxx xxxxx xxxxxxxxxx x mělo xx xxx xxxxxxxxxxxx, zda xxxxxx xxxxxxxxxxxxx mykoplasmaty; x xxxxxxx kontaminace xx xxxxxx xxx xxxxxxx. Xxx xxxxxxx xxxxx x xxxxxxxxx xxxxxxxx xx xxxx xxx xxxxx xxxxxxxx xxxxx buněčného xxxxx.
1.4.1.3 Xxxxxxxx kultur
Stabilizované xxxxxxx xxxxx x kmeny: xxxxx xx xxxxxxx x xxxxxxxxx xxxxxx, xxxxxx se do xxxxxxxxxxxx xxxxx v xxxxxx hustotě, aby xxxxxxxxx xxxxxxxxxx před xxxxxxxxx, x xxxxxxxx xx xxx 37 °X.
Xxxxxxxxx: xxxx xxxxxxxx xxxxxxxxxxxxxxx (xxxx. xxxxxxxxx) xxxx xxxxxxxx lymfocyty xxxxxxxx probandů se xxxxxxx xx kultivačního xxxxx xxxxxxxxxxxx xxxxxxx (xxxx. fytohemaglutinin) x xxxxxxxx xx xxx 37 °C.
1.4.1.4 Xxxxxxxxxxx xxxxxxxx
Xxxxx by xxxx xxx xxxxxxxxx xxxxxxxx xxxxx, x to x vhodnou xxxxxxxxxxxx xxxxxxxx x xxx xx. Nejčastěji používaným xxxxxxxx je xxxxxxxxxx xxxxxxxx postmitochondriální xxxxxx (X9) xxxxxxxxxx x xxxxx xxxxxxxx xxxxxxxxxx xxxxxxxx indukujícím xxxxxx, xxxx xx Xxxxxxx 1254 (6, 7, 8 x 9), xxxx xxxx xxxxxxxxxxxxx x β-xxxxxxxxxxxx (10, 11 x 12).
Postmitochondriální xxxxxx je x xxxxxxxx xxxxxxxxxx xxxxx xxxxxxx xxxxxxxxx x xxxxxxxxxxxxx 1 — 10 % obj. Xxxx xxxxxxxxxxxxx xxxxxxxxxxx xxxxxxx xxxx záviset xx xxxxx xxxxxxxx xxxxx, která xx xxxxxxxx. X některých xxxxxxxxx může xxx xxxxxx xxxxxx více xxx xxxxx xxxxxxxxxxx xxxxxxxxxxxxxxxxxxx xxxxxx.
Xxxx výsledků xxxxxx, včetně xxxxxxxx xxxxxxxxx modifikovaných buněčných xxxxx exprimujících xxxxxxxxxx xxxxxxxxx xxxxxx, poskytuje xxxxxxxx pro xxxxxxxxx xxxxxxxx. Xxxxx xxxxxxxxx xxxxxxxxx xxxxx by xxxx xxx xxxxxxx xxxxxxxxxx (xxxx. xxxxxxxxxxx xxxxxxxxx xxxxxxxxxx P450 xxx metabolismus xxxxxxxx xxxxx).
1.4.1.5 Zkoušená xxxxx/xxxxxxxx
Xxxxx xxxxxxxx xxxxx by xxxx xxx xxxx xxxxxxxx na xxxxx xxxxxxxxxx nebo xxxxxxxxxxxx xx xxxxxxxx xxxxxxxxxxxxxx xxxx xxxxxxxxxx x xxxxxxxxx xxxxxxx. Kapalné xxxxxxxx xxxxx xxxxx xxx přidány xxxxx x xxxxxxxxxx xxxxxxxx x/xxxx xxxxx xxx xxxx xxxxxxxx xxxxxxx. Xxxx xx xxx xxxxxxx xxxxxxx připravené xxxxxxxx látky, xxxxx xxxxx o xxxxxxxx xxxxxxxxxxx xxxxxxx xxxxxxxxxx.
1.4.2 Xxxxxxxx podmínky
1.4.2.1 Rozpouštědlo/vehikulum
Rozpouštědlo/vehikulum xx xxxx xxx xxxx xxxxxxxxx, xx xxxxxxx se xxxxxxxxx xxxxxx, x xxxx xx xxx slučitelné x xxxxxxxx xxxxx x s xxxxxxxxx X9. Xxxx-xx použita xxxx než známá xxxxxxxxxxxx/xxxxxxxx, mělo by xxx xxxxxx xxxxxxxx xxxxxxxxx xxxxx x xxxxxx kompatibilitě. Xxxxxxxxxx xx pokud xxxxx xxxxxxxx zvážit xxxxxxx xxxxxxx xxxxxxxxxxxx/xxxxxxx. Xxx xxxxxxxx látek xxxxxxxxx xx vodě xx xxxx xxx použita xxxxxxxxx xxxxxxxxxxxx neobsahující xxxx. Xxxx xxx xxxxxxxxx xxxxxxxx molekulového xxxx.
1.4.2.2 Xxxxxxxxx koncentrace
Mezi xxxxxxxx, xxxxx xxxx xxx xxxxxxxxxx xxx xxxxxxxxx xxxxxxxx koncentrace, xxxxx xxxxxxxxxxxx, rozpustnost x testovacím xxxxxxx x xxxxx xX xxxx osmolality.
Cytotoxicita xx xxxx být xxxxxxxxx x metabolickou aktivací x xxx xx x xxxxxxx xxxxxxxxxxx xx xxxxxxx xxxxxxxx xxxxxxxxxx buněčné xxxxxxxxx x růstu, xxxx xxxx xxxxxx xxxxxxxxxx, xxxxx životaschopných xxxxx xxxx xxxxxxxxx xxxxx. Xxxx xxx xxxxxxx xxxxxxxx xxxxxxxxxxxx x xxxxxxxxxxx v xxxxxxxxxx xxxxxxxxxxx.
Xxxx xx být xxxxxxx xxxxxxx xxx xxxxxxxxxxxxxx xxxxxxxxxxx. V xxxxxxx xxxxxxxxxxxx xx xxxx xxxx koncentrace xxxxxxxx xxxxxxx xxxx xxxxxxxxx xx xxxxxxxxx xxxxxxxxx, xxxxxxxx žádnou xxxxxxxxx, xxx xxxxxxx xxxxxxx, xx by xx xxxxxxxxxxx xxxxxx xxxxx xxxx xxxxx xxxxxxxx 2 xx Ö10. X okamžiku xxxxxxx xx xxxx xxxxxxxx xxxxxxxxxxx vykazovat xxxxxxxx xxxxxxx xxxxxx xxxxxxxxxx, počtu xxxxx xxxx xxxxxxxxxxx xxxxxx (xxx o více xxx 50 %). Xxxxxxxxx index xx xxxxx nepřímým xxxxxxxx xxxxxxxxxxxxx nebo xxxxxxxxxxxxxx xxxxxx x xxxxxx xx době, xxxxx xxxxxxxx xx expozice. Xxxxxxxxx xxxxx xx xxxx přijatelný u xxxxxxxxxxx xxxxxx, x xxxxx xxxxx xxx xxxx metody xxxxxxxxx xxxxxxxx obtížné x xxxxxxxxxxx. Xxxxxxxxx x xxxxxxxx buněčného cyklu, xxxxxxxxx průměrná xxxxxxxxx xxxx (XXX), xxxxx xxx xxxxxxx xxxx xxxxxxxxx xxxxxxxxx. X xxxxxxx XXX xxxx xxx x celkovou xxxxxxxxx hodnotu, z xxx xxxxx xxxxxxx xx existenci zpožděných xxxxxxxxxxx, x x xxxx přírůstek xxxxxxxx xxxxxxxxx doby může xxx za xxxxxxxx xxxxx xxxxxxxxx oddálení xxxxxxxx xxxxxxxxxxx xxxxxxx xxxxxxx.
X xxxxxxx xxxxxxxxx xxxxxxxxxxxxxxx xxxxx xx xxxx xxx maximální xxxxxxxx xxxxxxxxxxx 5 μx/xx, 5 mg/ml xxxx 0,01 M, xxxxx xxxx, xxxxx x nich xx xxxxxxxx.
X případě xxxxxxxxx xxxxxxxxxxxxx xxxxx, xxxxx xxxxxx xxxxxxx xxx xxxxxxxxxxxxx xxxxxxx, xxx xx jejich rozpustnost, xx xxxx být xxxxxxx xxxxxxxx dávka x xxxxxxxxxxx, xxx xx xxx mezí xxxxxxxxxxxx x xxxxxxxx xxxxxxxxxxx médiu xx xxxxx xxxx xxxxxxxx. X určitých xxxxxxxxx (xxxx. xxxxxxx-xx se xxxxxxxx xxxxx xxx xxxxxxx xxxxxxxxxxxxx, xxx xx xxxxxxxxxxx) se xxxxxxxxxx vyzkoušet více xxxxxxxxxxx, xxx xxxxx xxxxxxx ke xxxxxxx. Xxxx být xxxxxxxx xxxxxxxx xxxxxxxxxxx xx xxxxxxx x xx xxxxx xxxxxxxx, xxxxx xxxxxxxxxxx x xxxxxxxxxx xxxxxxx xx xxxx x průběhu expozice xxxxx v xxxxxxxx xxxxxxxxxxx xxxxx, xxxx X9 atd. Xxxxxxxxxxxxx xxx xxxxxxx xxxxxxxx. Xxxxxxxxx by neměla xxxxx xxx xxxxxxxxxxx.
1.4.2.3 Xxxxxxxxx x xxxxxxxxx xxxxxxxx
Xxxxxxxx xxxxxxx xxxxxxxxxxx xx měly xxx xxxxxxxxx a xxxxxxxxx xxxxxxxx (xxxxxxxx rozpouštědla xxxx vehikula). Xxx xxxxxxx xxxxxxxxxxx xxxxxxxx xx xxxx být xxx xxxxxxxxx xxxxxxxx xxxxxxx xxxxxxxx xxxxx, xxxxx x xxxxxxxxx xxxxxx xxxxxxxx xxxxxxxx.
X xxxxxxxxx xxxxxxxx xx xxx xxx xxxxxx xxxxx xxxxxxxxx v xxxxxxxxxxx xxxxxxxxxxxxx, které xxxxxxxx xxxxxxxxx xxxxxxxxxxxxxxxx x xxxxxxxxxxxxx xxxxxx xxx pozadí, xxxx xx xxxxxxx xxxxxxxxx xxxxxxxxxxx systému.
Koncentrace xxxxxxxxxxx xxxxxxx xx xxxx xxx zvoleny tak, xxx xxx xxxxxx xxxxxxxx, xxx xxx xxx xxxxxx xxxxxxx xxxxx najevo xxxxxxxx xxxxxxxxxxxx xxxxxxxxx. Xxxxxxxx xxxxxxxxxxx x xxxxxxxxxxx xxxxxxx:
Xxxx metabolické xxxxxxxx |
Xxxxx |
Xxxxx XXX |
Xxxxx podle XXXXXX |
Xxx xxxxxx xxxxxxxxxxx xxxxxxxx |
xxxxxx-xxxxxxxxxxxxxx |
66–27–3 |
200–625–0 |
xxxxx-xxxxxxxxxxxxxx |
62–50–0 |
200–536–7 |
|
1-xxxxx-1-xxxxxxxxxxxxxxx |
759–73–9 |
212–072–2 |
|
xxxxxxxxx X |
50–07–7 |
200–008–6 |
|
4-xxxxxxxxxxxxx-1-xxxx |
56–57–5 |
200–281–1 |
|
X xxxxxx xxxxxxxxxxxx xxxxxxxx |
xxxxx[x]xxxxx |
50–32–8 |
200–028–5 |
xxxxxxxxxxxxx |
50–18–0 |
200–015–4 |
|
xxxxxxxxxxxxx monohydrát |
6055–19–2 |
Pro pozitivní xxxxxxxx xxxxx xxx xxxxxxx x jiné xxxxxx xxxxx. Xxx xxxxxxxxx kontrolu xx xxxx být pokud xxxxx xxxxx x xxxxx xxxxxxx xxxxxxxxxx xxxxx xx xxxxxx xxxxxxxx třídy.
V xxxxxxxx xxxxxxxx xx xxxx xxx xxxxxxx negativní xxxxxxxx xxxxxxxxxx xx xx xxxxxxxxx xxxxxxxxxxxx xxxx vehikula x xxxxxxxxxxx médiu x xxxxxxxxxx stejným xxxxxxxx xxxx kultury. Xxxxx xxxx xx xxxx xxx neexponované xxxxxxxx xxxxxxx xxxx xxxxx, xxxxxxxxxx-xx xxxxx xxxxx xxxxxxxxx xxxxx xxxxxxxxxxx, xx xxxxxxx xxxxxxxxxxxx xxxxxxxxxx xxxxx xxxxxxx xxxx xxxxxxxxx účinky.
1.4.3 Xxxxxx
1.4.3.1 Xxxxxxxx xxxxxxxx xxxxx
Xxxxxxxxxxxxx xxxxx xx xxxxxxx xxxxxxxx xxxxx xxx za xxxxxxxxxxx xxxxxxxxxxxxx aktivačního systému, xxx xxx něho. Xxxxxxxx xxxxxxxxx by xxxx xxx xxxxxxxx xxx 48 xxxxx xx xxxxxxxxx xxxxxxxxx.
1.4.3.2 Xxx xxxxxx xxxxxxxxxxx xx měly být xxxxxxx xxxxxxx duplicitní xxxxxxx, x totéž xx xxxxxxx xxxxxxxxxx x xxxxxx pro xxxxxxxxx xxxxxxxx xxxx xxxxxxxx rozpouštědla. Jestliže xxx xx základě xxxxxxxxxxx xxxxx xxxxxxxx (13, 14), xx xxxx xxxxxxxxxxxx xxxxxxxxx xx xxxxxxxxx xxxxxx, xxxx xxx xxxxxxxxx xxxxxxx jediné kultury.
Plynné xxxx xxxxxx látky xx xxxx xxx xxxxxxxx vhodnými xxxxxxxx, xxxx. x xxxxx xxxxxxxxxx xxxxxxxxxxxx xxxxxxxx (15, 16).
1.4.3.3 Xxxx xxxxxxx xxxxxx
X xxxxxx xxxxxxxxxxx xx měly xxx xxxxx vystaveny xxxxxxxx látce, xxx x xxxxxxxxxxxx xxxxxxxx, xxx xxx xx, xx dobu 3 — 6 xxxxx, x xxxx by xxx odebrány xx xxxxxx xxxx od xxxxxxxx aplikace, která xxxxxxxx 1,5xxxxxxx normální xxxxx xxxxxxxxx cyklu (12). Xxxxxxxx tento xxxxxx xxxx xxxxxxxxx xxxxxxxx xxx s xxxxxxxx, xxx xxx xxxxxxxx, xxx xx xxx xxxxxxxx xxxxxxxxx xxxxxxxxxx xxx aktivace x xxxxxxxxxxxx expozicí xx xx xxxxxx x xxxx, která xxxxxxxx 1,5násobku xxxxxxxx xxxxx xxxxxxxxx xxxxx. Xxxxxx chemické látky xxx xxxxx detekovat xxx xxxxxx xxxxxxxx xxxx odběru xxxxxxx xxx 1,5xxxxxxx délky xxxxx. Xxxxxxxxx xxxxxxxx xxx xxxxxxxxxxx xxxxxxxx xxxx být potvrzeny xxxxxx od xxxxxxx. X xxxxxxxxx, kdy xx xxxxxxxxxx xxxxxxxxx xxxxxxxxxxx xxxxxxxx za xxxxxxxx, by xxxx xxx xxxxxx xxxxxxxxxx.
1.4.3.4 Xxxxxxxx preparátů xxx xxxxxxx xxxxxxxxxx
Xx buněčné xxxxxxx xx xxxxxxx 1-3 xxxxxx xxxx xxxxxxxxx přidá Colcemid® xxxx xxxxxxxxx. Xxx xxxxxxxx xxxxxxxxx pro xxxxxxx xxxxxxxxxx xx xxxxx xxxxxxx kultura xxxxxx a zpracovává xxxxxx. Xxxxxxxx preparátů xxx analýzu xxxxxxxxxx xxxxxxxx xxxxxxxxxxxx buněk, xxxxxx x xxxxxxxx xxxxx.
1.4.3.5 Xxxxxxx
Xxxxxxx preparáty, xxxxxx xxxxxxxxx xxxxxxxxxxx x xxxxxxxxxxx xxxxxxx, xx xxxx xxx xxxx xxxxxxxx pod xxxxxxxxxxx xxxxxxxxx kódovány. Xxxxxxxx xxx xxxxxx xxxxx xxxxxxx xx xxxxx xxxxx xxxxx x metafázi a xx xxxxxx chromozomů, xxxx xx xxxxxxxxxxx xxxxx xxxxxxxxx centromery x xxxxx xxxxxx xxxxxxx xxxxxxx ± 2 pro xxxxxxx xxxx xxxxx. Xx xxxxxx koncentraci x xxxxxxxx xx xxxx xxx xxxxxxxxx xxxxxxx 200 xxxxx xxxxxxxxxxxxxx xxxxxxxx, xxxxxxxx rovnoměrně xxxxxxxxxxx xxxx xxxxxxxxxx xxxxxxx. Tento počet xxx snížit, je-li xxxxxxxxx velký počet xxxxxxx.
Xxxxxx xx xxxxxx xxxxxxx xxxxxxxxx strukturní xxxxxxxxxxxx xxxxxxx, je xxxxxxxx zaznamenat xxxxxxxxxxx x endoreduplikace, xxxx-xx xxxxxxxxxx.
2. XXXXX
2.1 ZPRACOVÁNÍ XXXXXXXX
Xxxxxxxxxxxxxx jednotkou xx xxxxx x mělo xx tedy být xxxxxxxxxxx xxxxxxxx xxxxx xx xxxxxxxxxx chromozomovou xxxxxxx (xxxxxxxxx) xxxxxxxxx x xxxxxxxxxx. Xxx xxxxxxxxx x xxxxxxxxxxxxxx xxxxxxx by xxxx xxx xxxxxxx xxxxx xxxx xxxxxxxxxxxx chromozomových xxxxxxx x xxxxxx xxxxxx x četností. Xxxx xx zaznamenávají xxxxxxxx a xxxxxxx xx, ale xxxxxxxxxx xx xx xxxxxxx xxxxxxxx xxxxxxx.
Xxxx xx xxx také xxxxxxxxxxx xxxxxxxx, která byla xxxxxxxxx xxx xxxxxxxxx xxxxxxxxxxxx x xxxxx xxxxxxxxxxxx kultur x xxxxxxxxxxx xxxxxx x xxxxxxxx experimentech x xxxxxxxxx.
Xxxx xx xxx xxxxxxx xxxxx pro xxxxxxxxxx xxxxxxx. Dále xx měly xxx xxxxxxx xxxxx xxxxxxx xx xxxxx tabulky.
Ověření xxxxx pozitivní xxxxxxxx xx xxxxxxxxxx. Xxxxxxxxxx xxxxxxxx xx xxxx xxx xxxxxxxxx xxxxxx xxxxxxxxx, xxxxxxx s xxxxxxxx xxxxxxxxxxxxxxxx xxxxxxxx. Xxxxxxxxxx xxxxxxxx negativní xxxxxxxx xxxx diskutována x xxxx 1.4.3.3. Xxxxx parametrů xxxxxx x xxxxx xxxxxxxx xxxxxx xxxxxxxxxxxx podmínek xx měla xxx xxxxxxx v xxxxxxxxxx xxxxxxxxxxxxx. X xxxxxxxxxx xxxxxx, xxxxx by xxxxx xxx xxxxxxx, xxxxx xxxxxxx koncentrací x xxxxxxxx xxxxxxxxxxx xxxxxxxx.
2.2 HODNOCENÍ A XXXXXXXXXXXX XXXXXXXX
Xxx xxxxxxxxx xxxxxxxxxxx xxxxxxxx xxxxxxxx xxxxxxx xxxxxxxx, xxxx. xxxxxx počtu xxxxx x xxxxxxxxxxxxxx xxxxxxxxx x xxxxxxxxxx xx xxxxxxxxxxx, nebo xxxxxxxxxxxxxxxx xxxxxx xxxxxx xxxxx. Xxxxxxxx xx měla xxx xxxxxxx biologická xxxxxxxxx výsledků. Při xxxxxxxxx xxxxxxxx xxxxxxx xxxxx xxx xxxxxxx xxxx pomocný xxxxxxxxxx xxxxxxxxxxx xxxxxx (3, 13). Statistická xxxxxxxxxx xx xxxxxx být xxxxxxx xxxxxxxxx faktorem xxx xxxxxxxxx xxxxxxx.
Xxxxxx xxxxx xxxxxxxxxxx xxxxx xxxx znamenat, že xxxxxxxx xxxxx xx xxxxxxxxx xxxxxxxx mitotické xxxxxxx x indukovat xxxxxxxxx chromozomové xxxxxxx. Xxxxxx xxxxx buněk x xxxxxxxxxxxxxxxxxxx xxxxxxxxxx xxxx xxxxxxxx, že xxxxxxxx xxxxx má xxxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxxx cyklu (17, 18).
Xxxxxxxx xxxxx, xxxxx xxxxxxxx xxxxxxxxx xxxx xxxxxxx kritéria, se x xxxxx xxxxxxx xxxxxxxx xx xxxxxxxxxxx.
Xxxxxx xxxxxxx xxxxxxxxxxx poskytne xxxxx pozitivní xxxx xxxxxxxxx xxxxxxxx, x xxxxxxxxxxx případech xxxxxxxx xxxxxx xxxxx xxxxxxxx xxxxxxx xxxxx x xxxxxxxx xxxxxxxx xxxxx. Xxxxxxxx xxxxx zůstat xxxxxxxxxx xxxx xxxxxx xxx ohledu xx xx, kolikrát je xxxxxxxxxx opakován.
Pozitivní výsledky xx xxxxxxx xx xxxxxxxxxxxx xxxxxxx xx xxxxx znamenají, xx xxxxxxxx xxxxx indukuje x xxxxxxxxxxxxx somatických xxxxxxx savců xxxxxxxxxx xxxxxxxxxxxx xxxxxxx. Xxxxxxxxx xxxxxxxx xxxxxxxxx, xx xxxxxxxx xxxxx za xxxxxxxx zkoušky xxxxxxxxxx x xxxxxxxxxxxxx xxxxxxxxxxx xxxxxxx xxxxx xxxxxxxxxx xxxxxxxxxxxx aberace.
3. ZPRÁVY
PROTOKOL X XXXXXXX
Xxxxxxxx o xxxxxxx musí xxxxxxxxx xxxx xxxxxxxxx:
Xxxxxxxxxxxx/xxxxxxxxx:
- zdůvodnění xxxxx xxxxxxxx,
- xxxxxxxxxxx x xxxxxxx xxxxxxxx xxxxx x xxxxxxxxxxxx/xxxxxxxx, xx-xx xxxxx.
Xxxxx:
- xxx x xxxxx xxxxx,
- xxxxxxxxxx xxxxxxxxx x xxxxxxxx použitého xxxx xxxxx,
- xxxxxxxxx xxxxxxxxxxxx xxxxxxxxxxx,
- informace x xxxxx buněčného cyklu,
- xxxxxxx dárce xxxx, xxx xxxx xxxxxxx xxxx xxxx xxxx xxxxxxxxxx lymfocyty, xxxxxxx xxxxxxx,
- xxxxxxxx xxxxx xxxxxx,
- xxxxxxxx metody xxxxxxxxx xxxxxxx xxxxxxx,
- xxxxxxx hodnota xxxxx xxxxxxxxxx.
Xxxxxxxx xxxxxxxx:
- xxxxxxxxxxxx xxxxx xxxxxxxxxxx xxxxxxxx, xxxx xxxxxxxxxxx x xxxxx expozice xxxxx,
- xxxxxxxxxx výběru xxxxxxxxxxx x xxxxx kultur, xxxxxx xxxx. xxxxx x cytotoxicitě a xxxxxx rozpustnosti, xxxx-xx x xxxxxxxxx,
- xxxxxxx xxxxx, případně koncentrace XX2,
- xxxxxxxxxxx xxxxxxxx xxxxx,
- xxxxx xxxxxxxx x xxxxxxx zkoušené xxxxx,
- xxxxxxxxx teplota,
- xxxxxxxxx xxxx,
- délka xxxxxxxx,
- xxxxxxxx xxxxxxx xxxxx xxx xxxxxxxx,
- xxx x xxxxxxx xxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxx xxxxxxx, včetně xxxxxxxx xxxxxxxxxxxxx,
- xxxxxxxxx a xxxxxxxxx kontroly,
- metody xxxxxxxx xxxxxxxxx,
- xxxxxxxx xxxxxxxxx aberací,
- xxxxx xxxxxxxxxxxxx xxxxxxxx,
- metody xxxxxxxxx xxxxxxxx,
- xxxxxxxx xxxxxxxxxxx xxxxxx xx xxxxxxxxx, xxxxxxxxx xxxx xxxxxxxxxxx.
Xxxxxxxx:
- xxxxxx toxicity, xxxx. stupeň xxxxxxxxxx, xxxxx o xxxxxxxx xxxxx, xxxxx buněk, xxxxxxxxx xxxxx,
- známky xxxxxxx,
- údaje x xX a xxxxxxxxxx xxxxxxxxxxx média, xxxxx xxxx xxxxxxxxx,
- xxxxxxxx xxxxxxx, xxxxxx gapů,
- xxxxx buněk x xxxxxxxxxxxxxx aberacemi x xxxx aberací xxxxxx xxx každou xxxxxxxxxxx x kontrolní kulturu,
- xxxxx xxxxxxx, xxxxx xxxx xxxxxxxxxx,
- xxxxx xxxxxxxx xxxxxxxxx xxxxxxxx xx xxxxx,
- xxxxxxxx xxxxxxxxxxx analýzy,
- údaje x xxxxxxxx negativní (xxxxxxxxxxxx/xxxxxxxxx) a xxxxxxxxx xxxxxxxx,
- xxxxxxxxx xxxxx x xxxxxxxxx (xxxxxxxxxxxx/xxxxxxxxx) x xxxxxxxxx xxxxxxxx x xxxxxxxxx, středními xxxxxxxxx a xxxxxxxxxxxx xxxxxxxxxx.
Xxxxxx xxxxxxxx.
Xxxxxx.
4. LITERATURA
1) Xxxxx, X. X. (1976), Xxxxxxxxxxx Methods xxx Detecting Chemical Xxxxxxxx, xx: Chemical Xxxxxxxx, Xxxxxxxxxx xxx Xxxxxxx for xxxxx Xxxxxxxxx, Vol. 4, Xxxxxxxxxx, X. (xx) Xxxxxx Press, Xxx Xxxx xxx London, 1-29.
2) Xxxxxxxx, M. Xx., Sofumi, X. (1985), Xxx Xx xxxxx Chromozomal Xxxxxxxxxx Xxxx Using Chinese Xxxxxxx Xxxx (CHL) Xxxxxxxxxx Xxxxx xx Xxxxxxx, in: Xxxxxxxx xx Xxxxxxxxxx Xxxxxxxx, Xxx. 5, Xxxxx, X. xx al., (xxx) Xxxxxxxx Science Xxxxxxxxxx, Amsterdam-New Xxxx-Xxxxxx, 427-432.
3) Xxxxxxxx, S. X., Xxxxxxxxx, M. X., Xxxxxx, X., Xxxxxx, X., Brown, X., Xxxxxx, X., Xxxxx, X. X., Xxxxxxxx, X., Xxxxx, X., Duk, X., Xxxxx, J., Margolin, X. X., Xxxxxxx, X. X., Anderson, X., Xxxxxx X. (1978), Xxxxxxxxxx aberration xxx sister xxxxxxxxx xxxxxxxxx xx Chinese xxxxxxx ovary xxxxx: Xxxxxxxxxx of 108 xxxxxxxxx, Environ. Molec. Xxxxxxx. 10 (xxxxx. 10), 1-175.
4) Scott, X., Xxxxxxxx, X. X., Xxxxxxxx, X. X., Xxxxxxxx, M. Xx., Xxxxxxx, X., Xxxxx, X., Myhr, X. X. (1991), Xxxxxxxxxxxx xxxxx Xxxxxxx Xxxxxxx Xxxxxxxxxx. X xxxxxx xxxx ICPEMC Xxxx Group 9, Xxxxxxxxxx Xxx., 257, 147-204.
5) Xxxxxx, T., Xxxxxx, X., Xxxxxx, X., Okumura, X., (1992), Xxxxxxxxxxxxxx xx xxx pH to Xxxxxxx Xxxxxxxx Xxxxxxxxx Xxxxx, Xxxxxxxxxx Xxx., 268, 297-305.
6) Xxxx, X. X., McCann, X., Yamasaki, X. (1975), Methods xxx Xxxxxxxxx Carcinogens xxx Xxxxxxxx xxxx xxx Xxxxxxxxxx/Xxxxxxxxx Xxxxxxxxx Xxxxxxxxxxxx Xxxx, Xxxxxxxx Xxx., 31, 347-364.
7) Xxxxx, X. X., Xxxx, X. X. (1983), Xxxxxxx Xxxxxxx xxx xxx Xxxxxxxxxx Mutagenicity Xxxx, Xxxxxxxxxx Res., 113, 173-215.
8) Xxxxxxxxx, X. X., Tates, X. X., xxx Xxxx, P. X. X., Xxxxxxx, X., xx Xxxxx, X. (1976), Xxxxxxxxxxx Effects xx Xxxxxxx/Xxxxxxxxxxx after Xxxxxxxxxx xx x Xxxxxxxxxxx Xxxxxx Xx xxxxx, X. Xxxxxxxxx xx Chromozome Aberrations xxx Xxxxxx Chromatid Xxxxxxxx xx Diethylnitrosamine (XXX) and Xxxxxxxxxxxxxxxxxxx (XXX) xx CHO Xxxxx in the Xxxxxxxx xx Rat-Liver Xxxxxxxxxx, Xxxxxxxxxx Res., 37, 83-90.
9) Xxxxxxxx, X., Xxxxxxx, X., Xxxxxxxx, X. Xx. (1979), Xxxxxxxxxxx Xxxxxxxxxx Xxxxx on 29 Xxxxxxxxx Xxxxxxxx xxxx X9 Xxx Xx xxxxx, Mutation Xxx., 66, 277-290.
10) Xxxxxx, X. M., Xxxxxx, X. X., Xxxxxxx, X. R., Gatehouse, X. X., Xxxxxx, X. X., Mackay, X. X., Xxxx, X. C. (1992), Xxxxxx of XX Xxxxxxxxxxxxx Xxxxxxx Xxxxxxx Xxxxxxx Xxxxx. Alternative xx Xxxxxxx 1254-induced X9 xx In xxxxx Xxxxxxxxxxxx Xxxxxx, Xxxxxxxxxxx, 7, 175-177.
11) Xxxxxxxxxx, T., Xxxxxxxx, X., Xxxx, X., Xxxxxxxx, T. (1976), X. Safe Substitute xxx Xxxxxxxxxxxxxxx Biphenyls x. x. xx Xxxxxxx of Metabolic Xxxxxxxxxx Xxxxxxx, xx: xx Xxxxxx, F. X., Fouts, X. X. Bend, J. X., Xxxxxxx, X. X. (eds), In xxxxx Xxxxxxxxx Xxxxxxxxxx xx Xxxxxxxxxxx Testing, Xxxxxxxx, Xxxxx-Xxxxxxx, 85-88.
12) Xxxxxxxx, S. X., Xxxxxxx, M. X., Xxxxxxxx, X. Xx., Xxxxx, J. L., Xxxxxxxx, X. J., Xxxxxx, X., Xxxxxxx, X., Xxxxxx, X. (1994), Xxxxxx xxxx Xxxxxxx Xxxxx on Xx vitro Xxxxx xxx Chromozomal Xxxxxxxxxxx, Xxxxxxxxxx Xxx., 312, 241-261.
13) Xxxxxxxxxx, X., Xxxxxxxx, D. X., Xxxxx, X. X., Xxxxxxxx, G., Chanter, X. X., Xxxxxxxx, X. (1989), Xxxxxxxx xx Data from Xx xxxxx Xxxxxxxxxxx Xxxxxx, xx: Xxxxxxxxxxx Xxxxxxxxxx of Xxxxxxxxxxxx Xxxx Data, Kirkland, X. J., (xx) Xxxxxxxxx Xxxxxxxxxx Press, Xxxxxxxxx, 141-154.
14) Xxxxx, X. X., Xxxxxxxx, X. X. (1994), Xxxxxxxxx Xxxxxx xxx xxx Xxxxxxxxx xxx Xx xxxxx Xxxxxxxxxx Xxxxxxxxxx Xxxxxx xx XXX Cells, Mutatation Xxx., 312, 139-149.
15) Xxxxx, D. X., Xxxxxx, X. C., XxXxxxx, X. X. (1982), XXX/XXXXX Xxxxxxxx Xxxxx: Xxxxxxxxxx of Xxxxx xxx Xxxxxxxx Xxxxxxx, xx: Xxxx, X. R., Xxxxx, X. L., Xxxxxxx, X. X. (xxx), Xxxxxxxxx Effects xx Xxxxxxxx Xxxxxx, Xxx Xxxx, Plenum, 91-103.
16) Xxxxxx, P. X., Xxxxxx, X. X., Xx, X. X., Xxxxxx, X. L. (1983), Xxxxxxxxxx xx xx Exposure Xxxxxx Xxxxx Xxxxx Grown xx Xxxxxxxx Gels xxx Xxxxxxxxx Xxxxxx Xxxxxxxx Xxxxxxxx in xxx CHO/HGPRT Mutation Xxxxx, Environmental Xxxxxxx., 5, 795-801.
17) Xxxxx-Xxxxx, X. (1983), Xxxxxxxxxxxxxxxxx xx Xxxxxxx xxxxxxx xxxxx xxxxxx alpha-radiation xxxxxxx X2 arrest, Xxxxxxxxxx Xxx., 119, 403-413.
18) Huang, X., Xxxxxx, X., Xxxxxx, X. X. (1983), Xxxxxxxxxxx-xxxxxxx endoreduplication xx Xxxxxxx xxxxxxx cells, Xxxxxx Res., 43, 1362-1364."
XXXXXXX 4B
"B.11 XXXXXXXXXX–XXXXXXX XX CHROMOZOMOVÉ ABERACE X XXXXXXX KOSTNÍ XXXXX SAVCŮ IN XXXX
1. XXXXXX
Xxxx xxxxxx xx xxxxxxxx xxxxxx XXXX XX 475 — Zkouška xx xxxxxxxxxxxx aberace x xxxxxxx kostní xxxxx xxxxx (1997).
1.1 ÚVOD
Zkouška xx xxxxxxxxxxxx aberace x xxxxx xx xxxx xx xxxxxxxxx xxx xxxxxxx strukturních xxxxxxxxxxxxxx aberací indukovaných xxxxxxxxx xxxxxx v xxxxxxx xxxxxx dřeně xxxxx, xxxxxxx hlodavců (1, 2, 3, 4). Rozlišují se xxx typy xxxxxxxxxxxx xxxxxxx — xxxxxxxxxxxx x xxxxxxxxxxxx. Xxxxxx xxxxxxxxxxx xxxx znamenat, xx xxxxxxxx látka xx xxxxxxxxx indukovat xxxxxxxxx xxxxxxx. V xxxxxxx většiny xxxxxxxxxx xxxxxxxx xxxx xxxxxxxxxx xxxxxxx xxxxxxxxxxxxxx xxxx, xxxxx chromozomové aberace xx xxxxxx xxxxxxxxx. Xxxxxxxxxxxx xxxxxx a xxxxxxxxxxx jevy jsou xxxxxxxx xxxxx xxxxxxxxx xxxxxxxxxxx xxxxxx x xxxxxxx a xxxxxxxx xxxxx důkazů x xxx, že xxxxxxxxxxxx xxxxxx x xxxxxxxxxxx xxxx xxxxxxxxxxx xxxxx x onkogenech a x xxxxxx xxxxxxxxxxx xxxxx tlumících xxxxxx, xxxx xxxxx xx xxxxxxx xxxxxxxx u xxxxxxx a x xxxxxxxxxxxxxxxx xxxxxxxxx.
Xxx xxxx xxxxxxx xxxx xxxxxxx xxxxxxxxx xxxxxxxx. Cílovou xxxxx xx x xxxx xxxxxxx kostní xxxx, poněvadž xx xxxxxx vaskularizovanou xxxxx x obsahuje xxxxxxxx xxxxx s xxxxxxx xxxxxx, které xx xxxxxx xxxxxxx x xxxxxxxxxxxx. Xxxx druhy x xxxxxx xxxxx xxxxxx xxxxxxxxx xxxx xxxxxx.
Xxxx zkouška na xxxxxxxxxxxx xxxxxxx je xxxxxxx xxxxxx x xxxxxxxxx xxxxxxxxx xxxxxxxxxx, xxxxx xxxxxxxx zohlednit xxxxxxx xxxxxxxxxxx in xxxx, xxxxxxxxxxxxxxx x xxxxxxx xxxxxxxx DNA, xxxxxxx xx xxxxx x různých xxxxx x xxxxx xxxxx. Xxxxxxx xx vivo xx xxxxxx xxxxxxxx xxx xxxxx výzkum xxxxxxxxxxx xxxxxx zjištěných xxxxxxxx in xxxxx.
Xxxxxxxx xxxxxxxx xxxxx x xxx, že xx xxxxxxxx xxxxx xxxx xxxxxxxxx metabolity xxxxxxxxxx xx cílové tkáně, xxxx xxxxxx tuto xxxxxxx xxxxxx.
Xxx xxxx Xxxxxx xxxx, xxxx X.
1.2 XXXXXXXX
Xxxxxxxxxxxx aberace : xxxxxxxxxx poškození xxxxxxxxxx x podobě xxxxx xxxxxxxxxxxx xxxxxxxxx xxxx xxxxx a xxxxxxxx xxxxxxx xxxxxxxxx.
Xxxxxxxxxxxx xxxxxxx : xxxxxxxxxx xxxxxxxxx xxxxxxxxxx x xxxxxx zlomu nebo xxxxx x xxxxxxx xxxx xxxxxxxxx x xxxxxx xxxxx.
Xxxxxxxxxxxxxxx : xxxxxx, xxx xxxxxx x xxxxx xx X-xxxx xxxxxxxxx XXX xxxxxxx x xxxxxx, xxxxx xxxxxxxxx xxxxx X-xxxx. Xxxxxxxxx xxxx xxxxxxxxxx se 4, 8, 16,… chromatidami.
Gap : achromatická xxxx xxxxx xxx xxxxx xxxxxxx xxxxxxxxxx a x xxxxxxxxx xxxxxxxxx xxxxxxxxx.
Xxxxxxxxx aberace : xxxxxxxx xxxxx xxxxxxxxxx xx xxxxxxxx xxxxxxx xxxxxxx u xxxxxxxxx xxxxx.
Xxxxxxxxxxx : xxxxxxx xxxxxxxxxxx počtu chromozomových xxx (x), xxxx xxx xxxxxxxxx (tj. 3 n, 4 x xxx.).
Xxxxxxxxxx xxxxxxx : xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxx struktury xxxxxxxxxx xxx buněčném dělení xx xxxxxx metafáze; xxxx se xxxx xxxxxx a fragmenty, xxxxxxxxxxxxxxxxxx nebo xxxxxxxxxxxxxxxxxx xxxxx.
1.3 PODSTATA XXXXXXXX XXXXXX
Xxxxxxx xxxx xxxxxxxxx xxxxxxxx látce xxxxxxx xxxxxxxx x xx xxxxxxx xxxxxxxx po xxxxxxxx xx usmrtí. Xxxx xxxxxxxxx se xxxxxxxx podá látka xxxxxxxxxxx metafázi (xxxx. xxxxxxxxx xxxx Xxxxxxxx®). X buněk xxxxxx xxxxx xx poté xxxxxxxx xxxxxxxxx chromozomů, xxxxxx se x xxxxxxxxx se xxxxxxxxxxxx xxxxxxx buněk v xxxxxxxx.
1.4 POPIS XXXXXXXX XXXXXX
1.4.1 Xxxxxxxxx
1.4.1.1 Výběr xxxxx xxxxxxx
Xxxxx je xxxxxxxx potkan, xxx x xxxxxx čínský, xxxxxx lze xxxxxx xxxxxxxx vhodný xxxxx xxxx. Xxxx xx xxx xxxxxxx běžně xxxxxxx laboratorní xxxxx xxxxxxx xxxxxxxx xxxxxxxx xxxxxxxxx zvířat. V xxxxxxxx xxxxxxxx xxxxxx xx xxxx být xxxxxxxx x xxxxxxxxx xxxxxx minimální x xxxxxx by u xxxx xxxxxxx xxxxxxxxx ± 20 % xxxxxxx xxxxxxx xxxxxxxxx.
1.4.1.2 Xxxxxxxx xxxxx x xxxxxx
Xxxxx xxxxxx xxxxxxxx xxxxx xxxxxxxx xxxxx x části X, xxxxxxx xx mělo xxx xxxxxxxx xxxxxxxx xxxxxxx 50 – 60 %.
1.4.1.3 Xxxxxxxx xxxxxx
Xxxxxx xxxxx xxxxxxxx xxxxxxx xxxxxxx xx xxxxxxxx výběrem rozdělí xx kontrolní xxxxxxx x skupinu, xxxxx xx xxxxxxx xxxxxxxx xxxxx. Xxxxx xx xxxx xxx xxxxxxxxxx xxx, xxx byl xxxx xxxxxx polohy xxxxxxxxxxxxx. Zvířata se xxxxxxxxxxx xxxxxxxxxxxx. Xxxxxxx xx x xxxxxxxxxxxxx xxxxxxxxxx alespoň xxx xxx xxxxxxxxxxxxx.
1.4.1.4 Příprava xxxxx
Xxxxx zkoušené xxxxx xx xxxx xxx xxxx aplikací zvířatům xxxxxxxxxx nebo suspendovány xx xxxxxxxx xxxxxxxxxxxxxx xxxx xxxxxxxxxx x xxxxxxxxx zředěny. Kapalné xxxxxxxx xxxxx xxxxx xxx xxxxxxxx xxxxx xxxx xxxxx být xxxx podáním xxxxxxx. Xxxx by být xxxxxxx xxxxxxx xxxxxxxxxx xxxxxxxx xxxxxxxx xxxxx, xxxxx xxxxx x xxxxxxxx xxxxxxxxxxx možnost xxxxxxxxxx.
1.4.2 Zkušební xxxxxxxx
1.4.2.1 Xxxxxxxxxxxx/xxxxxxxxx
Xxxxxxxxxxxx/xxxxxxxxx xx xxxxxx xxx xxx xxxxxxxxx xxxxxxxx xxxxx toxické xxxxxx x mělo xx být vyloučeno xxxxxxxxx, xx reaguje xx zkoušenou xxxxxx. Xxxx-xx xxxxxxx jiná xxx známá xxxxxxxxxxxx/xxxxxxxx, xxxx by být xxxxxx xxxxxxxx xxxxxxxxx xxxxx x xxxxxx xxxxxxxxxxxxx. Xxxxxxxxxx xx xxxxx možno nejdříve xxxxxx xxxxxxx vodných xxxxxxxxxxxx/xxxxxxx.
1.4.2.2 Xxxxxxxx
Xxxxxxxx každého xxxxxxxxxxx xx xxxx xxx xxxxxxxxx x xxxxxxxxx (xxxxxxxxxxxx/xxxxxxxxx) kontroly xxx obě pohlaví. X výjimkou aplikace xxxxxxxx xxxxx xx xxxx zvířata kontrolní xxxxxxx xxxxxxxxxx xxxxxxxxx xxxxxx xxxx zvířata xx xxxxxxxxx, x xxxxx dojde x xxxxxxxx.
Xxxxxxxxx xxxxxxxx by xxxx poskytovat xxxxxxxxxx xxxxxxx in vivo xxx expozičních úrovních, x xxxxx se xxxxxxx, xx xxxxxxxxx xxxxxxxxxxxxx xxxxxx xxx xxxxxx. Xxxxx xxxxxxxxx xxxxxxxx xx xxxx xxx xxxxxxx xxx, xxx byl xxxxxx xxxxxxxx, xxx xxx xxx xxxxxx xxxxxxx xxxxx najevo xxxxxxxx xxxxxxxxxxxx xxxxxxxxx. Xx xxxxxxxxxx, xxx byla xxxxxxxxx kontrola xxxxxxxx xxxxx způsobem xxx xxxxxxxx xxxxx a xxx xxx odběr x xxxxx případě xxxxxxxx jen jednou. Xxx xxxxxxxxx kontrolu xxxxx být použity xxxxxxxx xxxxx xx xxxxxx xxxxxxxx xxxxx, xxxx-xx k xxxxxxxxx. Xxxxxxxx látek pro xxxxxxxxx xxxxxxxx:
Xxxxx |
Xxxxx XXX |
Xxxxx xxxxx EINECS |
ethyl-methansulfonát |
62–50–0 |
200–536–7 |
1-ethyl-1-nitrosomočovina |
759–73–9 |
212–072–2 |
mitomycin X |
50–07–7 |
200–008–6 |
xxxxxxxxxxxxx |
50–18–0 |
200–015–4 |
xxxxxxxxxxxxx xxxxxxxxxx |
6055–19–2 |
|
2,4,6-xxxx(xxxxxxxx-1-xx)- 1,3,5-xxxxxxx |
51–18–3 |
200–083–5 |
X xxxxxxxx xxxxxxx xxxxxx xx xxx xxx xxxxxxxx xxxxx u xxxxxxxxxxx xxxxxxx, xxxx xx xxxxxxxxxx xxxxx rozpouštědlo xxxx xxxxxxxxx a xxx jinak xxxxxxxxxx xxxxxx xxxxxx jako xxxxxxxxxx xxxxxxx, xxxxx xxxxxx z xxxxxxxxxxx xxxxxxxxxxx xxxxx x xxxxxxxxx přijatelné xxxxx x xxxxxxxxxxx xxxxxx x xxxxxxxx buněk x xxxxxxxxxxxxxx aberacemi. Xxxxxxx-xx xx xxx xxxxxxxxx xxxxxxxx xxxxx xxxxx, xx nejvhodnějším xxxxxxxxx xxxx xxxxxxx xxxxxx. Xxxxx xxxx xx xxxx xxx xxxxxxxxxxxx kontroly xxxxxxx xxxx xxxxx, xxxxxxxxxx-xx xxxxx kontrolní xxxxx xxxxxxxxxxx, xx xxxxxxx xxxxxxxxxxxx/xxxxxxxxx nevyvolává xxxxx xxxxxxx xxxx xxxxxxxxx xxxxxx.
1.5 POSTUP
1.5.1 Xxxxx x xxxxxxx xxxxxx
Xxxxx xxxxxxxxxx x xxxxxxxxx xxxxxxx xx skládá x xxxxxxx xxxx xxxxxxxxxxxxxxxx xxxxxx pro xxxxx xxxxxxx. Jestliže xxxx x xxxx xxxxxx k xxxxxxxxx xxxxx xx xxxxxx xx xxxxxxx druhem x xx xxxxxxx xxxxxxxx xxxxxxx xxxxxxxx, xxx xxxxxxxxx, xx xxxxxxxxxx xxxx pohlavími xxxxxx v xxxxxxxx, xxxx postačující xxxxxxxx xxxxxxx xxxxxxx. Xx-xx xxxxxxxx xxxxxxx specifická xxx xxxxxx xxxxxxx, xxxx xx xxxx xxxxxxxxx x některých xxxxxxxxxxxxxxx xxxxx, xxxx xx být zkouška xxxxxxxxx se xxxxxxx xxxxxxxxxxxxxx xxxxxxx.
1.5.2 Plán xxxxxxxx
Xxxxxxxx xxxxx by xxxx být pokud xxxxx xxxxxxxx xxxxxxxxxxx. Xxxxxxxx látky xxxxx xxx xxxxxxxx xxxx xx xxxx xxxxxxx, xxx. xxx xxxxx x xxx xxx x xxxxxxx ne xxxx než xxxxxxxx xxxxx, aby xxxx xxxxxxxxx xxxxxxxx xxxxxxx xxxxxx xxxxxxxxx. Xxxx xxxxxx podávání xx xxxx být xxxxxxx xxxxxxxxxx.
Xxxxxx xx xxxx xxx xxxxxxxx xx xxxx xxxxxxx xxxxxxxxxxx xx xxxxxxxx xxxxxx x jednom xxx. X hlodavců xx xxxxx provádí xx xxxxxx xxxx od xxxxxxxx, xxxxx odpovídá 1,5xxxxxxx normální délky xxxxxxxxx xxxxx (jenž xxxx xxxxxxx 12 — 18 x). Xxxxxxxx xxxx nezbytná xxx příjem a xxxxxxxxxxxx xxxxxxxx látky x rovněž xxx xxxxxx xx xxxxxxxx xxxxxxxxx cyklu xxxx xxx xxxx xx xxxxxxxxx xxxxxxx pro xxxxxxxxx chromozomových xxxxxxx, xxxxxxxxxx se xxxxxxx xxxxx xxxxx xx 24 x xx xxxxxxx xxxxxx. Xx-xx xxxxxxxx xxxxxxxxx do xxxx xxx xxxxxxx xxx, měl xx xxx odběr xxxxxxxx xx xxxxxx xxxx xx xxxxxxxx aplikace, xxxxx xxxxxxxx 1,5xxxxxxx xxxxxxxx xxxxx xxxxxxxxx xxxxx.
Xxxx xxxxxxxxx xx xxxxxxxx intraperitoneálně podá xxxxxx xxxxx xxxxx xxxxxxxxxxx xxxxxxxx (xxxx. Xxxxxxxx® xxxx xxxxxxxxx). Xxxx se xx xxxxxx xxxx provede x xxxxxx odběr. X myši xx xxxx xxxx přibližně 3 — 5 x; x křečka xxxxxxxx xx tato xxxx xxxxxxxxx 4 — 5 x. X kostní xxxxx xx xxxxxxxx buňky x analyzují se xx xxxxxxxxxxxx xxxxxxx.
1.5.3 Xxxxxxxxx
Xxxxxxx-xx xx xxxxx xxxxxxxxxxx xxxxxxxx dostupných xxxxx studie xxx xxxxxxxx xxxxxxx dávek, xxxx xx být xxxxxxxxx xx stejné xxxxxxxxxx, xx stejným xxxxxx, kmenem, xxxxxxxx x xx xxxxxxxx xxxxxx xxxxxxxx, xxx xx xxxxxxx x xxxxxx xxxxxx (5). X xxxxxxx xxxxxxxx xx pro xxxxx xxxxx xxxxxxx xxx xxxxxx dávky. Xxxx xxxxxx xxxxx xx xxxx xxxxxxxx xxxxxxx xxxx xxxxxxxxx x xxxxxxxxx toxicitou, xxxxxxxx xxxxxx xxxxxxxxx. Xxx xxxxxxxxx xxxxxx stačí, xxxx xxxx použita xxxxx nejvyšší xxxxx. Xxxxxxxx dávka je xxxxxxxxxx jako xxxxx xxxxxxxxxxxx takové známky xxxxxxxx, xx vyšší xxxxx xx xxxxx xxx xxxxxxx xxxxxx xxxxxxxxx xxxxx očekávání x xxxxxxxx. Xxxxx xx xxxxxxxxxxx biologickou xxxxxxxxx xxx xxxxxxx xxxxxxxxxxx dávkách (xxxx. xxxxxxx x xxxxxxxx) xxxxxx xxxxxxxxx xxxxxxxxx xxxxx xxxxxxxxx x xxxx xx být xxxxxxxxx případ xx xxxxxxx. Xxxxxxxx xxxxx xxxx být také xxxxxxxxxx xxxx xxxxx xxxxxxxxxxxx v xxxxxx xxxxx některé xxxxxx xxxxxxxx (xxxx. xxxx xxx 50 % xxxxxxx xxxxxxxxxxx xxxxxx).
1.5.4 Xxxxxxx xxxxxxx
Xxxxxxxx xxxxxxx x xxxxxx xxxxxx xxxxxxx 2000 xx/xx xxxxxxx xxxxxxxxx xxxxxxx xxxxxxxxxxx xxxx ve xxxx xxxxxxx x xxxxxx dni xxxxxxxxxx xxxxx xxxxxxxxxxxxx toxické xxxxxx a xxxx-xx xx xxxxxxx údajů x xxxxxxx, xxxxx xxxx xxxxxxxx strukturu, xxxxxxxxx xxxxxxxxxxxx, xxxxxxxxxx xx xxxxx xxxxxx xx xxxxx xxxxxxxx xxxxx za xxxxxxxxx. X xxxx trvajících xxxxxx xx xxxxxxx xxxxxx xxx 14xxxxx xxxxxxxx 2000 xx/xx xxxxxxx xxxxxxxxx/xxx x xxx xxxxx xxx 14xxxxx aplikaci xx xxxxxxx xxxxxx 1000 xx/xx xxxxxxx xxxxxxxxx/xxx. Xxxxxxxxx xxxxxxxx xxxxxxx xxxx xxxxxxxx potřebu xxxxxx v xxxxxxx xxxxxxx xxxxx úroveň xxxxx.
1.5.5 Xxxxxxxx xxxxx
Xxxxxxxx xxxxx xx obvykle xxxxxx xxxxxxxxxxxxxx, xxxxxxxxx xxxxxx xxxx xxxxxxx xxxxxxxxx xxxxxxx, nebo xxxxxxxxxxxxxxxxx xxxxxxx. Jiné xxxxxxx xxxxxxxx xxxx x xxxxxxxxxxxx xxxxxxxxx xxxxxxxxxx. Maximální xxxxx xxxxxxxx, který může xxx najednou xxxxx xxxxxxxxxxxxxx xxxx xxxxxxxx, xxxxxx xx xxxxxxxxx xxxxxxxxxxx zvířete. Xxxxx xx xxxxx překročit 2 xx/100 g xxxxxxx hmotnosti. Použití xxxxxxx xxxxxx, xxx xx xxxxxxx xxxxx, xxxx xxx zdůvodněno. Xx xx xxxxxxxx x xxxxxx látky, xxxxx xxxxxxx xxx xxxxxxx xxxxxxxxxxxxx xxxxxxxx xxxxxxxx účinky, xx xxxx xxx variabilita xxxxxxxxxx xxxxxx xxxxxxxxxxxxxx xxxxxxxxxx xxxxxxxxxxx zajišťující xxxxxxxxxx objem xxx xxxxx xxxxxxxx xxxxx.
1.5.6 Xxxxxxxx xxxxxxxxx xxx xxxxxxx chromozomů
Ihned po xxxxxxxx xx odebere xxxxxx xxxx, xxxxxxxxxxxx xx a xxxxxx. Xxxxx xx xxxxxxx xx xxxxxxxx xxxxxxx x xxxxxx xx.
1.5.7 Xxxxxxx
Xxxx xxxxxxx xxxxxxxxxxxx xx xxx být x xxxxx xxxxxxxxxxxx xxxxxx (včetně pozitivních xxxxxxx) x x xxxxxxxxxxxxxx xxxxxx xxx xxxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxxx index, a xx xxxxxxx x 1000 xxxxx xx xxxxx xxxxx.
X xxxxxxx xxxxxxx xx xxxx xxx xxxxxxxxxxx alespoň 100 xxxxx. Xxxxx xxxxx lze snížit, xx-xx xxxxxxxxx velký xxxxx xxxxxxx. Xxxxxxx xxxxxxxxx xxxxxxxxxxx x xxxxxxxxxxx xxxxxxx xx xxxx xxx před xxxxxxxxxxxxxx xxxxxxxx xxxxxxxxx xxxxxxxx. Xxxxxxx xxx xxxxxx často xxxxxxx xx xxxxxxxxxxxxxx zlomům xxxx xx ztrátě xxxxxxxxxx x xxxxx xxxxx x metafázi, xxxx by xxxxxxxxxxx xxxxx xxxxxxxxx centromery x počtu odpovídajícímu xxxxx 2 n ± 2.
2. XXXXX
2.1 XXXXXXXXXX XXXXXXXX
Xxxxx xxx xxxxxxxxxx xxxxxxx xx xxxx xxx xxxxxxxxxx xx xxxxx xxxxxxx. Xxxxxxxxxxxxxx jednotkou xx xxxxx. Xxx xxxxx xxxxx xx xxx xxx xxxxxxxxxx xxxxx xxxxx, xxxxx xxxxxxx xx xxxxx a xxxxx xxxxx x xxxxxxxxxxxxx aberací (xxxxxxxxxxxxxx xxxxxxxxx) xxxxxxxxx v xxxxxxxxxx. Xxx xxxxxxxxxx x xxxxxxxxx skupiny xx xxxx xxx xxxxxxx xxxxx typy xxxxxxxxxxxx chromozomových xxxxxxx x xxxxxx počtem x četností. Gapy xx xxxxxxxxxxxxx odděleně x xxxxxxx se, xxx xxxxxx se xxxxxxxxxx xx xxxxxxx xxxxxxxx xxxxxxx. Xxxxxxxxxx-xx xxxxx o rozdílu x xxxxxxxx xxxx xxxxxxxxx, mohou xxx xxx xxxxxxxxxxxx xxxxxxx xxxxx xxx xxx xxxxxxx xxxxxxxxxxxx.
2.2 HODNOCENÍ X INTERPRETACE XXXXXXXX
Xxx xxxxxxxxx xxxxxxxxxxx xxxxxxxx xxxxxxxx několik xxxxxxxx, xxxx. xxxxxx xxxxxxxxxxx xxxxx xxxxx x xxxxxxxxxxxxxx aberacemi x xxxxxxxxxx na xxxxx xxxx xxxxx xxxxxx xxxxx buněk s xxxxxxxxx pro skupinu x určitou dávkou x x xxxxxxxx xxxxxxxx xxxxxx. Xxxxxxxx xx xxxx být xxxxxxx xxxxxxxxxx relevance xxxxxxxx. Při xxxxxxxxx xxxxxxxx xxxxxxx xxxxx xxx použity xxxx xxxxxxx xxxxxxxxxx statistické xxxxxx (6). Statistická xxxxxxxxxx xx xxxxxx xxx xxxxxxx xxxxxxxxx xxxxxxxx xxx xxxxxxxxx xxxxxxx. Dvojznačné xxxxxxxx xx xxxx xxx xxxxxxxxx xxxxxx zkoušením, xxxxxxx x xxxxxxxx xxxxxxxxxxxxxxxx podmínek.
Nárůst xxxxxxxxxxx xxxx xxxxxxxx, xx xxxxxxxx xxxxx xx xxxxxxxxx xxxxxxxxx xxxxxxxxx xxxxxxxxxxxx aberace. Xxxxxx xxxxx xxxxx s xxxxxxxxxxxxxxxxxxx xxxxxxxxxx xxxx xxxxxxxx, xx xxxxxxxx xxxxx xx xxxxxxxxx xxxxxxxx xxxxxxxx buněčného xxxxx (7, 8).
Xxxxxxxx xxxxx, xxxxx xxxxxxxx xxxxxxxxx xxxx xxxxxxx xxxxxxxx, se považuje x xxxxx xxxxxxx xx nemutagenní.
Ačkoli xxxxxxx xxxxxxxxxxx poskytne xxxxx xxxxxxxxx xxxx negativní xxxxxxxx, x ojedinělých xxxxxxxxx neumožní xxxxxx xxxxx vyslovit xxxxxxx xxxxx x aktivitě xxxxxxxx xxxxx. Xxxxxxxx xxxxx xxxxxx xxxxxxxxxx xxxx xxxxxx xxx xxxxxx na xx, xxxxxxxx xx xxxxxxxxxx xxxxxxxx.
Xxxxxxxxx výsledky xxxxxxx xx xxxxxxxxxxxx xxxxxxx xx vivo xxxxxxxxx, xx xxxxxxxx xxxxx xxxxxxxx v xxxxxx xxxxx xxxxxxxxxxx druhu xxxxxxxxxxxx xxxxxxx. Negativní xxxxxxxx xxxxxxxxx, xx xxxxxxxx xxxxx za xxxxxxxx zkoušky xxxxxxxxxx x kostní xxxxx xxxxxxxxxxx druhu xxxxxxxxxxxx xxxxxxx.
Xxxx by xxx xxxxxxxxxxx pravděpodobnost, s xxxxx xx zkoušená xxxxx nebo její xxxxxxxxxx xxxxxxxx xx xxxxxxxx oběhu, xxxx xxxxxxxxxx do cílové xxxxx (např. xxxxxxxxx xxxxxxxx).
3. ZPRÁVY
PROTOKOL X XXXXXXX
Xxxxxxxx x xxxxxxx xxxx obsahovat xxxx xxxxxxxxx:
Xxxxxxxxxxxx/xxxxxxxxx:
- xxxxxxxxxx xxxxx xxxxxxxx,
- rozpustnost x xxxxxxx xxxxxxxx xxxxx x xxxxxxxxxxxx/xxxxxxxx, xx-xx xxxxx.
Xxxxxxxxx xxxxxxx:
- použitý xxxx/xxxx,
- xxxxx, stáří x xxxxxxx zvířat,
- xxxxx, podmínky chovu, xxxxxx atd.,
- xxxxxxxxxxxx xxxxxxxx xxxxxx na xxxxxxx xxxxxxx, xxxxxx xxxxxxx xxxxxxx hmotnosti, xxxxxxx hodnoty a xxxxxxxxxx xxxxxxxx xxx xxxxxx xxxxxxx.
Xxxxxxxx xxxxxxxx:
- xxxxxxxxx x xxxxxxxxx (xxxxxxxxx/xxxxxxxxxxxx) xxxxxxxx,
- xxxxx xx xxxxxx xxx xxxxxxxx xxxxxxx, xxxxx xxxx xxxxxxxxx,
- xxxxxxxxxx xxxxxxxxx úrovní xxxxx,
- xxxxx x xxxxxxxx xxxxxxxx látky,
- xxxxx x xxxxxxxx xxxxxxxx xxxxx,
- xxxxxxxxxx způsobu xxxxxxxx,
- xxxxxxxxx xxxxxx xxxxxxx, zda xx xxxxxxxx xxxxx dostala xx xxxxxxxx oběhu xxxx do xxxxxx xxxxx,
- případně přepočet xxxx xxxxxxxxxxx xxxxxxxx xxxxx x krmivu xxxx xxxx (xxx) xx xxxxxxxxxxxx dávku (xx/xx tělesné xxxxxxxxx/xxx),
- xxxxxxxx xxxxx x xxxxxxx krmiva x xxxx,
- xxxxxxxx popis xxxxxxx expozice x xxxxxx,
- xxxxxx xxxxxxxxx xxxxxxxx,
- identifikace xxxxx xxxxxxxxxxx xxxxxxxx, xxxx xxxxxxxxxxx x délka xxxxxxxx,
- xxxxxx xxxxxxxx xxxxxxxxx,
- xxxxxxxx xxxxxxxxx xxxxxxx,
- xxxxx analyzovaných xxxxx na xxxxx xxxxx,
- xxxxxxxx xxxxxxxxxxx xxxxxx xx xxxxxxxxx, xxxxxxxxx xxxx dvojznačnou.
Výsledky:
- xxxxxx toxicity,
- xxxxxxxxx xxxxx,
- xxx a xxxxx aberací xxxxxxx xxxxxxxxxx pro každé xxxxx,
- celkový xxxxx xxxxxxx xx skupině xx xxxxxxxxx xxxxxxxxx x xxxxxxxxxxxx xxxxxxxxxx,
- xxxxx xxxxx s xxxxxxxxx xx xxxxxxx xx xxxxxxxxx hodnotami x směrodatnými xxxxxxxxxx,
- xxxxx xxxxxxx, pokud xxxx xxxxxxxxxx,
- podle xxxxxxxx xxxxxxxxx odpovědi xx xxxxx,
- případné xxxxxxxxxxx xxxxxxx,
- xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxx,
- xxxxxxxxx xxxxx x xxxxxxxxx kontrole x xxxxxxxxx, xxxxxxxxx xxxxxxxxx x xxxxxxxxxxxx xxxxxxxxxx,
- xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxx.
Xxxxxx xxxxxxxx.
Xxxxxx.
4. XXXXXXXXXX
1) Xxxxx, X. X. (1984), Xxxxxxxxxxx Tests in Xxxxxxx, xx: Xxxxxxxxxxxx Xxxxxxx: a Xxxxxxxxx Xxxxxxxx, X. Xxxxxx, X. X. Parry (xxx), XXX Xxxxx, Xxxxxx, Xxxxxxxxxx X. X., 275-306.
2) Xxxxxxx, X. X., Dean, X. X., Xxxxxxxx, X., Xxxxxx, X., XxXxx, X. F., Xxxxxx, X. (1987), Xxxxxxxxx In vivo Xxxxxxxxxxx Xxxxxx: Xxxxxxxx xx Xxxxxxxxxx Aberrations xx Bone Marrow Xxxxx, Xxxxxxxxxx Xxx., 189, 157-165.
3) Richold, X., Xxxxxxxx, X., Xxxxx, J., Xxxxxxxxx, X. X., Xxxxxxx, X., Xxxxxxxxx, X. (1990), In vivo Xxxxxxxxxxx Assays, xx: X. J. Xxxxxxxx (xx.), Xxxxx Xxxxxxxxxxxx Xxxxx, XXXXX Xxxxxxxxxxx Xxxxxxxxxx. UKEMS Xxx-Xxxxxxxxx xx Guidelines for Xxxxxxxxxxxx Xxxxxxx. Report, Xxxx X xxxxxxx, Xxxxxxxxx Xxxxxxxxxx Press, Xxxxxxxxx, Xxx York, Xxxx Xxxxxxx, Melbourne, Xxxxxx, 115-141.
4) Xxxx, X. X., Xxxxxxx, X., MacGregaro, X. X., Xxxxxxxx, X., Xxxxxx, X. X., Xxxxxx, X. X., Xxxxxx-Xxxxxxx, X., Xxxxxx Xx., X. X., Xxxxxxxxxxxx, X., Xxxxxxx, X. X., Xxxxxxx, X., Xxxxxxx, X., Xxxxx, S., Vannier, X. (1994), Xxxxxx xxxx xxx Working Xxxxx xx xxx xx xxxx Xxxxxxxxx Xxxx Xxxxxx Xxxxxxxxxxx Xxxxxxxxxx Test, Mutatation Xxx., 312, 305-312.
5) Xxxxxxx, R. X., Xxxxx, J. A., Xxxxxx, X. X., Xxxxxx, X. A., Xxx, X., Xxxxxxx, X. X., Xxxxxxxxx, X. G., Xxxxxx-Xxxxxx, X., Morton, X. X., Xxxxxxxx, X. X., Xxxxxxx, X. (1992), Xxxxxx xx Xxxxxxx Toxicology Society/UK Xxxxxxxxxxxxx Mutagen Society Xxxxxxx Xxxxx: Xxxx Xxxxxxx xx In xxxx Xxxxxxxxxxxx Assays, Xxxxxxxxxxx, 7, 313-319.
6) Xxxxxx, X. X., Xxxxxxxx, X., Albanese, X., Amphlett, X. X., Clare, X., Xxxxxxxx, X., Richold, X., Xxxxxxxx, X. X., Xxxxxx, J. X. X. (1989), Xxxxxxxxxxx Xxxxxxxx xx Xx xxxx Xxxxxxxxxxx Xxxxxx, xx: XXXXX Xxx-Xxxxxxxxx xx Guidelines xxx Xxxxxxxxxxxx Testing, Xxxxxx Part III. Xxxxxxxxxxx Evaluation xx Xxxxxxxxxxxx Xxxx Xxxx, X. X. Xxxxxxxx (xx.) Xxxxxxxxx Xxxxxxxxxx Xxxxx, Cambridge, 184-232.
7) Xxxxx-Xxxxx, C. (1983), Xxxxxxxxxxxxxxxxx xx Xxxxxxx xxxxxxx cells xxxxxx xxxxx-xxxxxxxxx-xxxxxxx X2 xxxxxx, Xxxxxxxxxx Xxx., 119, 403-413.
8) Xxxxx, X., Xxxxxx, X., Trosko, X. E. (1983), Xxxxxxxxxxx-xxxxxxx xxxxxxxxxxxxxxxxx xx Xxxxxxx xxxxxxx xxxxx, Xxxxxx Xxx., 43, 1362-1364."
XXXXXXX 4C
"B.12 XXXXXXXXXX–XXXX XXXXXXX ERYTROCYTÁRNÍCH MIKROJADER XX XXXX
1. XXXXXX
Xxxx xxxxxx xx replikou xxxxxx OECD XX 474 — Test xxxxxxx xxxxxxxxxxxxxxx mikrojader xx vivo (1997).
1.1 XXXX
Xxxx xxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxx xx vivo xx používán pro xxxxxxx xxxxxxxxx xxxxxxxxxx xxxx mitotického aparátu xxxxxxxxxxxx, xxxxx xx xxxxxxxxxx xxxxxxxxx xxxxxx, x xx pomocí xxxxxxx erytrocytů xxxxxxxxxx x xxxxxx xxxxx x/xxxx xxxxx xxxxxxxxx xxxx, xxxxxxx xxxxxxxx.
Xxxxxx xxxxx xxxxxxx erytrocytárních xxxxxxxxxx xx xxxxxxxxxxxxx xxxxx, xxxxx xxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx, jehož xxxxxxxxx je xxxxxx xxxxxxxxxx xxxxxxxxxxxx xxxxxxxxxxxxx xx (lagging) xxxxxxxxxxxx xxxxxxxxx nebo celé xxxxxxxxxx.
Xxxx se erytroblast xxxxxx dřeně mění xx xxxxxxxxxxxxxxx xxxxxxxxx, xxxxxx jádro je xxxxxxxx x xxxxxxxxxx, xxxxx xxx xxx xxxxx xxxxxxxxx, xxxxxxxxx x xxxxxxxxxx, která xxxxx jádra xxxxxxxxxx. Xxxxxxxxxxxx mikrojader xx x xxxxxx xxxxxxx xxxxxxxxx xxx, xx xxxxxxxxxx xxxxxx xxxxx. Xxxxxx xxxxxxx xxxxxxxxxxxxxxxxx xxxxxxxxxx s xxxxxxxxxx x xxxxxxxxxxxx xxxxxxxxx xx známkou xxxxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxx.
X xxxxx xxxxx xx xxxxxxx xxxxxxxxx kostní xxxx xxxxxxxx, poněvadž xxxx xxxx xxxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxx. Xxxxxxxxx xxxxxxxxx (xxxxxxxxxxxxxxxxx) xxxxxxxxxx s xxxxxxxxxx x periferní xxxx xx rovnocenně xxxxxxxxxx x kteréhokoli xxxxx, x xxxxx xxxx prokázána xxxxxxxxxxx xxxxxxx xxxxxxxxxxx xxxxxxxxxx x mikrojádry, nebo xxxxxxxxxx xxxxxxxxx detekovat xxxxxxxx, xxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxxx. Xxxxxxxxxx xxx xxxxxxxx xxxxx xxxxxxxx. Xx zahrnují xxxxxxxxxxxx xxxxxxxxxxx xxxx xxxxxxxxxxxxx xxxxxxxxxxx (xxxxxxxxxxxx) XXX v xxxxxxxxxx. Xxxxxxxxx xx zejména xxxxxxx nezralých (xxxxxxxxxxxxxxxxx) xxxxxxxxxx s xxxxxxxxxx. Xxxxx xxxxxxx (xxxxxxxxxxxxxxxxxx) xxxxxxxxxx x periferní xxxx, xxxxx obsahují xxxxxxxxxx, xxxxxxxxxxx xx xxxxxx xxxxx xxxxxxx xxxxxxxxxx lze xxxxxx xxxxxx xxxx konečný xxxxxxxx xxxxxxx, jestliže xxxx zvířata exponována xxxxx xxxxx xxxx xxxx.
Xxxxx xxxx savčích xxxxxxxxxxxxxxx xxxxxxxxxx xx xxxx je zvláště xxxxxx x xxxxxxxxx xxxxxxxxx xxxxxxxxxx, xxxxx xxxxxxxx zohlednit xxxxxxx xxxxxxxxxxx in xxxx, xxxxxxxxxxxxxxx a procesy xxxxxxxx DNA, třebaže xx mohou xxxxx x xxxxxxx xxxxx x tkání, jakož x x xxxxxxxxxxx xxxxxxxx. Xxxxxxx xx xxxx xx xxxxxx xxxxxxxx xxx xxxxx xxxxxx xxxxxxxxxxx xxxxxx xxxxxxxxxx x systémech xx vitro.
Jestliže xxxxxxxx xxxxx x xxx, xx xx xxxxxxxx xxxxx nebo reaktivní xxxxxxxxxx xxxxxxxxxx xx xxxxxx xxxxx, není xxxxxx xxxx xxxxxxx xxxxxx.
Xxx xxxx Obecný xxxx, xxxx B.
1.2 XXXXXXXX
Xxxxxxxxxx (xxxxxxxxxx) : xxxxxx (oblasti) xxxxxxxxxx, x xxx (x xxxx) xx xxxxx xxxxxx xxxxx připojí xxxxxx vřeténko xxxxxxxxxx xxxxxxxxxx xxxxx dceřiných xxxxxxxxxx x xxxxx xxxxxxxxx buněk.
Mikrojádra : xxxx xxxxx xxxxxxxxxx xxxxxxxx xx xxxxxxxx xxxxx a vedle xxxx, vytvářená xxxxx xxxxxxxx xxxxxx (xxxxxx) xxxxxxxxxxxxxxx se (lagging) xxxxxxxxxxxxxx xxxxxxxxx xxxx xxxxxx chromozomy.
Normochromatický xxxxxxxxx : xxxxx erytrocyt xxxxxxxxxxxx ribozomy, který xxx rozlišit xx xxxxxxxxx xxxxxxxxxxxxxxxxx erytrocytů xxxxxxxx selektivním xxx xxxxxxxx.
Xxxxxxxxxxxxxxx erytrocyt : xxxxxxx xxxxxxxxx ve xxxxxxxxx xxxxxxxxxx, xxxxx xxxxx obsahuje xxxxxxxx, x xxxx xxx xxxx xxxxxxxx xx xxxxxxx xxxxxxxxxxxxxxxxxx erytrocytů xxxxxxxx xxxxxxxxxxx pro xxxxxxxx.
1.3 XXXXXXXX ZKUŠEBNÍ XXXXXX
Xxxxxxx se vhodným xxxxxxxx xxxxxxx zkoušené xxxxx. Xxx xxxxxxx xxxxxx xxxxx xx xxxxxxx ve xxxxxxx xxxxxxxx xx expozici xxxxxx, odebere xx xxxxxx xxxx, xxxxxxxx xx xxxxxxxxx a xxxxxx xx (1, 2, 3, 4, 5, 6, 7). Xxx xxxxxxx periferní xxxx xx krev xx xxxxxxx okamžiku xx xxxxxxxx xxxxxxx, xxxxxxxxxx xx xxxxxxxx xxxxxxxx x obarví xx (4, 8, 9, 10). Xxx xxxxxxxx x xxxxxxxxx xxxx by měla xxxx xxxxxxxx xxxxxxxx x sklizením xxxxx xxxxxxxx co nejkratší xxxx. Preparáty jsou xxxxxxxxxxx na xxxxxxxxxx xxxxxxxxxx.
1.4 XXXXX ZKUŠEBNÍ XXXXXX
1.4.1 Přípravky
1.4.1.1 Xxxxx xxxxx xxxxxxx
Xxx xxxxxxx xxxxxx xxxxx xx xxxx xxxxxxxxx xxxxx xxxxxxxxxx xxx xxxx xxxxxx, xxxxxx xxx xxxxxx jakýkoli vhodný xxxxx xxxx. Při xxxxxxx xxxxxxxxx xxxx xx xxxxxxxxxx xxx. Xxx xxxx použít xxxxxxxx xxxxxx druh xxxxx xx xxxxxxxxxxx, xx xxx o xxxx, x xxxxx xxxxxxx xxxxxxxxxxxx erytrocyty x mikrojádry, nebo xxxx vykazující xxxxxxxxxxx xxxxxxxxx xxxxxxxxx činitele, xxxxx způsobují xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxxx. Xxxx by xxx xxxxxxx xxxxx xxxxxxx laboratorní xxxxx xxxxxxx xxxxxxxx pohlavně xxxxxxxxx xxxxxx. X xxxxxxxx zahájení studie xx xxxx být xxxxxxxx x xxxxxxxxx xxxxxx xxxxxxxxx a xxxxxx xx x xxxx xxxxxxx xxxxxxxxx ± 20 % xxxxxxx xxxxxxx xxxxxxxxx.
1.4.1.2 Xxxxxxxx xxxxx x xxxxxx
Xxxxx xxxxxx xxxxxxxx xxxxx xxxxxxxx úvodu x části X, xxxxxxx xx mělo xxx xxxxxxxx xxxxxxxx xxxxxxx 50 – 60 %.
1.4.1.3 Příprava xxxxxx
Xxxxxx xxxxx pohlavně xxxxxxx xxxxxxx xx xxxxxxxx výběrem rozdělí xx kontrolní xxxxxxx x xxxxxxx, x xxx xx xxxxxxx xxxxxxxx. Xxxxxxx xx xxxxxxxxxxx xxxxxxxxxxxx. Nechají xx x xxxxxxxxxxxxx xxxxxxxxxx xxxxxxx xxx xxx xxxxxxxxxxxxx. Xxxxx xx uspořádají tak, xxx xxx xxxx xxxxxx xxxxxx xxxxxxxxxxxxx.
1.4.1.4 Xxxxxxxx xxxxx
Xxxxx zkoušené xxxxx by xxxx xxx xxxx xxxxxxxx xxxxxxxx xxxxxxxxxx nebo xxxxxxxxxxxx ve xxxxxxxx xxxxxxxxxxxxxx nebo xxxxxxxxxx x popřípadě xxxxxxx. Xxxxxxx xxxxxxxx látky xxxxx být xxxxxxxx xxxxx xxxx mohou xxx xxxx xxxxxxx xxxxxxx. Xxxx xx xxx xxxxxxx xxxxxxx xxxxxxxxxx xxxxxxxx xxxxxxxx xxxxx, pokud xxxxx x xxxxxx xxxxxxxx xxxxxxxxxxx možnost xxxxxxxxxx.
1.4.2 Xxxxxxxx xxxxxxxx
1.4.2.1 Rozpouštědlo/vehikulum
Rozpouštědlo/vehikulum xx xxxxxx xxx xxx použitých xxxxxxxx xxxxx toxické účinky x xxxx by xxx xxxxxxxxx xxxxxxxxx, xx xxxxxxx xx xxxxxxxxx xxxxxx. Xxxx-xx xxxxxxx xxxx xxx xxxxx xxxxxxxxxxxx/xxxxxxxx, xxxx xx xxx xxxxxx xxxxxxxx xxxxxxxxx xxxxx x jejich xxxxxxxxxxxxx. Xxxxxxxxxx xx pokud xxxxx nejdříve xxxxxx xxxxxxx xxxxxxx rozpouštědel/vehikul.
1.4.2.2 Xxxxxxxx
Xxxxxxxx každého xxxxxxxxxxx xx xxxx být xxxxxxxxx x negativní (xxxxxxxxxxxx/xxxxxxxxx) xxxxxxxx pro xxx xxxxxxx. X xxxxxxxx xxxxxxxx xxxxxxxx xxxxx xx xxxx xxxxxxx kontrolní xxxxxxx xxxxxxxxxx identický xxxxxx xxxx zvířata ve xxxxxxxxx, x xxxxx xxxxx x expozici.
Pozitivní xxxxxxxx xx xxxx xxxxxxxxxx xxxxxxxxxx xx xxxx při xxxxxxxxxxx xxxxxxxx, x nichž xx xxxxxxx, xx xxxxxxxxx detekovatelný nárůst xxx pozadí. Xxxxx xxxxxxxxx xxxxxxxx xx xxxx být xxxxxxx xxx, xxx xxx xxxxxx zřetelný, xxx xxx při xxxxxx xxxxxxx ihned xxxxxx xxxxxxxx xxxxxxxxxxxx xxxxxxxxx. Xx přijatelné, aby xxxxxxxxx xxxxxxxx xxxx xxxxxxxx xxxxx xxxxxxxx xxx xxxxxxxx látka x aby byl xxxxx x xxxxx xxxxxxx xxxxxxxx xxx xxxxxx. Pro xxxxxxxxx xxxxxxxx xxxxx může xxx vzato x xxxxx xxxxxxx chemických xxxxx xx xxxxxx xxxxxxxx xxxxx, xxxx-xx x xxxxxxxxx. Xxxxxxxx xxxxx xxx xxxxxxxxx xxxxxxxx:
Xxxxx |
Xxxxx CAS |
Číslo xxxxx XXXXXX |
xxxxx-xxxxxxxxxxxxxx |
62–50–0 |
200–536–7 |
1-xxxxx-1-xxxxxxxxxxxxxxx |
759–73–9 |
212–072–2 |
xxxxxxxxx X |
50–07–7 |
200–008–6 |
xxxxxxxxxxxxx |
50–18–0 |
200–015–4 |
xxxxxxxxxxxxx xxxxxxxxxx |
6055–19–2 |
|
2,4,6-xxxx(xxxxxxxx-1-xx)- 1,3,5-xxxxxxx |
51–18–3 |
200–083–5 |
X xxxxxxxx xxxxxx xx měl být xxxxxxxx odběr u xxxxxxx negativní kontroly, xxxxx je xxxxxxxxxx xxxxx xxxxxxxxxxxx nebo xxxxxxxxx x která xxxxx podstupuje xxxxxx xxxxxx xxxx exponované xxxxxxx, pokud xxxxxx x xxxxxxxxxxx kontrolních xxxxx x xxxxxxxxx xxxxxxxxxx xxxxx x xxxxxxxxxxx zvířat x xxxxxxxx xxxxx x xxxxxxxxxx. Xxxxxxx-xx xx xxx xxxxxxxxx kontrolu xxxxx xxxxx, je xxxxxxxxxxxxx okamžikem doba xxxxxxx xxxxxx. Xxxxx xxxx xx měly xxx neexponované kontroly xxxxxxx také xxxxx, xxxxxxxxxx-xx dosud xxxx xxxxxx-xx xxxxxxxxxxx kontrolní xxxxx xxxxxxxxxxx, že xxxxxxx rozpouštědlo/vehikulum xxxxxxxxxx xxxxx zhoubné xxxx xxxxxxxxx xxxxxx.
Xxx xxxxxxx xxxxxxxxx xxxx může xxx xxxx xxxxxxxxx xxxxxxxx xxxxxxxxxx xxxx xxxxxx xxxx xxxxxxxx xxxx expozicí, pouze xxxx x xxxxxxxx xxxxxx x xxxxxxxxx xxxx (xxxx. 1 — 3 xxxxxxxx) xx xxxxxxxxxxx, xx xxxxxxxx xxxxx budou x xxxxxxx, které xx na xxxxxxx xxxxxxxxxxx xxxxxxx očekává.
1.5 XXXXXX
1.5.1 Xxxxx a xxxxxxx xxxxxx
Xxxxx xxxxxxxxxx x kontrolní xxxxxxx xx musí skládat x xxxxxxx xxxx xxxxxxxxxxxxxxxx zvířat xxx xxxxx xxxxxxx (11). Xxxxxxxx jsou v xxxx xxxxxx x xxxxxxxxx xxxxx ze xxxxxx se stejným xxxxxx a za xxxxxxx stejného způsobu xxxxxxxx, xxx prokazují, xx xxxxxxxxxx xxxx xxxxxxxxx xxxxxx x xxxxxxxx, xxxx xxxxxxxxxxx xxxxxxxx jednoho xxxxxxx. Xx-xx xxxxxxxx xxxxxxx xxxxxxxxxx pro určité xxxxxxx, jako xx xxxx xxxxxxxxx x xxxxxxxxx xxxxxxxxxxxxxxx xxxxx, xxxx xx být xxxxxxx provedena se xxxxxxxx xxxxxxxxxxxxxx xxxxxxx.
1.5.2 Xxxx xxxxxxxx
Xxxxx xxxxxxxxx xxxxx xxxxxxxxxx xxxx (xx. xxxxx, dvě xxxx xxx aplikace x xxxxxxxxx 24 xxxxx). Vzorky ze xxxxxx x xxxxxxxxxxxx xxxxxxx xxxxxxxx jsou xxxxxxxxxx, pokud xx x xxxxxx studií xxxxxxx xxxxxxxxx xxxxxxxx, xxxx –x případě xxxxxxxxxxx xxxxxx — xxxxx xxxx prokázána xxxxxxxx xxxx xxxx xxxxxxxxx limitní dávka x xxxxxxxx xxxxxxxxx xx do okamžiku xxxxxx. Xxxxxxxx xxxxx xxxxx být xxxxxxxx xxxx xx xxxx xxxxxxx, xxx. xxx xxxxx v xxx xxx x xxxxxxx xx xxxx xxx xxxxxxxx xxxxx, xxx xxxx xxxxxxxxx xxxxxxxx xxxxxxx xxxxxx xxxxxxxxx.
Xxxx xxxx být proveden xxxxx způsoby:
a) xxxxxxxx xxxxx se aplikuje xxxxxxxx xxxxxx. Xxxxxx xxxxxx dřeně se xxxxxxxx xxxxxxx xxxxxxx, xxxxxxx xxxxx odběr xx provede nejdříve 24 xxxxx xx xxxxxxxx x poslední xxxxxxxxxx 48 hodin xx xxxxxxxx x x xxxxxxxxxx xxxxxxxx xxxx odběry. Odběr xxxxx xxx 24 xxxxx po xxxxxxxx xxxx xxx xxxxxxxxx. Xxxxxx periferní xxxx xx xxxxxxxx xxxxxxx xxxxxxx, xxxxxxx xxxxx xxxxx se provede xxxxxxxx 36 xxxxx xx xxxxxxxx x xxxxxxxx xxxxxxxxxx 72 xxxxx xx xxxxxxxx x po xxxxxxxxxxxx xx xxxxxx odpovídající xxxxxx. Xx-xx xx xxxxxx odběru pozorována xxxxxxxxx xxxxxxx, xxxx xxxxx xxxxx nutný;
b) xxxx-xx xxxxxxxx dvě xxxx xxxx xxxxx xxxxx (např. xxx xxxx xxxx dávek x intervalu 24 xxxxx), xxxx by xxx vzorky xxx xxxxxxx xxxxxx xxxxx xxxxxxxx xxxxxx xx 18 xx 24 xxxxxxxx po poslední xxxxxxxx x xxx xxxxxxx xxxxxxxxx krve xxxxxx po 36 xx 48 hodinách xx xxxxxxxx aplikaci (12).
Xxxxx xxxxxxx xxxxx xxx xxxxx xxxxxxx xxxx xxxx odběru.
1.5.3 Xxxxxxxxx
Xxxxxxx-xx se xxxxx xxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxx studie xxx xxxxxxxx xxxxxxx xxxxx, xxxx by xxx xxxxxxxxx ve stejné xxxxxxxxxx, xx xxxxxxx xxxxxx, kmenem, xxxxxxxx x za stejného xxxxxx xxxxxxxx, xxx xx použijí x xxxxxx studii (13). X případě xxxxxxxx xx xxx xxxxx xxxxx xxxxxxx tři xxxxxx xxxxx. Xxxx xxxxxx xxxxx by xxxx pokrývat rozpětí xxxx xxxxxxxxx až xxxxxxxxx toxicitou, xxxxxxxx xxxxxx xxxxxxxxx. Při xxxxxxxxx xxxxxx xxxxx, xxxx xxxx xxxxxxx xxxxx xxxxxxxx xxxxx. Xxxxxxxx xxxxx je xxxxxxxxxx xxxx dávka xxxxxxxxxxxx xxxxxx známky xxxxxxxx, že vyšší xxxxx by xxxxx xxx xxxxxxx režimu xxxxxxxxx xxxxx xxxxxxxxx x letalitě. Látky xx specifickou biologickou xxxxxxxxx xxx xxxxxxx xxxxxxxxxxx xxxxxxx (např. xxxxxxx a mitogeny) xxxxxx xxxxxxxxx xxxxxxxxx xxxxx xxxxxxxxx a xxxx xx být xxxxxxxxx případ od xxxxxxx. Nejvyšší xxxxx xxxx xxx xxxx xxxxxxxxxx xxxx dávka xxxxxxxxxxxx x kostní xxxxx xxxxxxx xxxxxx xxxxxxxx (např. xxxxxxx xxxxxx xxxxxxxxx erytrocytů x xxxxxxxxx xxxxxxxx xxxxxxxxxx x xxxxxx xxxxx nebo x xxxxxxxxx xxxx).
1.5.4 Xxxxxxx xxxxxxx
Xxxxxxxx xxxxxxx s xxxxxx xxxxxx x xxxxxxx 2000 xx/xx xxxxxxx xxxxxxxxx xxxxxxx xxxxxxxxxxx nebo xx xxxx xxxxxxx x xxxxxx dni xxxxxxxxxx xxxxx xxxxxxxxxxxxx toxické xxxxxx x není-li xx základě údajů x xxxxxxx, xxxxx xxxx xxxxxxxx xxxxxxxxx, xxxxxxxxx xxxxxxxxxxxx, není xxxxxxxxxx úplná studie xx třemi úrovněmi xxxxx za xxxxxxxxx. X déle trvajících xxxxxx xx limitní xxxxxx xxx 14xxxxx xxxxxxxx 2000 xx/xx xxxxxxx xxxxxxxxx/xxx x xxx xxxxx xxx 14xxxxx xxxxxxxx xx xxxxxxx dávkou 1000 xx/xx tělesné hmotnosti/den. Xxxxxxxxx xxxxxxxx člověka xxxx xxxxxxxx xxxxxxx xxxxxx x xxxxxxx xxxxxxx xxxxx xxxxxx xxxxx.
1.5.5 Xxxxxxxx dávek
Zkoušená xxxxx xx xxxxxxx xxxxxx xxxxxxxxxxxxxx, xxxxxxxxx xxxxxx xxxx xxxxxxx xxxxxxxxx xxxxxxx, nebo xxxxxxxxxxxxxxxxx xxxxxxx. Jiné xxxxxxx podávání xxxx xxxxxxxxxx x odůvodnitelných xxxxxxxxx. Maximální xxxxx xxxxxxxx, xxxxx může xxx najednou podán xxxxxxxxx xxxxxx xxxx xxxxxxxx, závisí na xxxxxxxxx xxxxxxxxxxx xxxxxxx. Xxxxx xx xxxxx xxxxxxxxx 2 xx/100 x xxxxxxx xxxxxxxxx. Xxxxxxx vyšších xxxxxx, xxx xx xxxxxxx xxxxx, xxxx xxx xxxxxxxxxx. Xx na xxxxxxxx x xxxxxx xxxxx, xxxxx xxxxxxx xxx vyšších xxxxxxxxxxxxx xxxxxxxx xxxxxxxx xxxxxx, xx xxxx být xxxxxxxxxxx xxxxxxxxxx xxxxxx xxxxxxxxxxxxxx xxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxx xxxxxxxxxx xxxxx xxx všech xxxxxxxx xxxxx.
1.5.6 Xxxxxxxx kostní xxxxx xxxx xxxx
Xxxxx xxxxxx xxxxx xx xxxxxxx xxxxxxxxx x xxxxxx nebo tibie xxxxx xx xxxxxxxx. Xxxxx xx xxxxxxxx x xxxxxx xxxx xxxxx x xxxxxxxxxx xxxxxxxx se xxxxxxxxx x xxxxxx. Xxxxxxxxx xxxx xx získává x xxxxxx žíly xxxx xxxx xxxxxx xxxxxx xxxx. Krevní xxxxx xx xxxxx xxxxxxxxxxxx obarví (8, 9, 10), xxxx xx xxxxxxxx xxxxxxxxx xxxxxxxx x xxxx xx xxxxxx. Xxxxxxxx xxxxxxx xxxxxxxxxxxx xxx XXX (např. xxxxxxxxxx xxxxx (14) nebo Xxxxxxx 33258 x xxxxxxx-X (15)) xx xxx xxxxxxx některým xxxxxxxxxx spojeným x xxxxxxxx xxxxxxx nespecifického xxx XXX. Xxxx xxxxxx nebrání xxxxxxx xxxxxxxxxxx barviv (xxxx. Xxxxxx). Xxxxxxxx systémy (xxxx. celulosová xxxxxx x xxxxxxxxxx xxxxx xxxxxxxxxxxx jádra (16)) xxx xxxxxx xx xxxxxxxxxxx, xx xx xxxxxxxxx xxxxxxxxxxxx xxxxxxxxx xxxxxx systémů xxx xxxxxxxxx xxxxxxxxxx x xxxxxxxxxx.
1.5.7 Xxxxxxx
Xxx xxxxx xxxxx xx xxxxxxx xxxxx xxxxxxxxx xxxxxxxxxx x celkového (nezralé + xxxxx) xxxxxxxx xxxxxxxxxx, xxxxxxx se x xxxxxxx xxxxxx xxxxx použije celkově xxxxxxx 200 xxxxxxxxxx x x případě xxxxxxxxx xxxx xxxxxxx 1000 xxxxxxxxxx (17). Xxxxxxx preparáty xxxxxx xxxxxxxxx pozitivních x xxxxxxxxxxx xxxxxxx, xx xxxx xxx před xxxxxxxx xxx xxxxxxxxxxx xxxxxxxxx xxxxxxxx. U xxxxxxx zvířete se xxxxxxx xxxxxxx 2000 xxxxxxxxx erytrocytů na xxxxxx xxxxxxxxxx x xxxxxxxxxxxxxxxxxxxxx. Další informace xxxxx xxx xxxxxxx xxxxxxxxxx zralých erytrocytů xx výskyt xxxxxxxxxx. Xxx xxxxxxxxxxxxx analýze xx xxxxx být xxxxx xxxxxxxxx xxxxxxxxxx x xxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxx xxx 20 % kontrolní xxxxxxx. Xxxxxxxx xxxx xxxxxxx exponována xxxxxxxxxxx xxxxx xxxxx xxxx xxxx, xxx xxxx xxxxxxxx xx xxxxxx xxxxxxxxxx xxxxxxx 2000 xxxxxxx xxxxxxxxxx xx xxxxx zvíře. Xxxxxxx xxx xxxxxxxxxxxx analýzu (xxxxxxx xxxxxx x xxxxxxxxx xxxxxxxxxxxx analýza xxxxxxx xxxxxxxx) xxxx xx odpovídajícím xxxxxxxxxx x validaci přijatelnými xxxxxxxxxxxxx xxxxxxxxxx xxxxxxxxx.
2. XXXXX
2.1 XXXXXXXXXX XXXXXXXX
Xxxxx xxx xxxxxxxxxx xxxxxxx xx měly xxx xxxxxxxxxx ve xxxxx xxxxxxx. Xxxxxxxxxxxxxx jednotkou xx xxxxx. Pro xxxxx xxxxxxxxxxx xxxxx xx xxx xxx xxxxxx xxxxx xxxxxxxxxxx xxxxxxxxx erytrocytů, xxxxx xxxxxxxxx erytrocytů s xxxxxxxxxx x xxxxx xxxxxxxxx xxxxxxxxxx z xxxxxxxxx xxxxxxxx xxxxxxxxxx. Xxxxxxxx xxxx zvířata xxxxxxxxxx xxxxxxxxxxx xxxxx xxxxx nebo xxxx, xxxx by být xxxx uvedeny xxxxx x xxxxxxx xxxxxxxxxxxx, xxxx-xx xxxxxxxxxxxxx. Xxx xxxxx xxxxx se xxxxx xxxxx xxxxxxxxx xxxxxxxxxx z xxxxxxxxx xxxxxxxx erytrocytů a xxxxxxxx xxxxxxxx xxxxxxxxxx x xxxxxxxxxx xxxxxxxxx x xxxxxxxxxx. Neexistuje-li xxxxx o xxxxxxx x xxxxxxxx mezi xxxxxxxxx, xxxxx xxx xxx statistickou xxxxxxx xxxxx xxx obě xxxxxxx xxxxxxxxxxxx.
2.2 XXXXXXXXX X XXXXXXXXXXXX XXXXXXXX
Xxx xxxxxxxxx xxxxxxxxxxx výsledku xxxxxxxx xxxxxxx xxxxxxxx, xxxx. nárůst xxxxx xxxxx x xxxxxxxxxx x xxxxxxxxxx na xxxxx xxxx jasný xxxxxx xxxxx buněk x xxxxxxxxxx xxx xxxxxxx x xxxxxxx xxxxxx a k xxxxxxxx xxxxxxxx odběru. Xxxxxxxx by xxxx xxx xxxxxxx biologická xxxxxxxxx xxxxxxxx. Xxx xxxxxxxxx xxxxxxxx xxxxxxx xxxxx být xxxxxxx xxxx xxxxxxx prostředek xxxxxxxxxxx xxxxxx (18, 19). Xxxxxxxxxxx významnost xx xxxxxx být xxxxxxx xxxxxxxxx xxxxxxxx xxx pozitivní odpověď. Xxxxxxxxxx xxxxxxxx xx xxxx být xxxxxxxxx xxxxxx zkoušením, nejlépe x xxxxxxx xxxxxxxxxxxxxxxx xxxxxxxx.
Xxxxxxxx xxxxx, xxxxx xxxxxxxx xxxxxxxxx výše xxxxxxx xxxxxxxx, xx xxxxxxxx x xxxxx xxxxxxx xx nemutagenní.
Ačkoli xxxxxxx xxxxxxxxxxx xxxxxxxx xxxxx xxxxxxxxx nebo xxxxxxxxx xxxxxxxx, v xxxxxxxxxxx xxxxxxxxx neumožní xxxxxx xxxxx xxxxxxxx xxxxxxx xxxxx x xxxxxxxx xxxxxxxx látky. Xxxxxxxx xxxxx xxxxxx xxxxxxxxxx xxxx xxxxxx xxx xxxxxx na xx, kolikrát xx xxxxxxxxxx xxxxxxxx.
Xxxxxxxxx xxxxxxxx xxxxx xx xxxxxxxxxx xxxxxxxxx, xx xxxxxxxx xxxxx xxxxxxxx xxxxxxxxxx, xxx jsou důsledkem xxxxxxxxxxxxxx xxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxx xxxxxxx xxxxxxxxxxxx xxxxxxxxxxx druhu. Xxxxxxxxx xxxxxxxx xxxxxxxxx, xx zkoušená xxxxx xx podmínek xxxxxxx xxxxxxxxxxx xxxxxxxxxx v xxxxxxxxx xxxxxxxxxxxx testovacího xxxxx.
Xxxx by xxx xxxxxxxxxxx pravděpodobnost, x xxxxx xx xxxxxxxx xxxxx xxxx její xxxxxxxxxx dostanou xx xxxxxxxx xxxxx, nebo xxxxxxxxxx do xxxxxx xxxxx (xxxx. xxxxxxxxx xxxxxxxx).
3. ZPRÁVY
PROTOKOL X XXXXXXX
Xxxxxxxx x xxxxxxx xxxx xxxxxxxxx xxxx xxxxxxxxx:
Xxxxxxxxxxxx/xxxxxxxxx:
- zdůvodnění xxxxx xxxxxxxx,
- xxxxxxxxxxx a xxxxxxx zkoušené xxxxx x xxxxxxxxxxxx/xxxxxxxx, xx-xx xxxxx.
Xxxxxxxxx zvířata:
- xxxxxxx xxxx/xxxx,
- xxxxx, xxxxx x xxxxxxx xxxxxx,
- xxxxx, podmínky xxxxx, xxxxxx xxx.,
- individuální xxxxxxxx xxxxxx xx xxxxxxx xxxxxxx, xxxxxx xxxxxxx tělesné xxxxxxxxx, xxxxxxx hodnota x xxxxxxxxxx odchylka xxx xxxxxx xxxxxxx.
Xxxxxxxx podmínky:
- xxxxx k xxxxxxxxx x negativní (xxxxxxxxx/xxxxxxxxxxxx) xxxxxxxx,
- xxxxx ze xxxxxx pro xxxxxxxx xxxxxxx, pokud byla xxxxxxxxx,
- xxxxxxxxxx xxxxxxxxx xxxxxx xxxxx,
- xxxxx x xxxxxxxx zkoušené xxxxx,
- xxxxx o xxxxxxxx xxxxxxxx xxxxx,
- xxxxxxxxxx xxxxxxx xxxxxxxx,
- xxxxxxxxx metody xxxxxxx, xxx se xxxxxxxx xxxxx dostala xx xxxxxxxx oběhu xxxx xx xxxxxx xxxxx,
- xxxxxxxx xxxxxxxx xxxx xxxxxxxxxxx xxxxxxxx xxxxx x krmivu xxxx xxxx (xxx) na xxxxxxxxxxxx dávku (xx/xx xxxxxxx hmotnosti/den),
- xxxxxxxx xxxxx o xxxxxxx xxxxxx x xxxx,
- xxxxxxxx popis xxxxxxx xxxxxxxx a xxxxxx,
- xxxxxx xxxxxxxx xxxxxxxxx,
- xxxxxx xxxxxxxxx xxxxxxxx,
- xxxxxxxx hodnocení mikrojader x nezralých xxxxxxxxxxxx,
- xxxxx xxxxxxxxxxxxx buněk xx xxxxx xxxxx,
- xxxxxxxx klasifikace xxxxxx xx pozitivní, negativní xxxx xxxxxxxxxxx.
Xxxxxxxx:
- známky xxxxxxxx,
- podíl xxxxxxxxx xxxxxxxxxx z celkového xxxxxxxx xxxxxxxxxx,
- xxxxx xxxxxxxxx erytrocytů x xxxxxxxxxx xxxxxxx xxxxxxxxxx xxx xxxxx xxxxx,
- xxxxxxx hodnota ± xxxxxxxxxx odchylka xxxxx xxxxxxxxx xxxxxxxxxx x xxxxxxxxxx xx skupině,
- xxxxx možnosti xxxxxxxxx xxxxxxxx xx xxxxx,
- xxxxxxxx statistické xxxxxxx x xxxxxx,
- xxxxx x xxxxxxxx x xxxxxxxxx xxxxxxxxx kontrole,
- xxxxx o xxxxxxxx xxxxxxxxx xxxxxxxx.
Xxxxxx xxxxxxxx.
Xxxxxx.
4. XXXXXXXXXX
1) Xxxxxx, X. X. (1973), A Xxxxx Xx vivo Xxxx for Xxxxxxxxxxx Xxxxxx, Mutatation Xxx., 18, 187-190.
2) Schmid, X. (1975), Xxx Xxxxxxxxxxxx Test, Mutatation Xxx., 31, 9-15.
3) Xxxxxx, J. A., Xxxxxxxx, M. X., Xxxx, X., Xxxxxxxx, X., Mavournin, K., XxxXxxxxx, X. G., Xxxxxx, X. X. (1983), The Xxxxxxxxx xx Xxxxxxxxxxx a. x. a Xxxxxxx xx Genotoxicity, Xxxxxxxxxx Xxx. 123, 61-118.
4) Xxxxxxxxx, X. H., Xxxxxx, D. H., Xxxxxx, X. C., Xxxxxxxx, M. X., Xxxxxx, J. X. (1990), Xxx Xx xxxx Xxxxxxxxxxxx Assay xx Xxxxxxxxx Bone Xxxxxx and Xxxxxxxxxx Xxxxx. X xxxxxx xx xxx X. X. Xxxxxxxxxxxxx Xxxxxxxxxx Xxxxxx Xxxx-Xxx Program, Xxxxxxxxxx Xxx., 239, 29-80.
5) XxxXxxxxx, X. X., Schlegel, X., Xxxx, X. N., Xxxx, X. X. (1983), Micronuclei xx Xxxxxxxxxxx Xxxxxxxxxxxx: X Xxxxx Screen xxx Xxxxxxxxxxx Xxxxxx During Xxxxxxx Toxicity Xxxxxxx xx Xxxx, xx: Xxxxxxxxxxxx in Xxxxxxx xxx Xxxxxxxx xx Xxxxxxxxxx, xx. A. X. Hayes, R. X. Schnell, X. X. Xxxx. Elsevier, Xxxxxxxxx, 555-558.
6) MacGregor, X. T., Xxxxxx, X. X. Xxxx, X., Xxxxxxxx, X. X., Xxxxx, X., Xxxxxxxx, X. X., Xxxx, X. R., Xxxx, X. (1987), Xxxxxxxxxx xxx xxx Xxxxxxx xx Xxxxxxxxxxxx Xxxxxx in Xxxxxxxxx Xxxx Marrow Xxxxxxxxxxxx, Xxxxxxxxxx Res., 189, 103-112.
7) MacGregor, J. X., Xxxx, C. X., Henika, X. X., Shelby, X. X. (1990), The xx vivo Xxxxxxxxxxx Xxxxxxxxxxxx Test: Measurement xx Steady State Xxxxxxxxx Assay Xxxxxxxxxx xxx Xxxxxxx Xxxxxxxxxxx xxxx Xxxxxxxx Xxxxxxx, Xxxxxx. Xxxx. Toxicol. 14, 513-522.
8) Xxxxxxx, X., Morita, X., Xxxxxx, X., Xxxxxx, X., Xxxxxxxx, X. Xx. (1990), Xxx Xxxxxxxxxxxx Xxxxx xxxx Xxxxx Peripheral Xxxxx Xxxxxxxxxxxxx Xxxxx Xxxxxxxx Xxxxxx-Xxxxxx Xxxxxx, Xxxxxxxxxx Xxx., 245, 245-249.
9) Xxx Xxxxxxxxxxxxx Study Xxxxx for xxx Xxxxxxxxxxxx Xxxx (1992). Xxxxxxxxxxxx Test xxxx Xxxxx Xxxxxxxxxx Xxxxx Xxxxxxxxxxxx by Xxxxxxxx Xxxxxx Xxxxxxxxxx Xxxxxxxx: Xxx Xxxxxxx Xxxxxx xx xxx 5th Xxxxxxxxxxxxx Xxxxx xx XXXXX/XXXXX, MMS, Xxxxxxxxxx Xxx., 278, 83-98.
10) Xxx Xxxxxxxxxxxxx Xxxxx Xxxxx for xxx Xxxxxxxxxxxx Test (CSGMT/JEMMS, XXX: Xxx Xxxxxxxxx Xxxxxxxxxxx Xxxxx Group xx xxx Environmental Xxxxxxx Society xx Xxxxx) (1995), Xxxxxxxx xxxxxxxxxxx for xxx xxxxx-xxxx xxxxx xxxxxxxxxx xxxxx micronucleus xxxx, Xxxxxxxxxxx, 10, 53-159.
11) Xxxxxxx, X., Tice, X. X., XxxXxxxxx, X. T., Anderson, X., Xxxxxxx, X. X., Kirsch-Volders, M., Xxxxxx, Xx. X. X., Pacchicrotti, X., Xxxxxxx, F., Shimada, X., Xxxxx, S., Xxxxxxx, X. (1994), Xx vivo Xxxxxx Xxxxxxxxxxx Micronucleus Xxxxx, Xxxxx. Xxx., 312, 293-304.
12) Xxxxxxxxxxx, N., Xxxxx, X. (1995), Xx optimal, xxxxxxxxxxx xxxxxxxx time of 30 ± 6 x xxxxx double xxxxxx xx xxx xxxxx xxxxxxxxxx micronucleus xxxx, Mutagenesis, 10, 313-319.
13) Fielder, X. X., Xxxxx, X. X., Xxxxxx, A. X., Botham, X. X., Doe, X., Xxxxxxx, X. J., Xxxxxxxxx, X. G., Xxxxxx-Xxxxxx, X., Morton, X. X., Kirkland, X. X., Rochold, X. (1992), Report xx Xxxxxxx Xxxxxxxxxx Xxxxxxx/XX Environmental Xxxxxxx Xxxxxxx Xxxxxxx Xxxxx: Xxxx Xxxxxxx xx Xx vivo Xxxxxxxxxxxx Xxxxxx, Xxxxxxxxxxx, 7, 313-319.
14) Xxxxxxx, X., Xxxxxx, X., Ishidate, X. Jr. (1983), Xx Xxxxxxxxxxx xx Xxxxxxxx Xxxxxx Xxxxxxxxxxx Xxxxxxxx xx xxx Xxxxxxxxxxxx Test, Xxxxxxxx Xxx., 120, 241-247.
15) XxxXxxxxx, X. T., Xxxx, C. X., Xxxxxxxx, X. G. (1983), A Simple Xxxxxxxxxxx Xxxxxxxx Procedure xxx Micronuclei xxx XXX xx Xxxxxxxxxxxx Xxxxx Xxxxxxx 33258 xxx Xxxxxxx X, Xxxxxxxx Res., 120, 269-275.
16) Xxxxxxx, F., Xxxxxxxxxx, X. D. (1989), The xxxxxxxxx xxxx marrow xxxxxxxxxxxx xxxx, Mutatation Xxx., 213, 91-104.
17) Xxxxxxxxx, X., McFadden, X. X. (1995), Xxxxxx Xxxx xxx xxx Xxxxxxxxxx of Xxxxxxxxxxxxx xx Xxxxxxxxxxxxxx Xxxxxxxxxxx Xxxxx xx xxx Xxxx Xxxxxx Micronucleus Xxxx, Mutatation Res., 347, 97-99.
18) Richold, X., Ashby, X., Xxxxxxx, J., Xxxxxxxx, X., Gatehouse, D. X., Xxxxxxxxx, X. (1990), Xx xxxx Xxxxxxxxxxxx Xxxxx, xx: X. X. Xxxxxxxx (xx.), Xxxxx Xxxxxxxxxxxx xxxxx, XXXXX Recommended Xxxxxxxxxx, XXXXX Sub-Committee xx Xxxxxxxxxx xxx Xxxxxxxxxxxx Xxxxxxx. Xxxxxx, Xxxx 1, xxxxxxx, Xxxxxxxxx Xxxxxxxxxx Xxxxx, Xxxxxxxxx, Xxx York, Xxxx Xxxxxxx, Xxxxxxxxx, Xxxxxx, 115-141.
19) Xxxxxx, X. X., Xxxxxxxx, X., Albanese, X., Xxxxxxxx, G. E., Xxxxx, X., Ferguson X., Xxxxxxx, X., Xxxxxxxx, X. X., Xxxxxx, X. X. X. (1989), Xxxxxxxxxx Xxxxxxxx of In xxxx Cytogenetic Assays, xx: D. X. Xxxxxxxx (xx.), Xxxxxxxxxxx Xxxxxxxxxx xx Mutagenicity Xxxx Data. XXXXX Xxx-Xxxxxxxxx xx Xxxxxxxxxx xxx Mutagenicity Xxxxxxx. Xxxxxx, Xxxx III, Xxxxxxxxx University Xxxxx, Xxxxxxxxx, New Xxxx, Xxxx Xxxxxxx, Xxxxxxxxx, Xxxxxx, 184-232."
XXXXXXX 4X
"X.13/14 XXXXXXXXXX — XXXXXXX XX XXXXXXXX XXXXXX X XXXXXXXXXX
1. XXXXXX
Xxxx xxxxxx xx xxxxxxxx xxxxxx XXXX XX 471 — Xxxxxxx xx xxxxxxxx xxxxxx s xxxxxxxxxx (1997).
1.1 XXXX
Xxx xxxxxxx xx xxxxxxxx xxxxxx x xxxxxxxxxx xx xxxxxxxxx bakteriální xxxxx xxxxxxx na xxxxxxxxxxxxxxx Xxxxxxxxxx xxxxxxxxxxx x Xxxxxxxxxxx coli, x xxxxxxx bodových xxxxxx, které xxxxxxxx xxxxxxxxxx, xxxxx a xxxxxx xxxxxxx nebo xxxxxxxx párů bází XXX (1, 2, 3). Podstata xxxx xxxxxxx xx xxxxxxxx xxxxxx s bakteriemi xxxxxxx x xxxxxxx xxxxxx, xxxxx xxxxxxxxx xxxxxx xxxxxxxx x xxxxxxxxxxx xxxxxxx x xxxxxxxx tak funkční xxxxxxxxx bakterií xxxxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx. Xxxxxxxx xx xxxxxxx jsou xxxxxxxxxx díky xxx xxxxxxxxxx xxxx x xxxxxxxxxxxxx aminokyselin, xxxxx xxxx xxxxxxxxxx mateřským xxxxxxxxxx xxxxxx.
Xxxxxx xxxxxx x xxxxxxx xxxx xxxx xxxxxxxx xxxxx xxxxxxxxx xxxxxxxxxxx xxxxxx x xxxxxxx x xxxxxxxx xxxxx xxxxxx x xxx, xx xxxxxx xxxxxx x xxxxxxxxxx x x xxxxxx somatických buněk xxxxxxxxx nádory xxxx xxxxx xx xxxxxx xxxxxxxx x člověka x u xxxxxxxxx xxxxxx. Zkouška xx xxxxxxxx xxxxxx s xxxxxxxxxx je xxxxxx, xxxxxxxxxx x relativně xxxxxx. Xxxxx xxxxxxxxxxx xxxxx má xxxx xxxxxxxxxx, xxxx xxxx xxxx citlivější xx xxxxxxx mutací, xxxxxx xxxxxxxxxxxxx xxxxxxxx XXX xx reverzních xxxxxxx, xxxxxxx permeability xxxxx xxx velké xxxxxxxx x eliminaci xxxxxxxxxxx xxxxxxx XXX xxxx xxxxxxxx reparačních xxxxxxx XXX xxxxxxxxxx k xxxxxx. Xxxxxxxxxxxx testovacích xxxxx xxxx xxxxxxxxxx xxxxxxx xxxxxxxx informace x xxxxxx xxxxxx, xxx xxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxx. Xxx xxxxxxx xx reverzní xxxxxx x xxxxxxxxxx xx k xxxxxxxxx xxxxx rozsáhlá xxxxxxxx xxxxxxxx pro xxxxxxx xxxxx xxxxxxxx a xxxx byly vyvinuty xxxxx xxxxxxxxxx xxxxxx xxxxxxxx xxxxxxxxxx xxxxx, xxxxxx xxxxxxxx xxxxxxxxx, x různými xxxxxxxxx-xxxxxxxxxx xxxxxxxxxxx.
Xxx xxxx obecný xxxx, část B.
1.2 XXXXXXXX
Xxxxxxx na xxxxxxxx xxxxxx x xxxxxxxxxx Xxxxxxxxxx typhimurium nebo Xxxxxxxxxxx coli slouží x xxxxxxx xxxxxx x kmeni xxxxxxxxxxx xxxxxxxxxxxxx (xxxxxxxx xxxx. xxxxxxxxx), xxxxxxx xxxxxx xxxx nezávislý na xxxxxxx xxxxxxx xxxxxxxxxxxxx.
Xxxxxxxx xxxxxxxxxx párů xxxx xxxx xxxxxxxx, jež xxxxxxxxx změny v xxxxxx XXX. Při xxxxxxx xxxxxxxxxx xxxxxx xx mohou xxxx xxxxx xxxxxxxxxx xx xxxxx xxxxxxx mutace xxxx jiném xxxxx xxxxxxxxxxxxx xxxxxx.
Xxxxxxxx xxxxxxxx xxxx činitele, xxx xxxxxxxxx adici xxxx xxxxxx xxxxxxx xxxx xxxx xxxx bází XXX x xxxxxxxx xxx xxxxx xxxxx XXX.
1.3 XXXXXXX XXXXX
Xxx xxxxxxxxx na reverzní xxxxxx s bakteriemi xx využívají xxxxxxxxxxxxx xxxxx, xxxxx se xxxx od buněk xxxxx xxxxxxx, jako xxxx xxxxxx, metabolismus, xxxxxxxxxxxx xxxxxxxxx x xxxxxxxxx xxxxxxx XXX. Xxxxxxx xxxxxxxxx xx xxxxx xxxxxx xxxxxxxx xxxxxxx xxxxxxxx xxxxxx xxxxxxxxxxx xxxxxxxx. Xxxxxxxxxxx xxxxxxxxx xxxxxxx xx xxxxx xxxxxxx xxxxx xxxxxxxxx xxxxxxxx in xxxx x savců. Xxxxxxx xxxx xxxxxxxxxxx xxxxxx xxxxxxxxx x xxxxxxxxxx x xxxxxxxxxxxxx xxxxxxxxxx xxxxx xxx xxxxx.
Xxxxxxx xx xxxxxxxx xxxxxx x xxxxxxxxxx xx xxxxxxxxx využívána xxx počáteční xxxxxxxxx xxxxxxxxxxx xxxxxxxx, x xxxxxxx xxxxxxxx xxxxxxxxxxxx xxxxxx xxxxxx. X xxxxxxxx xxxxxxxx xxxxxxx, xx xxxxx xxxxxxxxxx xxxxx, xxxxx xxxx x xxxx xxxxxxx xxxxxxxxx, xxxxxxxx xxxxxxxxx xxxxxxxx x x xxxxxx xxxxxxxxx. Xxxxxxxx xxxxxxxx mutagenních činitelů, xxxxx xxxxxx detekovány xxxxx xxxxxxxx. Xxxxxxx xxxxxx xxxxxxxxxxx lze xxxxxxxxx ve xxxxxxxxxx xxxxxx detekovanéhokonečného xxxx, x rozdílech x xxxxxxxxxxx xxxxxxxx xxxx x xxxxxxxxx x xxxxxxxxxx xxxxxxxxxxx. Xx xxxxx xxxxxx xxxxxxx, xxxxx zvyšují xxxxxxxxx xxxxxxx na xxxxxxxx xxxxxx xx bakteriích, xxxxx vést k xxxxxxxxxxxx xxxxxxxxx xxxxxxxx.
Xxxxxxx xx xxxxxxxx xxxxxx x xxxxxxxxxx nemusí xxx vhodná xxx xxxxxx xxxxx chemických xxxxx, xxxxxxxxx xxxxxx xxxxxxxxxxxx xxxxxxxxxx (xxxx. xxxxxx antibiotika) x xxx chemické xxxxx, x nichž xx xxxxxxxxxxx (xxxx x xxxxx xx ví), xx xxxxxxxxxx zasahují xx xxxxxxxxxxxx systému xxxxx xxxxx (xxxx. xxxxxxx inhibitory xxxxxxxxxxxxx x xxxxxxx xxxxxxx xxxxxxxxxx). X xxxxxxxx xxxxxxxxx xxxxx xxx xxxxxxxxx xxxxxxx xxxxxxxxxx x xxxxx.
Xxxxxxxx xxxxx xxxxxxxxx, xxx něž xx tato xxxxxxx xxxxxxxxx, xx xxxxxxxxxxxx xxx xxxxx, není xxxxxxxx xxxxxxxxx. Xxxxxx xx chemické xxxxx x existuje xxxxx xxxxxxxxxxx, xxx xxxxxx xxxxxxxxxx xxxxx xxxxxxxx, xxxxx xxxxxx xxxxxx, xxxxxxxxxxxxxxx xxxxxxxxxx, xxxx xxxxxxxxxx, které x xxxxxxxxxxxxx xxxxxxx neexistují.
1.4 XXXXXXXX ZKUŠEBNÍ XXXXXX
Xxxxxxxx xxxxxxxxxxxxx xxxxx xxxx xxxxxxxxx xxxxxxxx xxxxx, x xx xx xxxxxxxxxxx vnějšího xxxxxxxxxxxxx xxxxxxxxxxx xxxxxxx x xxx xxxx. Xx xxxxxxxxxxx miskovém testu xx xxxxxxxx xxxxxxxx x vrchním agarem x xxxxx se xxxxxxx xx xxxxxxxxx xxxx. X preinkubační xxxxxx xx xxxxxxxx xxxx inkubuje x xxxx xx xxxx xxxxxxxxx xx xxxxxxxxx xxxx smíchá s xxxxxxx xxxxxx. Xxx xxxx xxxxxxxxxx xx xx dvou xxxx xxxxx dnech inkubace xxxxxxxxx xxxxxxx revertantů x provede xx xxxxxxxx x xxxxxx xxxxxxx xxxxxxxxxxx xxxxxxxxxx xx xxxxxxxxx misce x rozpouštědlem.
Je xxxxxxx xxxxxxx xxxxxxx provedení xxxxxxx na xxxxxxxx xxxxxx s xxxxxxxxxx. Xxxx xxxxx používané xxxxx standardní miskový xxxx (1, 2, 3, 4), xxxxxxxxxxxx xxxxxx (2, 3, 5, 6, 7, 8), fluktuační test (9, 10) a xxxxxxxxx xxxxxx (11). Xxxxxx xxx xxxxxxxx xxxxx x xxx xxxx xxxxxxx (12).
Xxx xxxxxxx xxxxxxx xx xxxxxx hlavně xxxxxxxxxxxx xxxxxxxxx xxxxx x xxxxxxxxxxxxxx xxxxx. Každá x nich xx xxxxxxxxxx xxx provádění xxxxxxxxxxx jak x xxxxxxxxxxxx xxxxxxxx, xxx xxx ní. Některé xxxxx xxx xxxxxxxx xxxxxxxxx za xxxxxxx xxxxxxxxxxxx xxxxxx. Xxxx xxxxx patří xx xxxxxxxxxx xxxx, do xxxxx xxxxx xxxx xxxxx xxxxxx alifatické xxxxxxxxxxx, xxxxxxxxx xxxx, xxxxxxxx, azobarviva x xxxxxxxxxx xxxxxxxxxx, xxxxxxxxxxxxxxx xxxxxxxxx, allylové sloučeniny x xxxxxxxxxxxxxxx (3). Xxxxxx se připouští, xx xxxxxx třídy xxxxxxxx nelze vždy xxxxxxxxx xxxxxxxxxxxx xxxxxxx, xxxx xx xxxxxxxxxx xxxxxxx xxxx nebo xxxxxxxxxxxx metoda. Xxxx xx být xxxxxxxxxx xx "zvláštní xxxxxxx" x k xxxxxx xxxxxxx xx xxxxxxx xxxxxxxxxx xxxxxx alternativní xxxxxxx. Je xxxxx xxxxxxxxxxxxx xxxx "xxxxxxxx xxxxxxx" (xxxxxxxx x xxxxxxxx xxxxxxx jejich xxxxxxx): xxxxxxxxxx x xxxxxxxxxx sloučeniny (3, 5, 6, 13), xxxxx x xxxxxx xxxxxxxx xxxxx (12, 14, 15, 16), x glykosidy (17, 18). Xxxxxxxx od xxxxxxxxxxxx xxxxxxx musí xxx xxxxxxx xxxxxxxxxx.
1.5 XXXXX ZKUŠEBNÍ XXXXXX
1.5.1 Xxxxxxxxx
1.5.1.1 Xxxxxxxx
Xxxxxxx xxxxxxx xxxxxxxx xx měly xxx kultivovány xx xxxxxx exponenciální xxxx xxxx do xxxxx xxxxxxxxxxx fáze xxxxx (xxxxxxxxx 109 xxxxx xx xx). Xxxxx x xxxxxx stacionární xxxx xx xxxxxx xxx xxxxxxx. Je xxxxxxxx, xxx xxxx xxxxxxx xxxxxxxx xxxxxx xxxx xxxxxxxxxxxxxxx bakterií. Xxxx xxxx xxx xxxxxxxx xxx xx xxxxxxx xxxxxxxxxxx xxxxxxxxxxx xxxxx x růstové xxxxxx, nebo pro xxxxxx xxxxxxx xxxxxxxxxx xxxxx životaschopných xxxxx xx xxxxxxx.
Xxxxxxxxxx xxxxxxxxx xxxxxxx xx 37 °X.
Xxxx xx být xxxxxxx alespoň xxx xxxxx xxxxxxxx. Mezi xxxx xx xxxx xxx čtyři xxxxx X. xxxxxxxxxxx (XX1535; XX1537 nebo XX97x xxxx XX97; XX98 x TA100), xxxxxxx xxxxxxx se xxxxxxx x xxxxxxx xxxxxxxxxxxx xxxx xxxxxxxxxx x xxxxxxxxxxxxxxxx. Xxxx čtyři xxxxx X. xxxxxxxxxxx xxxx xxx xxxx XX xx xxxxxxxxx xxxxxxxxx místě a xx xxxxx, xx xxxxxx xxxxxxxxxxxxxxx xxxxx xxxxxxxxx určité xxxxxxxx xxxxxxxx, xxxxxxxx způsobující xxxxxxxxxx vláken DNA x hydraziny. Tyto xxxxx mohou xxx xxxxxxxxxx kmeny X. xxxx XX2 nebo X. xxxxxxxxxxx XX102 (19), xxxxx xxxx xx xxxxxxxxx xxxxxxxxx xxxxx xxx xxxx XX. Xxxxxxxxxx xxxxxxxxx xxxxx je xxxx xxxx:
- S. xxxxxxxxxxx XX1535 a
- X. xxxxxxxxxxx TA1537 nebo XX97x a
- S. xxxxxxxxxxx TA98 x
- X. typhimurium XX100 x
- X. coli XX2 xxxX, nebo X. coli XX2 xxxX (pKM101), nebo X. xxxxxxxxxxx TA102.
Pro xxxxxxx xxxxxxxx způsobujících xxxxxxxxxx xxxxxx XXX xxxx být xxxxxxxxx xxxxxxx XX102 xxxx xxxxxx xxxx X. xxxx s vysokou xxxxxxxxxx xxxxxxxx XXX, (xxxx. E. coli XX2 (xXX101)).
Xxxx xx xxx xxxxxxx xxxxxxxx xxxxxxx přípravy xxxxxxx xxxxxxx, xxxxxxxxxx markeru x skladování. Potřeba xxxxxxxxxxxxx xxx xxxx xx xxxx xxx xxxxxxxxx xxx xxxxxx xxxxxxxxx kmenovou xxxxxxx (xxxxxxxx xxx xxxxx X. xxxxxxxxxxx a xxxxxxxxx xxx X. xxxx). Podobně by xxxx být xxxxxxxxxxxx xxxx xxxxxxxxxx charakteristiky, xxxxxxxxx xxxxx xxxxxxx xxxxxxxxxx xxxx xxxxxxxxxxxx X-xxxxxxx plasmidů (xx. xxxxxxxxxxxx xxxxxxxxxx x xxxxx XX98, TA100 x XX97x nebo XX97, WP2 xxxX x XX2 xxxX (xXX101) x xxxxxxxxxxxx x xxxxxxxxxxxxxx rezistence x xxxxx XX102), xxxxxxxxxx xxxxxxxxxxxxxxxxxx xxxxxx (xx. xxx xxxxxx x X. xxxxxxxxxxx xxxxxxxxxx xx krystalovou xxxxxx a uvrA xxxxxx u E. xxxx xxxx uvrB xxxxxx x X. xxxxxxxxxxx xxxxxxxxxx na xxxxxxxxxxxx xxxxxx) (2, 3). Xxxxx xx xxxx xxxxxx xxxxx xxxxx xxxxxxx xxxxxxxxxxx xxxxxxxxxx xx xxxxx x rozmezí četností xxxxxxxxxxx xx xxxxxxx xxxxxxxxxxx údajů laboratorních xxxxxxx a xxxxxxx x xxxxxxx xxxxxxxx x literatuře.
1.5.1.2 Médium
Použije xx xxxxxx xxxxxxxxx xxxx (např. xxxxxxxxxx xxxxxxxxx xxxx X (Xxxxx-Xxxxxx) a xxxxxxx) x xxxxxx xxxx xxxxxxxxxx histidin x xxxxxx xxxx xxxxxxxxx xxxxxxxxxx xxxxxxx xxxxxxxxx xxxxxx (1, 2, 9).
1.5.1.3 Metabolická xxxxxxxx
Xxxxxxxx xx měly být xxxxxxxxx zkoušené xxxxx, x to s xxxxxxx systémem xxxxxxxxxxx xxxxxxxx x bez xxxx. Xxxxxxxxxx používaným xxxxxxxx xx xxxxxxxxxx xxxxxxxx xxxxxxxxxxxxxxxxxxx xxxxxx (X9) xxxxxxxxxx z xxxxx hlodavců ošetřených xxxxxxxxxxx xxxxxxxxxxx xxxxxx, xxxx xx Xxxxxxx 1254 (1, 2) xxxx fenobarbitonu a β-xxxxxxxxxxxx (18, 20, 21). Postmitochondriální xxxxxx xx obvykle používána x koncentracích v xxxxxxx 5 xx 30 % xxx. xx xxxxx X9. Xxxxx x xxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxx systému xxxx xxxxxxx xx xxxxx xxxxxxxx chemické xxxxx. X některých xxxxxxxxx může xxx xxxxxx použít xxxx xxx xxxxx xxxxxxxxxxx xxxxxxxxxxxxxxxxxxx xxxxxx. X xxxxxxxxx x xxxxxxxxxxxx xxxxxxxxx může xxx xxxxxxxxx xxxxxxx xxxxxxxxxx xxxxxxxxxxxxx aktivačního systému (6, 13).
1.5.1.4 Xxxxxxxx xxxxx xxxx přípravek
Pevné xxxxxxxx látky xx xxxx být xxxx xxxxxxxx na xxxxxxxx xxxxxxxxxx xxxx suspendovány xx xxxxxxxx xxxxxxxxxxxxxx xxxx xxxxxxxxxx x xxxxxxxxx xxxxxxx. Xxxxxxx xxxxxxxx látky xxxxx xxx přidány přímo x xxxxxxxxxx xxxxxxxx x/xxxx mohou xxx xxxx xxxxxxxx zředěny. Xxxx by být xxxxxxx čerstvě připravené xxxxxxxx xxxxxxxx xxxxx, xxxxx údaje o xxxxxxxx xxxxxxxxxxx xxxxxxx xxxxxxxxxx.
Xxxxxxxxxxxx/xxxxxxxxx xx mělo xxx mimo xxxxxxxxx, xx reaguje xx xxxxxxxxx xxxxxx, a xxxx xx xxx xxxxxxxxxx s přežitím xxxxxxxx a s xxxxxxxxx X9 (22). Xxxx-xx xxxxxxx jiná xxx xxxxx rozpouštědla/vehikula, xxxx by být xxxxxx xxxxxxxx podloženo xxxxx x xxxxxx xxxxxxxxxxxxx. Doporučuje xx xxxxx xxxxx xxxxxxxx xxxxxx xxxxxxx xxxxxxx xxxxxxxxxxxx/xxxxxxx. Při zkoušení xxxxx xxxxxxxxx xx xxxx xx měla xxx xxxxxxx xxxxxxxxx xxxxxxxxxxxx neobsahující xxxx.
1.5.2 Xxxxxxxx xxxxxxxx
1.5.2.1 Xxxxxxxx xxxxx (xxx 1.5.1.1)
1.5.2.2 Xxxxxxxxx koncentrace
Mezi xxxxxxxx, xxxxx mají xxx xxxxxxxxxx xxx xxxxxxxxx xxxxxxxxxx xxxxxxxx xxxxxxxx xxxxx xxxxx xxxxxxxxxxxx x xxxxxxxxxxx v xxxxxxx xxxxx pro xxxxxxxx.
Xxxx být užitečné xxxxxxxx xxxxxxxx x xxxxxxxxxxxxx v předběžných xxxxxxxxxxxxx. Xxxxxxxxxxxx xxxx xxx xxxxxxxxxx xxxxxxxx xxxxx xxxxxxx xxxxxxxxxx, xxxxxxxxx xxxx zeslabením xxxxxxxxxxxxx xxxxxxxx xxxx xxxxxxxx xxxxxx xxxxxxx xxxxxxxxxxxx xxxxxx. Cytotoxicita xxxxx xx xxxx xxxxxx x xxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxx xxxxxxx. Xxxxxxxxxxxxx by xxxx xxx posouzena xx xxxxxxx viditelného srážení x xxxxxxx xxxxx xx skutečných xxxxxxxxxx xxxxxxxx.
Xxxxxxxxxx maximální zkušební xxxxxxxxxxx xxx xxxxxxxxx xxxxxxxxxxxxx xxxxx xx 5 xx/xxxxx xxxx 5 μx/xxxxx. U xxxxxxxxxxxxxxx xxxxx xxxxxxxxxxxxx xxx xxxxxxxxxxxxx 5 xx/xxxxx xxxx 5 μx/xxxxx xx xxxx xxx xxxxx xxxx xxxx zkušebních xxxxxxxxxxx xxxxxxxx, xxx xxxxx xxxx v xxxxxxx xxxxx xxx aplikaci xxxxxxxxxxx. Zkoušené xxxxx, xxxxx jsou cytotoxické xxx při xxxxxxxxxxxxx xxxxxxx xxx 5 xx/xxxxx xxxx 5 μx/xxxxx, by měly xxx xxxxxxxx až xx xxxxxxxxxxx xxxxxxxxxxx. Xxxxxxxxx xx xxxxxx xxxxx při vyšetřování.
Mělo xx xxx xxxxxxx xxxxxxx pět xxxxxxx xxxxxxxxxxxxxxxx xxxxxxxxxxx xxxxxxxx xxxxx, přičemž xxx xxxxxx experimentu by xxxx být xxxxxxxxx xxxx xxxxxxxxxx xxxx xxxxx přibližně xxxxxxxx xxxxx xxxxxxxxxxxx xxxxxxxx (xx. Ö10). Xxxxx xxxxxxxxx jsou xxxxxx x xxxxxxx, xxx xx vyšetřuje xxxxxx xxxxxxxxxx xxxxxxxx xx xxxxxxxxxxx. Zkoušení koncentrací xxxxxxx xxx 5 xx/xxxxx nebo 5 μx/xxxxx může xxx xxxxxxx xxx xxxxxxxxx xxxxx xxxxxxxxxxxx xxxxxxxx xxxxxxxx potenciálně xxxxxxxxxxx xxxxxxxx.
1.5.2.3 Negativní a xxxxxxxxx xxxxxxxx
Xxxxxxxx každého xxxxxxxxx xx xxxx xxx xxxxxxx xxxxxxxxxx xxxxxxxxx x xxxxxxxxx (xxxxxxxxxxxx xxxx xxxxxxxxx) xxxxxxxx s xxxxxxxxxxxx xxxxxxxx a xxx xx. Xxx xxxxxxxxx xxxxxxxx xx měly xxx xxxxxxx koncentrace xxxxxxxxxxx xxxxxxxx každé xxxxxxx.
X xxxxxxx xxxxxxx x xxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxx xxxxxxx by xxxx xxx látka (xxxxx) xxx xxxxxxxxx xxxxxxxx xxxxxxx (xxxxxxx) xx xxxxxxx typu xxxxxxxxx xxxxx xxxxxxxx.
Xxxxxxxxx xxxxxx xxxxxxxxx kontroly x zkoušky s xxxxxxxxxxxx xxxxxxxx jsou xxxx xxxxx:
Xxxxx |
Xxxxx XXX |
Xxxxx xxxxx EINECS |
9,10-dimethylanthracen |
781–43–1 |
212–308–4 |
7,12-dimethylbenzo[a]anthracen |
57–97–6 |
200–359–5 |
benzo[a]pyren |
50–32–8 |
200–028–5 |
2-aminoanthracen |
613–13–8 |
210–330–9 |
Cyklofosfamid |
50–18–0 |
200–015–4 |
cyklofosfamid monohydrát |
6055–19–2 |
Tato xxxxx xx xxxxxxx xxxxxxxxx xxxxxxxxx xxx xxxxxx xxxxxxxx metabolické xxxxxxxx:
Xxxxx |
Xxxxx XXX |
Xxxxx xxxxx XXXXXX |
XX Xxxxxx Xxx 28 |
573–58–0 |
209–358–4 |
2-xxxxxxxxxxxxxx xx neměl xxx použit jako xxxxxx xxxxxxxxx xxxxxxxxx xxxxx X9. Xxx xxxxxxx 2-xxxxxxxxxxxxxxx xx xxxx xxx xxxxx xxxxx X9 xxxxxxxxxxxxxxxx xxxxxxxxx, xxxxx xxxxxxxx xxxxxxxxxxxx xxxxxxxx mikrosomálními xxxxxx, například xxxxx[x]xxxxx xxxx 7,12-dimethylbenzo[a]anthracen.
Příkladem kmenověspecifické xxxxxxxxx xxxxxxxx u xxxxxxx xxx xxxxxx xxxxxxxxxxx aktivace xxxx xxxx xxxxx:
Xxxxx |
Xxxxx XXX |
Xxxxx xxxxx XXXXXX |
Xxxx |
xxxx sodný |
26628–22–8 |
247–852–1 |
TA1535 x XX100 |
2-xxxxxxxxxxxx |
607–57–8 |
210–138–5 |
XX98 |
9-xxxxxxxxxxxx |
90–45–9 |
201–995–6 |
XX1537, TA97 x XX97x |
XXX 191 |
17070–45–0 |
241–129–4 |
TA1537, XX97 x XX97x |
Xxxxxxxxxxxxxxxxx |
80–15–9 |
201–254–7 |
XX102 |
xxxxxxxxx X |
50–07–7 |
200–008–6 |
XX2xxxX x XX102 |
1-xxxxxx-3-xxxxx-1-xxxxxxxxxxxxxxx |
70–25–7 |
200–730–1 |
XX2, XX2 xxxX x XX2 uvrA (xXX101) |
4-xxxxxxxxxxxxx-1-xxxx |
56–57–5 |
200–281–1 |
XX2, XX2 xxxX a XX2 xxxX (xXX101) |
α-[(5-xxxxx-2-xxxxx)xxxxxxxxxx]xxxxx-2-xxxxxxxx (XX2) |
3688–53–7 |
xxxxx xxxxxxxxxx plasmidy |
Pro xxxxxxxxx xxxxxxxx mohou xxx xxxxxxx xxxx xxxxxx referenční xxxxx. Xxx xxxxxxxxx xxxxxxxx xx xxxx xxx xxxxx x xxxxx xxxxxxx xxxxxxxxxx xxxxx xx xxxxxx xxxxxxxx xxxxx, xxxx xx x xxxxxxxxx.
Xxxx by xxx xxxxxxx negativní xxxxxxxx xxxxxxxxxx se xx samotného rozpouštědla xxxx vehikula, bez xxxxxxxx látky, zpracované xxxxx xxxxxxx xxxxxxxx xxxx exponované skupiny. Xxxxx xxxx by xxxx xxx xxxxxxxxxxxx xxxxxxxx xxxxxxx také xxxxx, xxxxxxxxxx-xx xxxxx xxxxxxxxx xxxxx xxxxxxxxxxx, xx zvolené xxxxxxxxxxxx xxxxxxxxxx xxxxx zhoubné xxxx mutagenní účinky.
1.5.3 Xxxxxx
X xxxxxxxxxx xxxxxxx xxxxxx (1, 2, 3, 4) bez xxxxxxxxxxx aktivace xx xxxxxxx xxxxxx 0,05 xx xxxx 0,1 xx zkušebních xxxxxxx, 0,1 xx xxxxxxx xxxxxxxxxxx xxxxxxx (obsahující xxxxxxxxx 108 xxxxxxxxxxxxxxx xxxxx) a 0,5 xx xxxxxxxxxx xxxxx x 2,0 ml xxxxxxxx xxxxx. X xxxxxxx xxxxxxx s xxxxxxxxxxxx xxxxxxxx se xxxxxxx xxxxxx 0,5 xx xxxxxxxxxxx aktivační xxxxx xxxxxxxxxx xxxxxxxxx xxxxxxxx xxxxxxxxxxxxxxxxxxx frakce (x xxxxxxx 5 xx 30 % xxx. x xxxxxxxxxxx xxxxxxxxx xxxxx) s xxxxxxx agarem (2,0 xx) x xxxxxxx x xxxxxxxxxx x xxxxxxxxx látkou xxxx xxxxxxxxx xxxxxxxx. Obsah xxxxx xxxxxxxx xx xxxxxxxx x xxxxxxx xxxx povrch xxxxxxxxxxx xxxxx na xxxxx. Xxxx xxxxxxxx se xxxxx xxxxxx xxxx xxxxxxxx.
X xxxxxxxxxxxx metody (2, 3, 5, 6) se xxxxxxxx xxxxx xxxx xxxxxxxx xxxxxx xxxx xxxxxxxxx x xxxxxxx agarem x xxxxxxxx xxxx xxxxxx minimálního xxxxx xx misce xxxxxxx 20 xxxxx xxxx xxxx preinkubuje x xxxxxxxxxx xxxxxx (obsahujícím xxxxxxxxx 108 xxxxxxxxxxxxxxx xxxxx) x sterilním xxxxxx xxxx xxxxxxxxxxxx xxxxxxxxxx systémem (0,5 xx) xxx 30 — 37 °X. Xxxxxxx se xxxxxx 0,05 nebo 0,1 xx zkoušené xxxxx xxxx xxxxxxxxxx roztoku, 0,1 ml xxxxxxxx x 0,5 xx xxxxx S9 nebo xxxxxxxxxx xxxxx s 2,0 xx xxxxxxxx xxxxx. Xxxxxxxx by xxxx xxx xxxxx xxxxxxxx xxxxxxxxxxxxxx xx xxxxxxxx.
X xxxxxxxxxxxx xxxxxx xxxxxxxx xx xxxx xxx xxx xxxxx xxxxxx xxxxx xxxxxxx 3 xxxxx. Xxxxxxx xxxx xxxxx xx xxxxxxxxxx xx xxxxxxxx xxxxxxxxxx. Xxxxxxxx xxxxxx xxxxx xxxxxx znamenat xxxxxxxxxxxx xxxxxxx.
Xxxxxx xxxx xxxxxx xxxxx by xxxx xxx zkoušeny xxxxxxxx xxxxxxxx, xxxx. x těsně xxxxxxxxxx xxxxxxxxxxxx nádobách (12, 14, 15, 16).
1.5.4 Xxxxxxxx
Xxxxxxx xxxxx x xxxx xxxxxxx xx xxxx být xxxxxxxxxx xxx 37 °X xx 48 –72 xxxxxxxx. Xx xxxxxxxx xxxxxxxxx xxxx xx xxxxxx počet xxxxxxx xxxxxxxxxx xx xxxxx.
2. XXXXX
2.1 XXXXXXXXXX VÝSLEDKŮ
Předloženými xxxxx xx xxxx xxx xxxxx xxxxxxx xxxxxxxxxx xxxxxxxxxxx na xxxxx. Xxx by xxx xxxxxx xxxxxx xxxxx xxxxxxx xxxxxxxxxx xxx xx miskách x negativní xxxxxxxxx (xxxxxxxx xxxxxxxxxxxx a xxxxxxxx xxxxxxxxxxxx xxxxxxxx), xxx na xxxxxxx x xxxxxxxxx xxxxxxxxx. Xxxxx na xxxxxxxxxxxx xxxxxxx, xxxxxxx xxxxxxx xxxxx kolonií xxxxxxxxxx xx xxxxx x xxxxxxxxxx odchylka xx xxxx xxx xxxxxxxxxx xxx zkoušenou xxxxx x pozitivní x xxxxxxxxx kontrolu (neexponovanou xxxxxxxx a/nebo xxxxxxxx xxxxxxxxxxxx).
Xxxxxxx jasně xxxxxxxxx xxxxxxxx se xxxxxxxxxx. Xxxxxxxxxx xxxxxxxx xx xxxx xxx vyjasněny xxxxxx xxxxxxxxx, nejlépe x úpravou experimentálních xxxxxxxx. Xxxxxxxxx výsledky xxxx xxx potvrzeny xxxxxx xx xxxxxxx. Xxxxxxxx xx xxxxxxxxx xxxxxxxxxxx xxxxxxxx nepovažuje xx xxxxxxxx, xxxx xx xxx xxxxxx xxxxxxxxxx. Xxxxx xxxxxxxxx xxxxxx s xxxxx xxxxxxxx xxxxxx posuzovaných xxxxxxxx xx xxxx xxx xxxxxxx v xxxxxxxxxx xxxxxxxxxxxxx. K xxxxxxxxxx studie, xxxxx xx xxxxx xxx xxxxxxx, patří xxxxxxx xxxxxxxxxxx, xxxxxx zpracování (xxxxxxxxxx xxxxxxx xxxxxx xxxx xxxxxxxxxxx v xxxxxxxx xxxxx) x xxxxxxxx xxxxxxxxxxx xxxxxxxx.
2.2 XXXXXXXXX A XXXXXXXXXXXX XXXXXXXX
Xxx xxxxxxxxx pozitivního xxxxxxxx existuje xxxxxxx xxxxxxxx, např. xxxxxx xxxxx kolonií revertantů xx xxxxx xxx xxxxxxxxx xxxxxx x xxxxxxx xxxxxxx kmene x xxxxxxxxxxxx xxxxxxxxxx xxxxxxxx nebo xxx xxxx, x to x xxxxxxxxxx na xxxxxxxxxxx, nebo reprodukovatelný xxxxxx xxxxxx xxxxx xxx xxxxx xxxx xxxx xxxxxxxxxxx (23). Xxxxxxxx by xxxx xxx xxxxxxx biologická xxxxxxxxx výsledků. Xxx xxxxxxxxx výsledků xxxxxxx xxxxx být xxxxxxx xxxx xxxxxxx xxxxxxxxxx xxxxxxxxxxx xxxxxx (24). Xxxxxxxxxxx xxxxxxxxxx xx xxxxxx být jediným xxxxxxxxx faktorem pro xxxxxxxxx xxxxxxx.
Xxxxxxxx látka, xxxxx xxxxxxxx xxxxxxxxx xxxx xxxxxxx xxxxxxxx, xx považuje v xxxxx xxxxxxx xx xxxxxxxxxxx.
Xxxxxx xxxxxxx experimentů xxxxxxxx xxxxx xxxxxxxxx xxxx negativní xxxxxxxx, x xxxxxxxxxxx případech xxxxxxxx xxxxxx údajů xxxxxxxx xxxxxxx xxxxx x xxxxxxxx zkoušené xxxxx. Výsledky xxxxx xxxxxx dvojznačné xxxx xxxxxx xxx xxxxxx xx xx, xxxxxxxx xx experiment xxxxxxxx.
Xxxxxxxxx xxxxxxxx zkoušky xx xxxxxxxx xxxxxx x xxxxxxxxxx xxxxxxxxx, xx xxxxxxxx xxxxx xxxxxxxx x genomu kmenů Xxxxxxxxxx typhimurium a/nebo Xxxxxxxxxxx xxxx bodové xxxxxx xxxxxxxxxx bází xxxx xxxxxxx čtecího xxxxx. Xxxxxxxxx výsledky xxxxxxxxx, že zkoušená xxxxx xxxx za xxxxxxxx xxxxxxx xxx xxxxxxxxx xxxxx xxxxxxxxx.
3. XXXXXX
XXXXXXXX O XXXXXXX
Xxxxxxxx x xxxxxxx musí xxxxxxxxx tyto xxxxxxxxx:
Xxxxxxxxxxxx/xxxxxxxxx:
- xxxxxxxxxx volby xxxxxxxxxxxx/xxxxxxxx,
- xxxxxxxxxxx x xxxxxxx xxxxxxxx látky x xxxxxxxxxxxx/xxxxxxxx, xx-xx xxxxx.
Xxxxx:
- xxxxxxx xxxxx,
- xxxxx xxxxx x xxxxxxx,
- xxxxxxxxxxxxxxx kmene.
Zkušební podmínky:
- xxxxxxxx zkoušené xxxxx xx xxxxx (xx/xxxxx xxxx μx/xxxxx) s xxxxxxxxxxx xxxxxx xxxxx x xxxxx misek xx xxxxxxxxxxx,
- použitá xxxxx,
- xxx x xxxxxxx xxxxxxxxxxxxx xxxxxxxxxxx xxxxxxx, včetně xxxxxxxx xxxxxxxxxxxxx,
- xxxxxx xxxxxxxx.
Xxxxxxxx:
- xxxxxx xxxxxxxx,
- xxxxxx xxxxxxx,
- xxxxx na xxxxxxxxxxxx xxxxxxx,
- střední xxxxxxx xxxxx xxxxxxx xxxxxxxxxx xx misku x xxxxxxxxxx xxxxxxxx,
- xxxxx možnosti závislost xxxxxxxx xx xxxxx,
- xxxxxxxx xxxxxxxxxxx analýzy,
- xxxxx o xxxxxxxx xxxxxxxxx (rozpouštědlo/vehikulum) x xxxxxxxxx xxxxxxxx x xxxxxxxxx, xxxxxxxxx xxxxxxxxx x xxxxxxxxxxxx odchylkami,
- xxxxxxxxx xxxxx x xxxxxxxxx (rozpouštědlo/vehikulum) a xxxxxxxxx kontrole x xxxxxxxxx, xxxxxxxxx xxxxxxxxx x směrodatnými odchylkami.
Rozbor xxxxxxxx.
Xxxxxx.
4. XXXXXXXXXX
1) Xxxx, X. N., XxXxxx, X., Xxxxxxxx X. (1975), Xxxxxxx of Xxxxxxxxx Carcinogens xxx Xxxxxxxx with xxx Xxxxxxxxxx/Xxxxxxxxx-Xxxxxxxxx Mutagenicity Xxxx, Xxxxxxxxxx Xxx., 31, 347-364.
2) Xxxxx, X. X., Xxxx, X. X. (1983), Xxxxxxx Xxxxxxx xxx xxx Xxxxxxxxxx Mutagenicity Xxxx, Xxxxxxxxxx Xxx., 113, 173-215.
3) Gatehouse, D., Xxxxxxx, X., Cebula, X., Gocke, E., Xxxx, X., Matsushima, X., Xxxxxxx, X., Xxxxx, X., Xxxxxx, X., Xxxxxx, X. (1994), Recommendations for xxx Performance xx Xxxxxxxxx Mutation Assays, Xxxxxxxxxx Xxx., 312, 217-233.
4) Kier, L. X., Xxxxxxx X. X., Xxxxxxx, X. X., Xxx Halle, X. X., Xxxxx, X. X., Xxxxxx, X. X., Xxxxxx, X., McCann, J., Xxxxxxxxxx, X., Prival, X., Xxx, X. X., Ray X. (1986), Xxx Xxxxxxxxxx xxxxxxxxxxx/Xxxxxxxxx Xxxxxxxxxx Xxxxx: X Xxxxxx of xxx X. X. Xxxxxxxxxxxxx Xxxxxxxxxx Xxxxxx Xxxx-Xxx Program, Xxxxxxxxxx Xxx., 168, 69-240.
5) Xxxxxx, X., Xxxxxx, X., Seino, X. X., Xxxxxxxxxx, X., Xxxxx, X., Sugimura, X., Hashimoto, X. (1975), Mutagenicity xx Xxxxxxxxxx Azo Xxxx xxx xxxxx Xxxxxxxxxxx, Xxxxxx Lett. 1, 91-96.
6) Xxxxxxxxxx, M., Xxxxxxxx, T., Nagao, X., Yahagi, X., Xxxxxx, X., Sawamura, X. (1980), Factors Xxxxxxxxxx Mutagenicity Xxxxxxxxx Xxxxx, xx: Xxxxx-xxxx Xxxx Xxxxxxx for Xxxxxxxxx Xxxxxxxxxxx, xx. Xxxxxxx X. X., Xxxxxx, R. C., Xxxxxxxx, Xxxxxx-Xxxxxxxxxx-Xxx Xxxx, 273-285.
7) Xxxxxxxxx, X. X., Rowland, X. X., Wilcox, X., Xxxxxxxxx, X. X., Xxxxxx, R. (1980), Xxxxxxxxx Mutation Xxxxxx, xx: Xxxxx Xxxxxxxxxxxx Xxxxx: XXXXX Xxxx 1 Xxxxxxx, xx. X. X. Xxxxxxxx, Xxxxxxxxx University Xxxxx, 13-61.
8) Xxxxxxxxxx, X. X., Xxxxxx, U., Xxxxxxx, X. (1987), Xxxxxx Xxxxxxxxxxxxx Mutagenicity Xxxx for Foods, X. Xxxx Xxxxxx., 8, 167-177.
9) Green, X. X. X., Xxxxxx, W. X., Xxxxxxx, X. X. (1976), Xxx xx x simplified fluctuation xxxx xx detect xxx xxxxxx xx xxxxxxxx, Mutatation Xxx., 38, 33-42.
10) Hubbard, X. X., Xxxxx, X. X. L., Xxxxxxxxx, D., Xxxxxxx, X. W. (1984), Xxx Xxxxxxxxxxx Xxxx xx Xxxxxxxx, xx: Xxxxxxxx xx Mutagenicity Xxxx Xxxxxxxxxx, 2. xxx., Kilbey, X. X., Xxxxxxx, M., Xxxxxxx, X., Ramel, X. (xxx.), Xxxxxxxx, Xxxxxxxxx-Xxx Xxxx-Xxxxxx, 141-161.
11) Xxxxxxxx, X. D., Xxxxxxx, X. J. (1981), Xx Xxxxxxxxxxx xx the Xxxxxxxxxxxx Xxxxxxxxxx Xxxxx xxx Xxxxxxxxxxx xxxx Xxxxxxx xx Xxxxxxxxxx typhimurium, Xxxxxxxxxxxxx Xxxxxxxxxxx, 3, 453-465.
12) Araki, X., Xxxxxxx, X., Xxxx, X., Xxxxxxxxxx, X. (1994), Xxxxxxxx Xxxxxx xxx Xxxxxxxxxxxx Xxxxxxx xx Gaseous Xxxxxxxxx xx Xxxxx a Xxx Xxxxxxxx Xxx, Xxxxxxxxxx Xxx., 307, 335-344.
13) Xxxxxx, X. X., Xxxx, X. X., Mitchell, X. X., Reipert, M. X., Vaughan, X. X. (1984), Mutagenicity xx Xxxxxxxxx xxx Xxxxxxxxx-Xxxxxxxx Xxxx xxx Xxxxxxxx Xxxxxxx Xxxx xx a Modified Xxxxxxxxxx Assay, Xxxxxxxxxx Xxx., 136, 33-47.
14) Xxxxxx, E., Xxxxxxxx, X. X., Xxxxxxx, X., Xxxxxx, X., Xxxxxxxxxx, X. (1992), Xxxxxxxxxx Xxxxxxxxxxxx Xxxxx. X. Xxxxxxx xxxx xxx Xxxxxxx xx 311 Chemicals, Xxxxxxx. Xxx. Xxxxxxx., 19, 2-141.
15) Xxxxxx, X., Xxxxxxxx, X., Xxxxxxx, X. X. (1977), Xxxxxxxxx Activity xx Xxxxxxxxx Identified in Xxxxxxxx Water, xx Xxxxxxxx xx Xxxxxxx Xxxxxxxxxx, D. Scott, X. Bridges, X. Xxxxxx (xxx.) Elsevier, Xxxxxxxxx, 249-258.
16) Xxxxxx, X. X., Simmons, X. M., Xxxxxxxx, X. G., Xxxxxxx, X. X. (1987), Xxxxxxxxxxxx Xxxxxxxxx to Xxxxxxx Mutagenic Activity xx Xxxxxxxx Xxxxxxx Xxxxxxxxx xx xxx Xxxx/Xxxxxxxxxx Assay, Environmental Xxxxxxxxxxx, 9, 421-441.
17) Xxxxxxxxxx, X., Matsumoto, X., Xxxxxx, M., Xxxxxxxx, M., Xxxxxxxx, X. (1979), Mutagenicity xx xxx Xxxxxxxxx Xxxxxxxxx Xxxxxxxxxx Cycasin xxx Synthetic Xxxxxxxxxxx Xxxxxxx Xxxxxxxxxx in Xxxxxxxxxx xxxxxxxxxxx, Cancer Xxx., 39, 3780-3782.
18) Xxxxxx, G., Xxxx, X., Xxxxx-Xxxxx, X., Xxxx, B. N. (1980), Xxxxxxxx: A Xxxxx xxx Xxxxxxxxxx xx Xxxxxxx Xxxxxxxxxx xx Xxxxxxxx xx Xxxxxxxxxx Flora, Proc. Xxxx. Xxxx. Xxx. X. X. A, 77, 4961-4965.
19) Wilcox, X., Naidoo, X., Xxxx, X. J., Xxxxxxxxx, D. X. (1990), Xxxxxxxxxx of Xxxxxxxxxx xxxxxxxxxxx XX 102 with Xxxxxxxxxxx xxxx WP2 Xxxxxx xxxxxxx, Xxxxxxxxxxx, 5, 285-291.
20) Xxxxxxxxxx, T., Xxxxxxxx, X., Xxxx, X., Xxxxxxxx, X. (1976), X Safe Xxxxxxxxxx xxx Xxxxxxxxxxxxxxx Xxxxxxxxx a. x. xx Xxxxxxx or Xxxxxxxxx Activation Systems, xx: In xxxxx Xxxxxxxxx Xxxxxxxxxx xx Xxxxxxxxxxx Testing, xxx. X. J. xx Xxxxxx xx xx. Xxxxxxxx, Xxxxx Holland, 85-88.
21) Elliot, X. X., Xxxxxx, X. X., Elcombe, X. X., Gatehouse, D. X., Gibson, X. X., Xxxxxx, X. X., Xxxx, R. X. (1992), Xxxxxxxxxxxx xx Xxxxxxx 1254-xxxxxxx X9 in xx xxxxx Genotoxicity Assays, Xxxxxxxxxxx, 7, 175-177.
22) Xxxxx, X., Xxxxxxxxxxxxxxxx, X., Xxxx, B. X. (1981), Compatibility xx Xxxxxxx Xxxxxxxx xxxx xxx Xxxxxxxxxx/Xxxxxxxxx Xxxx, Mutatation Res., 88, 343-350.
23) Claxton, X. D., Allen, X., Xxxxxxx, X., Xxxxxxxxxx, K., Xxxxxxxx, X., Zeiger, X. (1987), Guide xxx xxx Xxxxxxxxxx xxxxxxxxxxx/Xxxxxxxxx Xxxxxxxxx Tests for Xxxxxxxxx Xxxxxxxxxxxx, Xxxxxxxxxx Xxx., 189, 83-91.
24) Xxxxx, X. A. X., Green, X. X. X., Middleton, X., Xxxxxxx, I., Xxxxxxxx, X. X., Xxxxxx, X. X. (1989), Xxxxxxxx xx Xxxx from Xxxxxxxxx Xxxxxx Xxxxxx, xx: XXXXX Xxx-Xxxxxxxxx xx Xxxxxxxxxx xxx Xxxxxxxxxxxx Xxxxxxx, Part II. Xxxxxxxxxxx Evaluation xx Xxxxxxxxxxxx Xxxx Xxxx, xx. Kirkland, D. X., Cambridge University Xxxxx, 28-65."
XXXXXXX 4X
"X.17 XXXXXXXXXX — XXXXXXX NA XXXXXX MUTACE X XXXXXXX XXXXX XX XXXXX
1. XXXXXX
Xxxx xxxxxx xx xxxxxxxx metody XXXX XX 476 — Xxxxxxx xx xxxxxx xxxxxx v xxxxxxx xxxxx xx xxxxx (1997).
1.1 XXXX
Xxxxxxx xx xxxxxx xxxxxx x xxxxxxx xxxxx xx vitro xxx xxxxxx pro detekci xxxxxxxx mutací indukovaných xxxxxxxxxx xxxxxxx. Xxxx xxxxxx xxxxxxx xxxxx xxxxx buňky lymfomu X5178X xxxx, buněčné xxxxx XXX, XXX-XX52 x X79 křečka xxxxxxxx a lymfoblastoidní xxxxx XX6 člověka (1). X xxxxxx xxxxxxxxx linií xxxx xxxxxxxxxxxxxxx xxxxx genetických xxxxxx xxxxxx genů xxx xxxxxxxxxxxxxx (XX) x xxxxxxxxxxx-xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (XXXX) x xxxxxxxx xxxxxxx-xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (XXXX). Zkoušky xx xxxxxx XX, HPRT x XXXX xxxxxxxx xxxxx xxxxxxxx genetických xxxxxxxx. Xxxxxxxxxxx lokace XX x XPRT xxxx xxxxxxx xxxxxxx xxxxxxxxxxx událostí (xxxx. xxxxxxxx xxxxxx), xxxxx xxxxx detekovat x XXXX xxxxxx xx X xxxxxxxxxxxx (2, 3, 4, 5, 6).
Xx zkoušce xx xxxxxx xxxxxx x xxxxxxx xxxxx xx xxxxx xxx xxxxxx xxxxxxx xxxxxxxxxx xxxxx xxxxx xxxx buněčné xxxxx. Xxxxx xx xxxxxxxx xxxxx xxxxxxxxxx xxxxx v xxxxxxx x stálosti četnosti xxxxxxxxxxx xxxxxx.
Xxxxxxx xxxxxxxxx xx vitro obecně xxxxxxxx xxxxxxx xxxxxxxx xxxxxx xxxxxxxxxxx xxxxxxxx. Xxxxx xxxxxxxxxxx aktivační xxxxxx xxxxxx xxxxx xxxxxxxxx podmínky xx xxxx x savců. Xx xxxxx xx xxxxx xxxxxxxxx xxxxxxxx, xxxxx xx xxxxx x pozitivním xxxxxxxxx, xxx neodrážejí xxxxxxx xxxxxxxxxx. X xxxxxxxxxx xxxxxxxxx, jež neodrážejí xxxxxxx xxxxxxxxxx, xxxx xxxxx xxxxxx xX, xxxxxxxxxx xxxx vysokých xxxxxx xxxxxxxxxxxx (7).
Xxxx xxxxxxx xx xxxxxxx xx zjištění xxxxxxx xxxxxxxx x karcinogenů xxxxx. Xxxxx sloučenin, xxx xxx xx xxxx zkouška xxxxxxxxx, xxxx karcinogeny xxxxx; xxxx xxxxx xxxxxxxx x xxxxxxxxxxxxxx xxxx xxxx xxxxxxxxx xxxxxxxx. Xxxxxxxx xxxxxx xx xxxxxxxx xxxxx a xxxxxxxxx xxxxxx x xxx, xx existují xxxxxxxxxxx, xxxxx xxxxxx xxxxxxxx xxxxx zkouškou, xxxxx xxxxxx xxxxxx xxxxxx, xxxxxxxxxxxxxxx xxxxxxxxxx, xxxx mechanismy, xxxxx x xxxxxxxxxxxxx buňkách xxxxxxxxxx (6).
Xxx xxxx xxxxxx xxxx, část X.
1.2 DEFINICE
Přímá xxxxxx : xxxxxx xxxxxx xxxxxxxxx xxxx mutované xxxxx, xxxxx xxxxxxxxx xxxxx xxxx xxxxxx xxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxx.
Xxxxxxxx xxxxxxxxxx xxxx xxxx : xxxxx, xxxxx xxxxxxxxx substituci xxxxxxx xxxx xxxx xxxx bází x XXX.
Xxxxxxxx xxxxxxxx : xxxxx, xxxxx xxxxxxxxx xxxxx nebo xxxxxx xxxxxxx xxxx xxxx xxxx bází x xxxxxxxx XXX.
Xxxx xxxxxxx xxxxxxxx : xxxx, xxxxx xxx xxxxxx x xxxx xxxxxxxxxx xxxxx nezměněné xxxxxx xxxxxxxx.
Xxxxxxx mutantů : xxxxx xxxxxxxxxxxx mutantních xxxxx xxxxxx xxxxxx xxxxxxxxxxxxxxx xxxxx.
Xxxxxxxxx xxxxxxx xxxx : xxxxxx xxxxx buněk x xxxx ve xxxxxxxx x xxxxxxxxx xxxxxxxx xxxxx; xxxxxxx xx xxxx xxxxxx xxxxxx xxxxxxxxx xxxxx x xxxxxxxx x x xxxxxxxxx kontrole a xxxxxxxxx účinnosti xxxxxxxxx xxxxxxxx k xxxxxxxxx xxxxxxxx.
Xxxxxxxxx xxxx x xxxxxxxx : xxxxxx xxxxx xxxxx x xxxxxxx xxxxxxx xxxxxxxx x negativní kontrole.
Životaschopnost : účinnost xxxxxxxxx xxxxx x xxxxxxxx xxxxxxxx na xxxxx xx selektivních xxxxxxxx xx xxxxxxx.
Xxxxxxx : xxxxxxxx xxxxxxxxx xxxxx xxx xxxxxxxx na xxxxx xx xxxxx xxxxxx xxxxxxxx; xxxxxxx xx xxxxxxx xxxxxxxxx x poměru x xxxxxxx xxxxxxxxx xxxxxxxx xxxxx.
1.3 XXXXXXXX XXXXXXXX XXXXXX
Xxxxx, xxxxx v xxxxxxxx mutace XX+/-® XX— /- xxxxxxxxxx xxxxxxxxxxxxxx (XX) jsou xxxxxxxxxxx k xxxxxxxxxxxx xxxxxxx xxxxxxx xxxxxxxxxx xxxxxxxxxxxxxxxxx (XXX). Xxxxx xxxxxxxxxxx thymidinkinasu xxxx xxxxxxx xx XXX, xxx xxxxxxxxx xxxxxxxx xxxxxxxxx xxxxxxxxxxx x xxxxxxxxx další xxxxxxx xxxxxx. Xxxxxxxx buňky xxxx tedy xxxxxxx xxxxxxxxxxx za xxxxxxxxxxx XXX, xxxxxxx xxxxxxxx xxxxx, xxxxx xxxxxxxx xxxxxxxxxxxxxx tuto xxxxxxxxx xxxxxx. Xxxxxxx xxx x xxxxx x xxxxxxxxxxxx XXXX nebo XXXX xxxxxxx xxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxx x 6-xxxxxxxxxxx (XX) nebo 8-xxxxxxxxxx (AG). Vlastnosti xxxxxxxx látky xx xxxx xxx pečlivě xxxxxxx, xxxxxxxx je xx xxxxxxx xx xxxxxx mutace x xxxxxxx xxxxx zkoušen xxxxxx báze nebo xxxxxxxxxx xxxxxxx selekčnímu xxxxxxx. Xxxx by xxx xxxxxxxxx vyšetřeno xxxxxxxx podezření na xxxxxxxxxx toxicitu xxxxxxxx xxxxx pro mutantní xxxx xxxxxxxxxx xxxxx. Xxx xxxxxxxx chemických xxxxx, xxxxx xxxx xxxxxxxx strukturu xxxx xxxxxxxx xxxxxxx, xxxx xxxx xxx xxxxxxxxx xxxxxxxx systému xxxx xxxxxxx xxx selekci (8).
Xxxxx v xxxxxxxxx xxxx xxxxxxxxxxxxx xxxxxxx xxxx xxxxxxx dobu xxxxxxxxx xxxxxxxx xxxxx xxx x xxxxxxxxxxxx xxxxxxxx, tak xxx xx, a xxxxxxxxxxxxxx xx účelem stanovení xxxxxxxxxxxx a za xxxxxx exprese xxxxxxxx xxxx xxxxxxx xxxxxxx (9, 10, 11, 12, 13). Cytotoxicita xx xxxxxxx zjistí xxxxxxxxxx xxxxxxxxx xxxxxxxxx xxxxxxxxx (xxxxxxx) xxxx xxxxxxxxxx xxxxxxxxxxx xxxxxxxxx xxxxx kultur xx xxxxxxxx doby expozice. Xxxxxxxxxx xxxxxxx xx xxxxxxx x xxxxxxxx xxxxx po vhodnou xxxx charakteristickou xxx xxxxx xxxxxxx lokus x xxx xxxxx, xxx xxxxxxx xxxxxxxxx xxxxxxxxx fenotypová exprese xxxxxxxxxxxx xxxxxx. Četnost xxxxxxx xx xxxxxxx xxx, xx se xxxxxx xxxxx xxxxx xxxxx do xxxxx xxxxxxxxxxxx xxxxxxxx činidlo xxx xxxxxxx xxxxxxxxxx xxxxx x xx xxxxx bez selekčního xxxxxxx, xxx byla xxxxxxxxx xxxxxxxx xxxxxxxxx (xxxxxxxxxxxxxxx). Xx xxxxxx xxxxxxxxx xxxx se xxxxxxxxx xxxxxxx. Xxxxxxx xxxxxxx xx xxxxxxx x xxxxx xxxxxxxxxx xxxxxxx x selekčním xxxxx a xxxxx xxxxxxx x médiu xxx xxxxxxxxxx xxxxxxx.
1.4 XXXXX XXXXXXXX METODY
1.4.1 Xxxxxxxxx
1.4.1.1 Xxxxx
Xxx xxxxxxx x xxxx xxxxxxx xxxx x xxxxxxxxx xxxxx xxxx xxxxx, xxxxxx subklonů buněk X5171X, XXX, CHO-AS52, X79 nebo TK6. Xxxx buněk x xxxx xxxxxxx xx xxxx vykazovat citlivost x chemickým xxxxxxxxx, xxxxxxx xxxxxxxxx xxxxxxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxxx xxxxxx. Xxxxx xx měly být xxxxxxxxxxxx, xxx xxxxxx xxxxxxxxxxxxx xxxxxxxxxxxx, a x xxxxxxx kontaminace xx xxxxxx být xxxxxxx.
Xxxxxxx xx měly xxx navrženy xxx, xxx xxxx předem xxxxxxxxxx xxxxxxxxx x xxxx. Počet xxxxxxxxx xxxxx, xxxxxx x xxxxxxxxxxx xxxxxxxx xxxxx xx měl xxxx xxxxxxxxxx xxxxxxxxx odrážet (14). Xxxxxxxxx xxxxx xxxxx, xxxxx xxxxxxx xxxxxxxx x xxxxx xxxxx použity v xxxxxx xxxxxx zkoušky, xx xxx být xxxxxxx xx četnosti xxxxxxxxxxx mutací. Xxxxxxx xxxxxxxxx je, aby xxx xxxxxx xxxxx xxxxx, xxxxx xx xxxxxxxxxxxxxx xxxxxxxxxx xxxxxxx xxxxxxxx xxxxxxxxxxx xxxxxx. Xx xxxx doporučeno, xxx xxxx xxxxxxx xxxxxxx 106 xxxxx. Xxxx by xxx x xxxxxxxxx xxxxxxxxxx xxxxxxxxx xxxxx x xxxxxxxx xxxxxxxx systému, xxx xxxx xxxxxxxx xxxxxxxxxxxx xxxxxxxxx xxxxxxx xxxxxxx.
1.4.1.2 Média x xxxxxxxxxx xxxxxxxx
Xxx xxxxxxxxx xxxxxx xx měla xxx použita vhodná xxxxxxxxxx xxxxx a xxxxxxxxx podmínky (kultivační xxxxxx, xxxxxxxxxxx XX2, xxxxxxx a vlhkost). Xxxxx xx měla xxx xxxxxxx xxxxx xxxxxxxxxx xxxxxxx a xxxx buněk xxxxxxxxx xxx xxxxxxx. Xx xxxxxxx důležité, xxx xxxxxxxxxx xxxxxxxx byly xxxxxxx tak, xxx xxxx xxxxxxxxx optimální xxxx xxxxx během xxxxxx exprese x xxxxxxxxx jak mutovaných, xxx xxxxxxxxxxxx xxxxx xxxxxx xxxxxxx.
1.4.1.3 Xxxxxxxx xxxxxx
Xxxxx xx xxxx xxx získávány x xxxxxxxxx xxxxxx, nasazeny xx xxxxxxxxxxxx xxxxx x xxxxxxxxxx při 37 °X. Xxxx xxxxxxxx x xxxx xxxxxxx může být xxxxxxxx odstranit x xxxxxxx xxx xxxxxxxx xxxxxxxx xxxxx.
1.4.1.4 Xxxxxxxxxxx xxxxxxxx
Xxxxx xx xxxx xxx vystaveny zkoušené xxxxx, x to x vhodným xxxxxxxx xxxxxxxxxxx aktivace a xxx něho. Nejčastěji xxxxxxxxxx xxxxxxxx je xxxxxxxxxx xxxxxxxx postmitochondriální xxxxxx (X9) xxxxxxxxxx x jater hlodavců xxxxxxxxxx xxxxxxxx indukujícím xxxxxx, xxxx je Xxxxxxx 1254 (15, 16, 17 a 18), nebo směs xxxxxxxxxxxxx x β-xxxxxxxxxxxx (19, 20).
Postmitochondriální xxxxxx xx x konečném xxxxxxxxxx médiu xxxxxxx xxxxxxxxx v xxxxxxxxxxxxx 1 — 10 % xxx. Xxxxx x xxxx xxxxxxxxxxxxx xxxxxxxxxxx xxxxxxx xxxx xxxxxxx xx xxxxx xxxxxxxx látky, xxxxx xx zkoušena. X xxxxxxxxx xxxxxxxxx xxxx xxx xxxxxx použít xxxx xxx jednu xxxxxxxxxxx xxxxxxxxxxxxxxxxxxx xxxxxx.
Xxxx xxxxxxxx vývoje, xxxxxx xxxxxxxx geneticky xxxxxxxxxxxxxx xxxxxxxxx xxxxx xxxxxxxxxxxxx xxxxxxxxxx xxxxxxxxx xxxxxx, xxxxxxxxx xxxxxxxx pro xxxxxxxxx aktivaci. Xxxxx xxxxxxxxx xxxxxxxxx xxxxx xx xxxx xxx xxxxxxx zdůvodněna (xxxx. xxxxxxxxxxx xxxxxxxxx xxxxxxxxxx X450 xxx xxxxxxxxxxxx xxxxxxxx xxxxx).
1.4.1.5 Příprava xxxxxxxx látky
Pevné zkoušené xxxxx by xxxx xxx xxxx xxxxxxxx xx buňky xxxxxxxxxx xxxx suspendovány ve xxxxxxxx rozpouštědlech xxxx xxxxxxxxxx x xxxxxxxxx xxxxxxx. Xxxxxxx xxxxxxxx xxxxx mohou xxx xxxxxxx xxxxx x xxxxxxxxxx xxxxxxxx x/xxxx xxxxx xxx xxxx xxxxxxxx xxxxxxx. Xxxx xx být xxxxxxx xxxxxxx xxxxxxxxxx xxxxxxxx xxxxxxxx xxxxx, pokud xxxxx x xxxxxxxx xxxxxxxxxxx možnost xxxxxxxxxx.
1.4.2 Xxxxxxxx xxxxxxxx
1.4.2.1 Xxxxxxxxxxxx/xxxxxxxxx
Xxxxxxxxxxxx/xxxxxxxxx xx mělo xxx xxxx xxxxxxxxx, že xxxxxxx xx xxxxxxxxx xxxxxx, a xxxx xx xxx xxxxxxxxxx x přežitím xxxxx x s xxxxxxxxx X9. Jsou-li použita xxxx xxx xxxxx xxxxxxxxxxxx/xxxxxxxx, xxxx by xxx xxxxxx xxxxxxxx xxxxxxxxx údaji o xxxxxx kompatibilitě. Xxxxxxxxxx xx pokud xxxxx xxxxxxxx xxxxxx použití xxxxxxx xxxxxxxxxxxx/xxxxxxx. Při xxxxxxxx látek xxxxxxxxx xx xxxx xx xxxx být xxxxxxx xxxxxxxxx xxxxxxxxxxxx xxxxxxxxxxxx xxxx. Xxxx lze xxxxxxxxx xxxxxxxx molekulového xxxx.
1.4.2.2 Xxxxxxxxx xxxxxxxxxxx
Xxxx xxxxxxxx, která xxxx xxx xxxxxxxxxx xxx xxxxxxxxx xxxxxxxx xxxxxxxxxxx, xxxxx cytotoxicita, xxxxxxxxxxx x xxxxxxxxxx xxxxxxx x změny pH xxxx xxxxxxxxxx.
Xxxxxxxxxxxx xx xxxx xxx xxxxxxxxx x xxxxxxxxxxxx xxxxxxxx x bez xx x hlavním xxxxxxxxxxx xx xxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxx xxxxxxxxx x xxxxx, xxxx xxxx xxxxxxxxx xxxxxxxx xxxxxxxxx (xxxxxxx) xxxx xxxxxxxxx xxxxxxx xxxx. Xxxx xxx výhodné xxxxxxxx cytotoxicitu a xxxxxxxxxxx x xxxxxxxxxx xxxxxxxxxxx.
Xxxx by xxx xxxxxxx alespoň xxxxx xxxxxxxxxxxxxx xxxxxxxxxxx. X xxxxxxx xxxxxxxx xx xxxx xxxx xxxxxxxxxxx xxxxxxxx xxxxxxx xxxx xxxxxxxxx a xxxxxxxxx xxxxxxxxx, případně žádnou xxxxxxxxx, což bude xxxxxxx xxxxxxxx, že xx xx xxxxxxxxxxx xxxx lišit xxxxxxxx 2 xx Ö10. Xx-xx xxxxxxxxx xxxxxxxxxxx xxxxxxxx xx xxxxxxxxxxxx, xxxx xx být xxxxxxxxx přibližně 10 — 20 % (xxx xxxxxxx 10 %) přežití (relativní xxxxxxxx klonování) xxxx xxxxxxxxx xxxxxxx xxxx. X xxxxxxx xxxxxxxxx xxxxxxxxxxxxxxx xxxxx by xxxx xxx xxxxxxxxx xxxxxxxx koncentrace 5 μx/xx, 5 xx/xx xxxx 0,01 X, xxxxx xxxx, xxxxx x xxxx xx xxxxxxxx.
Xxxxxxxxx nerozpustné xxxxx xx xxxx xxx xxxxxxxx xx k xxxx xxxxxxxxxxxx xx xxxxxxxxxxxx xxxxxxxx, xxxx xx xx xxxx xxx. Xxxx xx xxx xxxxxxxxx xxxxxxxx xxxxxxxxxxxxx v xxxxxxxx xxxxx, xx kterému xxxx xxxxx exponovány. Xxxx xxx xxxxxxx xxxxxxxx rozpustnost na xxxxxxx a xx xxxxx xxxxxxxx, xxxxx xxxxxxxxxxx xx xxxx x xxxxxxx expozice x xxxxxxxxxx xxxxxxx xxxxx v xxxxxxxx xxxxxxxxxxx buněk, S9 xxxx, xxx. Xxxxxxxxxxxxx xxx xxxxxxx xxxxxxxx. Xxxxxxxxx xx xxxxxx xxxxx xxx vyšetřování.
1.4.2.3 Xxxxxxxx
Xxxxxxxx xxxxxxx xxxxxxxxxxx xx xxxx xxx xxxxxxxxx x xxxxxxxxx (xxxxxxxxxxxx nebo xxxxxxxxx) xxxxxxxx xxx x xxxxxxxxxxxx xxxxxxxx, tak xxx ní. Xxx xxxxxxx xxxxxxxxxxx xxxxxxxx xx xxxx být xxxxxxxxx xxxxxxxxx chemická xxxxx, xxxxx x xxxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxx.
Xxxxxxxxx xxxxxxxxx kontroly xxxxx xxx tyto xxxxx:
Xxxx xxxxxxxxxxx xxxxxxxx |
Xxxxx |
Xxxxx |
Xxxxx XXX |
Xxxxx xxxxx Xxxxxx |
Xxx xxxxxx metabolické xxxxxxxx |
XXXX |
xxxxx-xxxxxxxxxxxxxx |
62–50–0 |
200–536–7 |
1-xxxxx-1-xxxxxxxxxxxxxxx |
759–73–9 |
212–072–2 |
||
XX (xxxx a xxxxx xxxxxxx) |
xxxxxx-xxxxxxxxxxxxxx |
66–27–3 |
200–625–0 |
|
XXXX |
xxxxx-xxxxxxxxxxxxxx |
62–50–0 |
200–536–7 |
|
1-xxxxx-1-xxxxxxxxxxxxxxx |
759–73–9 |
212–072–2 |
||
X xxxxxx metabolickou xxxxxxxx |
XXXX |
3-xxxxxxxxxxxxxxxxx |
56–49–5 |
200–276–4 |
X-xxxxxxxxxxxxxxxxxxx |
62–75–9 |
200–549–8 |
||
7,12-xxxxxxxxxxxxxxxxxxxxxx |
57–97–6 |
200–359–5 |
||
XX (xxxx x xxxxx xxxxxxx) |
xxxxxxxxxxxxx |
50–18–0 |
200–015–4 |
|
xxxxxxxxxxxxx xxxxxxxxxx |
6055–19–2 |
|||
xxxxx[x]xxxxx |
50–32–8 |
200–028–5 |
||
3-xxxxxxxxxxxxxxxxx |
56–49–5 |
200–276–5 |
||
XXXX |
X-xxxxxxxxxxxxxxxxxxx (xxx vysoké úrovně X9) |
62–75–9 |
200–549–8 |
|
xxxxx[x]xxxxx |
50–32–8 |
200–028–5 |
Xxxxx xxx použity xxxx jiné xxxxxxxxxx xxxxx xxx pozitivní xxxxxxxx, např. xx-xx xxxxxxxxx databázi xxxxxxxxxxx xxxxx x 5-brom-2′-deoxyuridinu (XXX 59–14–3, XXXXXX 200–415–9), může xxx xxxx xxxxxxxxxx látka xxxxxx xxxxxxx. Xxx xxxxxxxxx xxxxxxxx xx xxxx být vzato x xxxxx xxxxxxx xxxxxxxxxx xxxxx pokud xxxxx xx stejné xxxxxxxx xxxxx.
Xxxx xx xxx použity negativní xxxxxxxx xxxxxxx médiem xxxxxxxxxxx xxxxxxx rozpouštědlo xxxx xxxxxxxxx x xxxxxxxxxx jinak xxxxxxx xxxxxxxx xxxx exponované xxxxxxx. Xxxxx xxxx xx xxxx xxx xxxxxxxxxxxx xxxxxxxx použity xxxx tehdy, xxxxxxxxxx-xx xxxxx xxxxxxxxx údaje xxxxxxxxxxx, xx zvolené xxxxxxxxxxxx xxxxxxxxxx xxxxx xxxxxxx xxxx xxxxxxxxx xxxxxx.
1.4.3 Xxxxxx
1.4.3.1 Expozice xxxxxxxx látce
Proliferující xxxxx xx xxxx xxx xxxxxxxxx xxxxxxxx látce xxx za xxxxxxxxxxx xxxxxxxxxxxxx aktivačního xxxxxxx, xxx xxx něho. Xxxxxxxx xx měla xxxxx xxxxxxx xxxx (xxxxxxx xx xxxxxx xxxx 3 až 6 hodin). Xxxxxxxxx xxxx xxxx xxx xxxxxxxxxxx xx xxxxx xxxx více buněčných xxxxx.
Xxx xxxxxx zkušební xxxxxxxxxxx xxxxx být xxxxxxx xxxxxxxxxx kultury xxxx xxxxx xxxxxxxxxx xxxxxxx. Xx-xx použita xxxxx xxxxxxx, měl xx xxx xxxxx xxxxxxxxxxx xxxxxx xxx, xxx xxx xxxxxxxx xxxxxxxxxxxx počet xxxxxx xxx xxxxxxx (xxxx. xxxxxxx xxx analyzovatelných xxxxxxxxxxx). Xxxx xx xxx xxxxxxx xxxxxxxxxx xxxxxxxxx xxxxxxxxx kultury (xxxxxxxx xxxxxxxxxxxx).
Xxxxxx xxxx xxxxxx xxxxx xx xxxx být xxxxxxxx xxxxxxxx metodami, např. x těsně uzavřených xxxxxxxxxxxx nádobách (21, 22).
1.4.3.2 Xxxxxxxxx přežití, xxxxxxxxxxxxxxxx x xxxxxxxx xxxxxx
Xx xxxxx xxxxxxxxx xxxx se buňky xxxxxxx x xxxxxxxxx xx účelem xxxxxxxxx xxxxxxx x xx xxxxxx xxxxxxxx xxxxxxx xxxxxxxx xxxxxxx. Xx xxxxxxxxxx xxxxxxxxxxxx prostřednictvím xxxxxxxxx xxxxxxxxx xxxxxxxxx xxxxxxxxx (xxxxxxx) xxxx xxxxxxxxxxx celkového xxxxx xxxxxx xx započne xxxxxxx po xxxxxxxxx xxxx.
Xxxxx xxxxx xx xxxxxxxxxx minimální xxxxxx xxxxxx, aby xxxxxxx xxxxxxxxx optimální fenotypovou xxxxxxx nově xxxxxxxxxxxx xxxxxxx (HPRT x XXXX vyžadují xxxxxxx 6 xx 8 xxx, XX alespoň xxx dny). Buňky xxxx xxxxxxxxxxx v xxxxx se selekčním xxxxxxxx (selekčními činidly) x xxx něho (xxx nich) xx xxxxxx xxxxxxxxx xxxxx xxxxxxx a xxxxxxxxx xxxxxxxxx. Xx xxxxxxxxxx xxxxxxxxxxxxxxxx (xxxxxxx pro xxxxxxx četnosti mutantů) xx xxxxxxx xx xxxxx doby xxxxxxx xxxxxxxxx na xxxxx xxx xxxxxxxxxx xxxxxxx.
Xx-xx xxxxxxxx xxxxx xxxxxxxxx xx xxxxxxx X5178X XX+/-, xxxx xx xxx xxxxxxxxx xxxxxxx xx xxxxx ze xxxxxxxxxx xxxxxx (x xxxxxxxx pozitivní xxxxxxxxxxx) x xx xxxxxxxxxxx x xxxxxxxxxxx xxxxxxxxxx xxxxxxxxx xxxxxxx xxxxx xxxxxxxxx kolonií. Xx-xx xxxxxxxx xxxxx ve xxxxxxx X5178X XX+/- xxxxxxxxx, xxxx xx xxx xxxxxxxxx xxxxxxx xxxxx xxxxxxxxx xxxxxxx xxxxxxxxx na negativních x xxxxxxxxxxx kontrolách. Xxx xxxxxxxx xx xxxxxxx XX6 XX+/- xxxx xxx xxxx xxxxxxxxx xxxxxxxxx xxxxxxx xxxxx xxxxxxxxx xxxxxxx.
2. XXXXX
2.1 XXXXXXXXXX VÝSLEDKŮ
Údaje xx xxxx zahrnovat xxxxxxxxx xxxxxxxxxxxx x xxxxxxxxxxxxxxxx, počtu xxxxxxx x xxxxxxxx xxxxxxx xxx exponované x xxxxxxxxx xxxxxxx. X xxxxxxx xxxxxxxxx xxxxxxxx xx xxxxxxx L5178Y XX+/- se xxxxxxx xxxxxxxxx alespoň u xxxxx xxxxxxxxxxx xxxxxxxx xxxxx (xxxxxxxx pozitivní xxxxxxxxxxx) a u xxxxxxxxx a xxxxxxxxx xxxxxxxx xx xxxxxxx xxxxxxxx xxxx kolonie — xxxxx kolonie. Xxxxxxxxxxx a cytogenetická xxxxxx xxx mutantů xxxxxxxxx xxxxx xxxxxxx, xxx xxxxxxx tvořících xxxx kolonie byla xxxxxxxx zkoumána (23, 24). Xx xxxxxxx XX+/- xxxx xxxxxxx xxxxxxxxxxx xx použití xxxxxxxx kolonie x xxxxxxxxx xxxxxx (xxxxx) x xxxxxxx x xxxxxxx xxxxxx (xxxx) (25). U xxxxxxxxxx xxxxx, které xxxxxxx xxxxxxxxxxxxxx genetické xxxxxxxxx, xx xxxxxxxxxxx doby xxxxxxxx, x tvoří xxxx malé xxxxxxx. Xxxxxxxxx má obvykle xxxxxx od xxxxx xxxxxx xxxx až xx karyotypické xxxxxxxxx xxxxxxxxxxxx xxxxxxx. Indukce xxxxxxx tvořících malé xxxxxxx se xxxxxxx x xxxxxxxxxx xxxxxxx, xxxxx xxxxxxxx xxxxx xxxxxxxxxxxx aberace (26). Xxxx závažně xxxxxxxxx xxxxx xxxxxxx xxxxxx xxxxxxxx tempem xxxx xxxxxxxx buňky x xxxxx xxxxx xxxxxxx.
Xxxx xx xxx xxxxx xxxxxxx (relativní xxxxxxxx xxxxxxxxx) xxxx xxxxxxxxx xxxxxxx xxxx. Xxxxxxx xxxxxxx by měla xxx vyjádřena jako xxxxx xxxxxxx x xxxxx přeživších buněk.
Měly xx xxx uvedeny xxxxx xxx jednotlivé xxxxxxx. Xxxx xx xxxx být xxxxxxx xxxxx shrnuty ve xxxxx xxxxxxx.
Xxxxxxx xxxxx xxxxxxxxx odpovědi xx xxxxxxxxxx. Xxxxxxxxxx výsledky xx měly xxx xxxxxxxxx xxxxxx xxxxxxxxx, xxxxxxx x úpravou xxxxxxxxxxxxxxxx xxxxxxxx. Xxxxxxxxx xxxxxxxx musí xxx xxxxxxxxx případ xx xxxxxxx. Xxx, kde xxxx xxxxxxxxx negativních xxxxxxxx xxxxxxxxxx za xxxxx, xx třeba xxxxx xxxxxxxxxx. Změna xxxxxxxxx studie x xxxxx xxxxxxxx xxxxxx xxxxxxxxxxxx podmínek xx xxxx xxx xxxxxxx x následných xxxxxxxxxxxxx xxx pro xxxxxxxxxx xxxxxxxx, xxx pro xxxxxxxxx xxxxxxxx. X xxxxxxxxxx xxxxxx, které xx xxxxx xxx xxxxxxx, xxxxx xxxxxxx xxxxxxxxxxx x podmínky xxxxxxxxxxx xxxxxxxx.
2.2 HODNOCENÍ X XXXXXXXXXXXX VÝSLEDKŮ
Pro xxxxxxxxx xxxxxxxxxxx výsledku xxxxxxxx několik kritérií, xxxx. xxxxxx xxxxxxxx xxxxxxx v závislosti xx xxxxxxxxxxx, xxxx xxxxxxxxxxxxxxxx nárůst této xxxxxxxx. Nejdříve xx xxxx xxx xxxxxxx xxxxxxxxxx xxxxxxxxx xxxxxxxx. Xxx xxxxxxxxx xxxxxxxx xxxxxxx xxxxx xxx xxxxxxx xxxx pomocný xxxxxxxxxx xxxxxxxxxxx xxxxxx. Xxxxxxxxxxx xxxxxxxxxx xx xxxxxx xxx xxxxxxx xxxxxxxxx xxxxxxxx xxx xxxxxxxxx odpověď.
Zkoušená xxxxx, xxxxx xxxxxxxx nesplňují xxxx uvedená xxxxxxxx, xx v xxxxx xxxxxxx považuje za xxxxxxxxxxx.
Xxxxxx většina experimentů xxxxxxxx xxxxx xxxxxxxxx xxxx xxxxxxxxx výsledky, x ojedinělých případech xxxxxxxx soubor xxxxx xxxxxxxx xxxxxxx xxxxx x xxxxxxxx xxxxxxxx xxxxx. Xxxxxxxx xxxxx xxxxxx xxxxxxxxxx nebo xxxxxx xxx ohledu xx xx, kolikrát xx xxxxxxxxxx xxxxxxxx.
Xxxxxxxxx xxxxxxxx xxxxxxx xx xxxxxx xxxxxx x xxxxxxx xxxxx xx xxxxx xxxxxxxxx, xx xxxxxxxx xxxxx indukuje x xxxxxxxxx kultivovaných xxxxxxx xxxxx genové xxxxxx. Xxxxxxxxxxxxxxxx xxxxxxxxx xxxxxxxxx odpovědi xx xxxxxxxxxxx xx velmi xxxxxxxx. Negativní xxxxxxxx xxxxxxxxx, že zkoušená xxxxx za xxxxxxxx xxxxxxx xxxxxxxxxx v xxxxxxxxx xxxxxxxxxxxxx buňkách xxxxx xxxxxx xxxxxx.
3. XXXXXX
XXXXXXXX X XXXXXXX
Xxxxxxxx x xxxxxxx musí xxxxxxxxx xxxx xxxxxxxxx:
Xxxxxxxxxxxx/xxxxxxxxx:
- xxxxxxxxxx xxxxx xxxxxxxxxxxx/xxxxxxxx,
- xxxxxxxxxxx a xxxxxxx xxxxxxxx xxxxx v xxxxxxxxxxxx/xxxxxxxx, je-li známa.
Buňky:
- xxx a xxxxx xxxxx,
- xxxxx xxxxxxxxx xxxxxx,
- xxxxxxxx počet xxxxxx,
- xxxxxxxx xxxxxx xxxxxxxxx xxxxxxx kultury,
- xxxxxxxxxxxx mykoplasmat.
Zkušební xxxxxxxx:
- xxxxxxxxxx výběru koncentrací x počtu xxxxxx, xxxxxx např. xxxxx x cytotoxicitě x xxxxxx xxxxxxxxxxxx, jsou-li x dispozici,
- xxxxxxx xxxxx, případně xxxxxxxxxxx XX2,
- xxxxxxxxxxx xxxxxxxx xxxxx,
- xxxxx xxxxxxxx x xxxxxxx xxxxxxxx xxxxx,
- inkubační xxxxxxx,
- xxxxxxxxx xxxx,
- délka xxxxxxxx,
- xxxxxxxx xxxxxxx xxxxx během xxxxxxxx,
- xxx x složení xxxxxxxxx metabolického xxxxxxxxxxx xxxxxxx, včetně xxxxxxxx xxxxxxxxxxxxx,
- pozitivní x xxxxxxxxx xxxxxxxx,
- xxxxx xxxx xxxxxxx (xxxxxxxx xxxxxx počtu xxxxxxxxxx xxxxx, xxxxxxxxx a xxxxxx média),
- xxxxxxxx xxxxxxx,
- xxxxxxxx xxxxxxxxxxx xxxxxxx na xxxxxxxxx, xxxxxxxxx nebo xxxxxxxxxxx,
- xxxxxx xxxxxxx x xxxxxxxx xxxxxxxxxxxxxxx a xxxxxxxxxx xxxxx,
- definice xxxxxxx xxxxx xxxxxxxxx x typu (xxxxxxxx xxxxxx xxxxxxxx pro "xxxx" x "xxxxx" xxxxxxx).
Xxxxxxxx:
- xxxxxx toxicity,
- xxxxxx xxxxxxx,
- údaje x pH a xxxxxxxxxx xxxxx xxxxxxxx xxxxxxxx xxxxx, xxxxx xxxx stanoveny,
- velikost xxxxxxx, byla-li vyšetřována, xxxxxxx xxx negativní x xxxxxxxxx xxxxxxxx,
- xxxxxxxxx xxxxxxxxxxx xxxxxxxxxx xxxxxxxxx xxxxxxx xxxxxxx xxxx xxxxxxx systémem X5178X XX+/-,
- xxxxx xxxxxxxx xxxxxxxxx xxxxxxxx xx dávce,
- xxxxxxxx xxxxxxxxxxx xxxxxxx,
- xxxxx x xxxxxxxx negativní (xxxxxxxxxxxx/xxxxxxxxx) x xxxxxxxxx xxxxxxxx,
- xxxxxxxxx údaje x xxxxxxxxx (xxxxxxxxxxxx/xxxxxxxxx) x pozitivní xxxxxxxx x xxxxxxxxx, xxxxxxxxx xxxxxxxxx x xxxxxxxxxxxx xxxxxxxxxx,
- xxxxxxx xxxxxxx.
Xxxxxx xxxxxxxx.
Xxxxxx.
4. XXXXXXXXXX
1) Moore, X. M., XxXxxxxx, X. X., XxXxxxxx, X. X., Tindal, X. X. (eds.) (1987), Xxxxxxx Xxxxxx 28; Xxxxxxxxx Xxxx Xxxxxxxxxxx, Xxxx Spring Xxxxxx Xxxxxxxxxx, New Xxxx.
2) Xxx, X. X. X., Xxxxxxx X. X. (1968), Xxxxxxxxx Xxxx Xxxxxxxx. XX. Xxxxxxxx Induction xx Xxxxxxxx Locus Xxxxxxxxx xx Xxxxxxx Xxxxxxx Cells Xx xxxxx, Proc. Xxxx. Xxxx. Xxx. X. X. X, 61, 1306-1312.
3) Xxxxx, X. X., Thilly, X. X. (1982), Xxxxxxxx Xxxxx xx xxx Xxxxxxxxx Xxxxxx Locus xx Diploid Xxxxx Xxxxxxxxxxxx, Xxxxxxxx Xxx. 94, 467-485.
4) Xxxxx, X. X., Harington-Brock, X., Xxxxx, C. X., Xxxxxxxxx, K. X. (1989), Differential Xxxxxx Quantitation at xxx Xxxxx Xxxxxxxx XX xxx XXX XXXXX Loci, Xxxxxxxxxxx, 4, 394-403.
5) Xxxxx, X. X., Xxxxxxxxxx, Xx. X. X., (1989), Comparison of xxx XX52/XXXX xxx xxx XXX/XXXX Xxxxxx: Xxxxxxxxxx of Xxx Xxxx Candidates, Xxxxxxxxxx Xxx. 223, 121-128.
6) Xxxxx, C. X., Xxxxxxxxxx, G., Xxxxx, X. X., Xxxxx, X., Xxxxx, X., Xxxxxxxxxx, Jr. L. X., Xxxxxx, X., Xxxxxxxx, X. (1994), Xxxxxxxxx Xxxx Gene Xxxxxxxx Assays Xxxxxxx Xxxxx Report. Report xx xxx Xxxxxxxxxxxxx Xxxxxxxx xx Xxxxxxxxxxxxxxx xx Xxxxxxxxxxxx Test Xxxxxxxxxx. Xxxxxxxx Res. 312, 235-239.
7) Scott, X., Xxxxxxxx, S. X., Marshall, X. X., Xxxxxxxx, X., Xxxxxxx, X., Xxxxx, X., Xxxx, X. X. (1991), Xxxxxxxxxxxx Xxxxx Extreme Xxxxxxx Xxxxxxxxxx. X xxxxxx xxxx ICPEMC Xxxx Xxxxx 9, Xxxxxxxx Xxx. 257, 147-204.
8) Xxxxx, X., XxXxxx, X., Spector, X. X. X., Xxxxx, X., Mavournin, K. X. (1983), Specific Xxxx Xxxxxxxxx in X5178X Xxxxx in Xxxxxxx. X Report xx xxx X. X. Xxxxxxxxxxxxx Protection Xxxxxx Xxxx-Xxx Xxxxxxx, Xxxxxxxxxx Xxx., 115, 225-251.
9) Xx, A. X., Xxxxx, X. X., Xxxxxxx, X. X., Wasson, J. X. (1988), X Xxxxxx xxx Xxxxxxxx xx xxx Chinese Xxxxxxx Ovary/Hypoxanthine Xxxxxxx Xxxxxxxxxxxxxx Xxxxxxxxxxx Xxxxxx xx Xxxxxxxxx the Xxxxxxxxxxxx xx Xxxxxxxx Xxxxxx: X Report xx Phase III xx xxx U. X. Xxxxxxxxxxxxx Protections Xxxxxx Xxxx-Xxx Xxxxxxx, Xxxxxxxxxx Res., 196, 17-36.
10) Xx, X. X., Xxxxxx, J. X., Xxxx, W. X., Xxxx, X. X., Gupta, R. X., Xxxxxxx, K. X., O'Νeill, J. X., Xxxxxx, X. X., Xxxxxxxxxx, X. X. Xx., Yang, X. L. (1987), X Xxxxx xxx xxx Performance xx xxx Xxxxxxx Xxxxxxx Xxxxx Xxxx/Xxxxxxxxxxxx-Xxxxxxx Xxxxxxxxxxxxxx Xxxxxxxxxxx Xxxx Xxxxxxxx Xxxxx, Xxxxxxxxxx Res., 189, 135-141.
11) Xxxxx, X. L., Xxxxxxx, X. X., Little, X. B. (1989), X Xxxxxxxxxx of Xxxxxxxx Induction at xxx XX xxx XXXX Loci xx Xxxxx Xxxxxxxxxxxxxx Cells: Xxxxxxxxxxxx Xxxxxxxxxxx xxx Xxx to xx Xxxxxxxxxx Class xx Xxxxxxxxx xx xxx Xxxxxxxxx XX Xxxxx, Xxxxxxxxxx Xxx., 216, 9-17.
12) Xxxxxxxxxx, L. X. Jr., Xxxxxx, X. X., Hsie, X. X. (1986), Xxxxxxxxxxxx xxx Molecular Xxxxxxxx of Xxxxx Xxxxxxxxxxxxxxxxx and XXX 191-Xxxxxxx Xxxxxxxxx Xxxxxxxx xx Xxxxx Xxxxxxxxxxxxxxxxx xxx XXX 191 Xxxxxxx Mutation xx XX52 Xxxxx, Mutatation Xxx., 160, 133-147.
13) Xxxxxx, N. X., Xxxxxx, X. X., Xxxxx, X. (1984), Xxxxxxxxx xxx xxx X5178X/XX+/--XX+/- Xxxxx Xxxxxxxx Xxxx Mutagenicity Assay, xx: Kilbey, X. X. xx xx (xxx.) Xxxxxxxx of Xxxxxxxxxxxx Test Procedures, Xxxxxxxx Xxxxxxx Publishers, Xxx Xxxx, 239-268.
14) Xxxxxx, X. X., Xxxxx, X. M., Xxxxxx, X. X., Xxxxx, X. X. X., Xxxx, J., XxXxxxxx, X. X., Xxxxxxx X. C. (1989), Xxxxxxxxx Xxxx Xxxx Mutation Assays Xxxxx upon Colony Xxxxxxxxx, xx: Xxxxxxxxxxx Xxxxxxxxxx xx Xxxxxxxxxxxx Xxxx Data, Xxxxxxxx, X. X., xx., Xxxxxxxxx Xxxxxxxxxx Xxxxx, 66-101.
15) Xxxxxxxxxxxx, A., Xxxxxxx, S., Xxxxx, X., Fiorio, X., Xxxxxxxx, X., Xxxxxxxxxx, X. (1977), Xxxxxxxxx xx 6-Thioguanine-Resistant Mutants xx V79 Xxxxxxx Xxxxxxx Xxxxx xx Xxxxx-Xxxxx Xxxxxxxxx-Xxxxxxxxx Dimethylnitrosamine, Xxxxxxxxxx Xxx. 46, 365-373.
16) Xxxx, X. X., McCann, J., Xxxxxxxx, X. (1975), Xxxxxxx for Xxxxxxxxx Xxxxxxxxxxx and Xxxxxxxx xxxx xxx Xxxxxxxxxx/Xxxxxxxxx-Xxxxxxxxx Xxxxxxxxxxxx Xxxx, Mutatation Xxx. 31, 347-364.
17) Xxxxx, D., Johnson, X. O., Xxxxxxx, X. X. X., Xxxxxx A. X., Xxxxx X. X. X. (1979), Xxxxxxxxxx xxx Xxxxxxxxxxxxxxxx of xxx L5178Y/TK+/--Mouse Xxxxxxxx Xxxxxxx Assay System, Xxxxx. Res. 59, 61-108.
18) Xxxxx, X. X., Ames, X. X. (1983), Xxxxxxx Xxxxxxx xxx xxx Xxxxxxxxxx Xxxxxxxxxxxx Test, Xxxxxxxxxx Xxx. 113, 173-215.
19) Elliott, X. X., Combes, X. X., Elcombe, C. X., Gatehouse, D. X., Xxxxxx, X. X., Mackay, X. X., Wolf, X. X. (1992), Alternatives xx Xxxxxxx 1254-Induced X9 xx: Xx xxxxx Genotoxicity Xxxxxx, Xxxxxxxxxxx 7, 175-177.
20) Xxxxxxxxxx, X., Xxxxxxxx, X., Xxxx, X., Xxxxxxxx, X. (1976), X Safe Xxxxxxxxxx xxx Xxxxxxxxxxxxxxx Xxxxxxxxx x. x. an Xxxxxxx xx Xxxxxxxxx Xxxxxxxxxx Xxxxxxx, X: Xx xxxxx Xxxxxxxxx Xxxxxxxxxx in Mutagenesis Xxxxxxx, xx Serres, X. X., Xxxxx, X. X., Xxxx, X. R., Xxxxxxx, X. X. (eds), Xxxxxxxx, Xxxxx-Xxxxxxx, 85-88.
21) Xxxxx, X. X., Xxxxxx, F. X., XxXxxxx, K. X. (1982), CHO/HGPRT Xxxxxxxx Xxxxx: Xxxxxxxxxx xx Xxxxx xxx Volatile Xxxxxxx, xx: Xxxx, X. X., Xxxxx, X. X., Schaich, X. M. (eds), Xxxxxxxxx Xxxxxxx xx Xxxxxxxx Xxxxxx, Xxx Xxxx, Xxxxxx, 91-103.
22) Xxxxxx, X. X., Xxxxxx, X. X., Xx, X. X., Xxxxxx, X. X. (1983), Xxxxxxxxxx of xx Xxxxxxxx Xxxxxx Xxxxx Xxxxx Xxxxx xx Collagen Xxxx xxx Detecting Highly Xxxxxxxx Mutagens in xxx CHO/HGPRT Xxxxxxxx Xxxxx, Environ. Xxxxxxxxxxx, 5, 795-801.
23) Xxxxxxxxx, X. X., Xxxxx, X. M., Broder, X. X., Xxxxxxx, X., Hozier, J. X. (1990), Molecular Xxxxxxxxxx xx Xxxxxxxxx xx the Xxxxxxxxxxxx Xxxxxxxxx Kinase Locus xx Xxxxx Lymphoma Xxxxx, Xxxx. Natl. Xxxx. Sci. X. X. X, 87, 51-55.
24) Moore, X. X., Xxxxx, X., Xxxxxx, X. X., Xxxxxx, X. E., Xxxxxx, X. X., Xxxxxx, X. X., Xxxxxx, J. (1985), Xxxxxxxx xx Trifluorothymidine, Xxxxxxxxx (TFT+) Mutants xx X5178X/XX+/--Xxxxx Lymphoma Xxxxx, Xxxxxxxxxx Xxx. 151, 161-174.
25) Yandell, X. W., Xxxxx, X. X., Xxxxxx, X. B. (1990), Xxxxxxxxx Xxxxxxx Analysis xx Xxxxxxxxx Mutations xx x Xxxxxxxxxxxx Xxxxxxxxx Xxxxx xx Xxxxx Xxxxx, Xxxxxxxxxx Xxx. 229, 89-102.
26) Xxxxx, M. M., Xxxxx, X. L. (1990), Comparison xx Xxxxxxxxxx Xxxxxxxxxx Frequency xxx Small Xxxxxx XX-Xxxxxxxxx Mutant Frequency xx X5178X/XX+/- 3.7.2C Xxxxx Lymphoma Xxxxx, Xxxxxxxxxxx, 5, 609-614."
XXXXXXX 4F
"B.23 XXXXXXX XX XXXXXXXXXXXX XXXXXXX XX XXXXXXXXXXXXXXX XXXXX
1. XXXXXX
Xxxx xxxxxx je xxxxxxxx xxxxxx OECD XX 483 — Xxxxxxx xx chromozomové xxxxxxx xx xxxxxxxxxxxxxxx xxxxx (1997).
1.1 XXXX
Xxxxxx xxxxxxx xx xxxxxxxxxxxx xxxxxxx xx xxxxxxxxxxxxxxx xxxxx in xxxx xx xxxxxxxxxxxxx takové xxxxx, xxxxx xxxxxxxxx xxxxxxxxxx chromozomové xxxxxxx xx spermatogoniích savců (1, 2, 3, 4, 5). Xxxxxxxxx xx dva xxxx xxxxxxxxxxxx xxxxxxx: chromozomové x xxxxxxxxxxxx. X xxxxxxx xxxxxxxxxx mutagenů xxxx xxxxxxxxxx xxxxxxx xxxxxxxxxxxxxx xxxx, xxxxx xxxxxxxxxxxx aberace xx xxxxxx xxxxxxxxx. Xxxx xxxxxx xxxx xxxxxx xx xxxxxxxxx numerických xxxxxxx x xxxx x tomuto xxxxx xxxxxxx používána. Xxxxxxxxxxxx xxxxxx a xxxxxxx xxxx xxxx xxxxxxxx xxxxx xxxxxxxxx xxxxxxxxxxx xxxxxx u člověka.
Touto xxxxxxxx xx stanovují xxxxxxxxxxxx xxxxx xx xxxxxxxxxxxxxxx a xxxxxxxxxxx xx tedy, xx xxxx xxxxxxx xxxxxxxx xxxxxxxxx xxxxxxx xxxxxxxxx xxxxxx x germinálních xxxxxxx.
X xxxx xxxxxxx xxxx rutinně xxxxxxxxx xxxxxxxx. Xxxxx xxxxxxxxxxxxxx xxxxxxxx xx vivo xx xxxxxxxx chromozomové xxxxxxx xxx xxxxxx xxxxxxxxxxxxx. Jiné xxxxxx xxxxx xxxxxx xxxxxxxxx xxxx zkoušky.
Pro xxxxxxx xxxxxxx chromatidového typu xx xxxxxxxxxxxxxxx by xxxx být — xxxxx xxx dojde xx xxxxxx xxxx — xxxxxxxxx xxxxx xxxxxxxxx buněčné dělení, xxxxx xxxxxxxxx po xxxxxxxx. Xxxxx informace x xxxxxxxxxxxx spermatogoniálních xxxxxxxxx buněk lze xxxxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxx aberací xxxxxxxxxxxxxx xxxx v xxxxxxxxx-xxxxxxxx X, kdy xx xxxxxxxxxx buňky stávají xxxxxxxxxxxx.
Xxxx xxxxxxx xx xxxx je navržena xxx xxxxxxxxx, zda xxxx xxxxxxxx xxxxxxxxxxx xxxxx aktivní také x xxxxxxxxxxxx xxxxxxx. Xxxxx xx tato xxxxxxx se spermatogoniemi xxxxxxxx xxx posouzení xxxxxxxxx mutagenese, xxxxx xxxxxxxx xxxxxxxxx xxxxxxx xxxxxxxxxxx xx vivo, xxxxxxxxxxxxxxx x xxxxxxx xxxxxxxx DNA.
Ve varlatech xx xxxxxxxx řada xxxxxxxx spermatogonií s xxxxxx xxxxxxxxxx xx xxxxxxxx xxxxxxxx látce. Xxxxxxxxxx xxxxxxx xxxx xxxxxxxxxxx souhrnnou xxxxxxx xxxxxxxxxx xxxxxxxx xxxxxxxxxxxxx x převládajícími xxxxxxxxxxxxxxx xxxxxxxxxxxxxxx. X xxxxxxxxxx xx xxx xxxxxx xx varlatech, xxxxx xxxx nemusí xxx xxxxx generace spermatogonií xxxxxxxxxx celkovému xxxxxxxx xxxxx v xxxxxxxx xxxxxxxxx x xxxxxxxxxxxx xxxxxxx Xxxxxxxxx xxxxx x xxxxxxx xxxx xxxxxxx xxxxxx x xxxxxxx.
Xxxxxxxx xxxxxxxx důkaz x xxx, xx xx zkoušená xxxxx xxxx reaktivní xxxxxxxxxx xxxxxxxxxx xx xxxxxx xxxxx, xxxx vhodné xxxx xxxxxxx xxxxxx.
Xxx xxxx xxxxxx xxxx, xxxx B.
1.2 DEFINICE
Chromatidová xxxxxxx : strukturní xxxxxxxxx xxxxxxxxxx x xxxxxx zlomu xxxxxxxxxxxx xxxxxxxxx xxxx xxxxx x xxxxxxxx spojení xxxxxxxxx.
Xxxxxxxxxxxx xxxxxxx : xxxxxxxxxx poškození chromozomu x xxxxxx xxxxx xxxx zlomu a xxxxxxx xxxx xxxxxxxxx x xxxxxx místě.
Gap : achromatická xxxx xxxxx než xxxxx xxxxx chromatidy x x minimální xxxxxxxxx xxxxxxxxx.
Xxxxxxxxx xxxxxxx : xxxxxxxx počtu xxxxxxxxxx xx xxxxxxxx xxxxxxx x xxxxxxxxx xxxxx.
Xxxxxxxxxxx : xxxxxxx xxxxxxxxxxx xxxxx xxxxxxxxxxxxxx sad (x), jiný xxx xxxxxxxxx (tj. 3 x, 4 x xxx.).
Xxxxxxxxxx xxxxxxx : xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxx xxxxxxxxx xxxxxxxxxx xxx xxxxxxxx dělení xx xxxxxx metafáze pod xxxxxxxxxxx, xxxx xx xxxx delece x xxxxxxxxx, intrachromozomální xxxx xxxxxxxxxxxxxxxxxx xxxxx.
1.3 XXXXXXXX XXXXXXXX XXXXXX
Xxxxxxx jsou xxxxxxx způsobem xxxxxxxxxx xxxxxxxx xxxxx x xx xxxxxx době xx xxxxxxxx usmrcena. Xxxx xxxxxxxxx xx xxxxxxxx xxxx xxxxx xxxxxxxxxxx metafázi (např. xxxxxxxxx xxxx Xxxxxxxx®). X xxxxxxxxxxxx xxxxx xx poté xxxxxxxx xxxxxxxxx xxxxxxxxxx, obarví xx x analyzují xx xxxxxxxxxxxx xxxxxxx xxxxxxxxxxxxxx xxxxx.
1.4 POPIS XXXXXXXX METODY
1.4.1 Xxxxxxxxx
1.4.1.1 Xxxxx xxxxx xxxxxxx
Xxxxx xxxx používáni xxxxx xxxxxx čínského a xxxx; lze však xxxxxx xxxxx jakéhokoli xxxxxx xxxxxxxx xxxxx xxxxx. Xxxx xx xxx xxxxxxx běžně xxxxxxx xxxxxxxxxxx xxxxx xxxxxxx xxxxxxxx xxxxxxxx xxxxxxxxx xxxxxx. X xxxxxxxx xxxxxxxx studie xx xxxx být xxxxxxxx v xxxxxxxxx xxxxxx xxxxxxxxx a xxxxxx xx xxxxxxxxx ± 20 % xxxxxxx hodnoty xxxxxxxxx.
1.4.1.2 Xxxxxxxx chovu x xxxxxx
Xxxxx obecné xxxxxxxx xxxxx obecného xxxxx x xxxxx X, xxxxxxx xx xxxx xxx dosaženo vlhkosti xxxxxxx 50 – 60 %.
1.4.1.3 Příprava xxxxxx
Xxxxxx mladí pohlavně xxxxxxx xxxxx xx xxxxxxxx xxxxxxx xxxxxxx xx kontrolní xxxxxxx x xxxxxxx, xxxxx xx xxxxxxxx. Xxxxx xx měly xxx xxxxxxxxxx xxx, xxx xxx vliv xxxxxx xxxxxx xxxxxxxxxxxxx. Zvířata xx xxxxxxxxxxx identifikují. Xxxx xxxxxxxxx xxxxxx xx xxxxxxx x xxxxxxxxxxxxx xxxxxxxxxx xxxxxxx xxx dní aklimatizovat.
1.4.1.4 Xxxxxxxx xxxxx
Xxxxx xxxxxxxx xxxxx by měly xxx před aplikací xxxxxxxx xxxxxxxxxx nebo xxxxxxxxxxxx ve xxxxxxxx xxxxxxxxxxxxxx xxxx xxxxxxxxxx x popřípadě zředěny. Xxxxxxx xxxxxxxx xxxxx xxxxx xxx xxxxxxxx xxxxx xxxx xxxxx xxx před xxxxxxx xxxxxxx. Xxxx xx xxx xxxxxxx xxxxxxx xxxxxxxxxx xxxxxxxx chemické xxxxx, xxxxx údaje x stálosti neprokazují xxxxxxx xxxxxxxxxx.
1.4.2 Zkušební xxxxxxxx
1.4.2.1 Xxxxxxxxxxxx/xxxxxxxxx
Xxxxxxxxxxxx/xxxxxxxxx xx xxxxxx xxx při xxxxxxxxx xxxxxxxxx xxxxx xxxxxxx xxxxxx x xxxx xx xxx xxxxxxxxx xxxxxxxxx, xx xxxxxxx xx zkoušenou xxxxxx. Xxxx-xx použita xxxx xxx známá xxxxxxxxxxxx/xxxxxxxx, xxxx xx xxx xxxxxx zařazení xxxxxxxxx xxxxx o xxxxxx xxxxxxxxxxxxx. Doporučuje xx xxxxx xxxxx xxxxxxxx xxxxxx xxxxxxx xxxxxxx xxxxxxxxxxxx/xxxxxxx.
1.4.2.2 Kontroly
Součástí xxxxxxx xxxxxxxxxxx xx xxxx xxx xxxxxxxx xxxxxxxxx x xxxxxxxxx (xxxxxxxxxxxx/xxxxxxxxx) kontroly. S xxxxxxxx xxxxxxxx xxxxxxxx xxxxx xx xxxx xxxxxxx xxxxxxxxx xxxxxxx xxxxxxxxxx identický xxxxxx xxxx xxxxxxx ve xxxxxxxxx, x xxxxx xxxxx x xxxxxxxx.
Xxxxxxxxx xxxxxxxx by xxxx xxxxxxxxxx xxxxxxxxxx xxxxxxx xx spermatogoniích in xxxx xxx expozičních xxxxxxxx, x xxxxx xx xxxxxxxxxxx, že xxxxxxxxx xxxxxxxxxxxxx xxxxxx xxx xxxxxx.
Xxxxx xxxxxxxxx xxxxxxxx by xxxx xxx xxxxxxx xxx, xxx byl xxxxxx xxxxxxxx, ale aby xxx xxxxxx xxxxxxx xxxxx najevo kódovaná xxxxxxxxxxxx xxxxxxxxx. Xx xxxxxxxxxx, aby byla xxxxxxxxx xxxxxxxx xxxxxxxx xxxxx způsobem xxx xxxxxxxx xxxxx x xxx byl xxxxx x xxxxx xxxxxxx xxxxxxxx xxx jednou. Xxx xxxxxxxxx xxxxxxxx xxxx být xxxxx xxxxx x xxxxx xxxxxxx xxxxxxxxxx xxxxx xx xxxxxx xxxxxxxx xxxxx, xxxx-xx x xxxxxxxxx. Xxxxxxxx xxxxx xxx xxxxxxxxx xxxxxxxx:
Xxxxx |
Xxxxx XXX |
Xxxxx xxxxx Xxxxxx |
xxxxxxxxxxxxx |
50–18–0 |
200–015–4 |
xxxxxxxxxxxxx xxxxxxxxxx |
6055–19–2 |
|
xxxxxxxxxxxxxx |
108–91–8 |
203–629–0 |
xxxxxxxxx X |
50–07–7 |
200–008–6 |
xxxxxxxxx (xxxxxxx) |
79–06–1 |
201–173–7 |
2,4,6-xxxx(xxxxxxxx-1-xx)-1,3,5-xxxxxxx |
51–18–3 |
200–083–5 |
X xxxxxxxx xxxxxxx xxxxxx xx měl xxx xxxxxxxx xxxxx u xxxxxxx negativní xxxxxxxx, xxxxx xx aplikováno xxxxx xxxxxxxxxxxx xxxx xxxxxxxxx x která xxxxx xxxxxxxxxx xxxxxx xxxxxx xxxx xxxxxxxxxx xxxxxxx, pokud nejsou x xxxxxxxxxxx kontrolních xxxxx x xxxxxxxxx xxxxxxxxxx xxxxx o xxxxxxxxxxx zvířat x xxxxxxxx xxxxx x xxxxxxxxxxxxxx aberacemi. Xxxxx xxxx xx xxxx xxx xxxxxxxxxxxx xxxxxxxx xxxxxxx xxxx xxxxx, xxxxxxxxxx-xx dosud kontrolní xxxxx prokazující, xx xxxxxxx rozpouštědlo/vehikulum xxxxxxxxxx xxxxx xxxxxxx nebo xxxxxxxxx xxxxxx.
1.5 XXXXXX
1.5.1 Xxxxx xxxxxx
Xxxxx xxxxxxxxxx x xxxxxxxxx skupina xxxx xxxxxxxxx xxxxxxx xxx xxxxxxxxxxxxxxxx xxxxx.
1.5.2 Xxxx xxxxxxxx
Xxxxxxxx xxxxx xx xxxx xxx xxxxx možno podávány xxxxxxxxxxx xxxx nadvakrát (xx. xxx xxxxx xxxxxxxx nebo xxxx xxxxxxxxxx). Xxxxxxxx xxxxx xxxxx být podávány xxxx ve dvou xxxxxxx, xxx. xxx xxxxx x týž xxx x xxxxxxx xx xxxx xxx xxxxxxxx xxxxx, xxx xxxx usnadněno xxxxxxxx xxxxxxx objemů xxxxxxxxx. Xxxx xxxxxx xxxxxxxx xx xxxx xxx xxxxxxx xxxxxxxxxx.
Xx skupině x nejvyšší xxxxxx xx měly být xx xxxxxxxx provedeny xxx odběry. Xxxxxxxx xxxxxxxx xxxxxxxxx cyklu xxxx být xxxxxxxxx xxxxxx xxxxxxxxx, xxxxxxx xx jeden časný xxxxx a xxxxx xxxxxxxx xxxxx xxxxxxxxx 24 a 48 xxxxx xx xxxxxxxx. X xxxxxxx xxxx xxx xxxxxxxx xxxxx xx xxx být xxxxx xxxxxxxx xx 24 xxxxx xxxx xx takové xxxx xxxxxxxx, která odpovídá 1,5xxxxxxx délky xxxxxxxxx xxxxx, pokud není xxxxx xxxx xxxxxxxxx xxxx xxx detekci xxxxxx (6).
Xxxxx mohou xxx xxxxxx xxxxxxxxx xxxx v xxxx xxxx. Xxxxxxxxx x xxxxxxx xxxxxxxxxx xxxxx, xxxxx xxxxx xxxxxxxxx xxxxxxxx xxxxxxxxx (xxxxxxx) xxxxxxxxxx xxxx xxxxx xxxxxxxxxx S-nezávislé účinky, xxxx být xxxxxxxxx xxxxxxxx xxxxx (1).
Vhodnost xxxxx xxxxxxxxx xxxxxxxx xxxx být xxxxxx xxxxxx xx xxxxxxx. X xxxxxxx plánu x xxxxxxxxxx expozicí xx xxxx xxx xxxxxxx xxxxxxxx 24 xxxxx (1,5násobek xxxxx xxxxx) xx xxxxxxxx xxxxxxxx. Podle xxxxxxx xxxxx být prováděny xxxxx odběry x xxxx xxxx.
Xxxx xxxxxxxxx xx xxxxxxxx intraperitoneálně xxxx xxxxxx xxxxx xxxxx xxxxxxxxxxx metafázi (xxxx. Xxxxxxxx® xxxx xxxxxxxxx). Xxxx se xx vhodné xxxx xxxxxxx x xxxxxx xxxxx. X myši xx xxxx xxxx xxxxxxxxx 3 — 5 xxxxx; x xxxxxx xxxxxxxx xx xxxx xxxx xxxxxxxxx 4 — 5 xxxxx.
1.5.3 Dávkování
Provádí-li xx xxxxx xxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxx studie xxx zjištění xxxxxxx, xxxx xx xxx xxxxxxxxx ve xxxxxx xxxxxxxxxx, se xxxxxxx xxxxxx x xxxxxx x xx stejného xxxxxx expozice, xxxxx xx xxxxxxx x xxxxxx studii (7). X xxxxxxx toxicity xx xxx xxxxx xxxxx xxxxxxx tři xxxxxx xxxxx. Xxxx xxxxxx xxxxx xx xxxx xxxxxxxx xxxxxxx xxxx xxxxxxxxx a xxxxxxxxx xxxxxxxxx, xxxxxxxx xxxxxx xxxxxxxxx. Při xxxxxxxxx xxxxxx xxxxx, xxxx xxxx xxxxxxx xxxxx xxxxxxxx xxxxx. Xxxxxxxx dávka je xxxxxxxxxx xxxx xxxxx xxxxxxxxxxxx xxxxxx xxxxxx xxxxxxxx, xx xx xxxxx xxxxx xxxxx xxx stejném xxxxxx xxxxxxxxx podle xxxxxxxxx x letalitě.
Látky xx xxxxxxxxxxx xxxxxxxxxxx xxxxxxxxx xxx nízkých netoxických xxxxxxx (xxxx. xxxxxxx x xxxxxxxx) xxxxxx xxxxxxxxx stanovení xxxxx xxxxxxxxx x xxxx xx být hodnoceny xxxxxx od xxxxxxx. Xxxxxxxx xxxxx xxxx xxx xxxx xxxxxxxxxx xxxx xxxxx vyvolávající xx xxxxxxxxxxxxxxx xxxxxxx xxxxxx xxxxxxxx (xxxx. xxxxxxx počtu xxxxxxxxxxxxx x mitose xxxxxxxx x xxxxx x xxxxx xxxxxxxxx xxxxxxxx; xxxx xxxxxxx by xxxxxx překročit 50 %).
1.5.4 Xxxxxxx xxxxxxx
Xxxxxxxx xxxxxxx x jednou xxxxxx xxxxxxx 2000 xx/xx xxxxxxx hmotnosti xxxxxxx xxxxxxxxxxx xxxx xx xxxx xxxxxxx x xxxxxx xxx xxxxxxxxxx žádné xxxxxxxxxxxxx xxxxxxx xxxxxx a xxxx-xx xx xxxxxxx xxxxx x látkách, xxxxx mají xxxxxxxx xxxxxxxxx, očekávána genotoxicita, xxxxxxxxxx xx xxxxx xxxxxx xx xxxxx xxxxxxxx xxxxx za xxxxxxxxx. Xxxxxxxxx xxxxxxxx xxxxxxx může xxxxxxxx xxxxxxx xxxxxx x xxxxxxx xxxxxxx xxxxx xxxxxx dávky.
1.5.5 Xxxxxxxx xxxxx
Xxxxxxxx látka xx xxxxxxx podává xxxxxxxxxxxxxx, xxxxxxxxx sondou nebo xxxxxxx xxxxxxxxx kanylou, xxxx intraperitoneální xxxxxxx. Xxxx způsoby xxxxxxxx xxxx xxxxxxxxxx, xxxx-xx xxxxxxxxxxxxx. Maximální objem xxxxxxxx, xxxxx může xxx xxxxxxxx xxxxx xxxxxxxxx sondou xxxx xxxxxxxx, závisí xx xxxxxxxxx xxxxxxxxxxx xxxxxxx. Xxxxx xx xxxxx xxxxxxxxx 2 xx/100 x tělesné hmotnosti. Xxxxxxx xxxxxxx objemů, xxx xx uvedený xxxxx, musí xxx xxxxxxxxxx. Xx xx xxxxxxxx x xxxxxx xxxxx, které xxxxxxx xxx xxxxxxx xxxxxxxxxxxxx xxxxxxxx xxxxxxxx xxxxxx, xx xxxx xxx xxxxxxxxxxx xxxxxxxxxx xxxxxx xxxxxxxxxxxxxx nastavením xxxxxxxxxxx xxxxxxxxxxx xxxxxxxxxx xxxxx xxx xxxxx úrovních xxxxx.
1.5.6 Xxxxxxxx xxxxxxxxx xx xxxxxxx chromozomů
Ihned xx xxxxxxxx xx x xxxxxxx nebo xxxx xxxxxx získá xxxxxxx xxxxxxxx, hypotonizuje xx a xxxxxx. Xxxx xx nanese xx podložní xxxxxxx x xxxxxx xx.
1.5.7 Xxxxxxx
X xxxxxxx xxxxxxx xx xxxx xxx xxxxxxxxxxx xxxxxxx 100 xxxxx x dobře xxxxxxxxxxxx metafázi (xx. xxxxxxxxx 500 metafází xx skupinu). Tento xxxxx xxx xxxxxx, xx-xx xxxxxxxxx xxxxx xxxxx xxxxxxx. Xxxxxxx xxxxxxxxx xxxxxx preparátů xxxxxxxxxxx x xxxxxxxxxxx xxxxxxx, xx xxxx xxx xxxx xxxxxxxxxxxxxx xxxxxxxx xxxxxxxxx xxxxxxxx. Xxxxxxxx xxx fixaci xxxxx dochází ke xxxxxxxxxxxxxx xxxxxx xxxx xxxxxx xxxxxxxxxx x xxxxx xxxxxxxx, měly xx xxxxxxxxxxx xxxxx xxxxxxxxx xxxxxxxxxx x xxxxx odpovídajícímu číslu 2 n ± 2.
2. XXXXX
2.1 XXXXXXXXXX XXXXXXXX
Xxxxx pro xxxxxxxxxx xxxxxxx xx xxxx xxx zpracovány xx xxxxx xxxxxxx. Experimentální xxxxxxxxx xx xxxxx. Xxx xxxxx xxxxx xx xxx xxx xxxxxxxxxx xxxxx xxxxx xx xxxxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxx x xxxxx xxxxxxxxxxxxxx xxxxxxx na xxxxx. Pro xxxxxxxxxx x kontrolní xxxxxxx xx xxxx xxx xxxxxxx xxxxx typy xxxxxxxxxxxx chromozomových aberací x xxxxxx xxxxxx x xxxxxxxx. Gapy xx zaznamenávají xxxxxxxx x xxxxxxx xx, xxx xxxxxx xx xxxxxxxxxx xx celkové xxxxxxxx aberací.
Je-li pozorována xxxxxx a také xxxxxx, měl by xxx xxx stanovení xxxxxxx xxxxxxxxxxxxx účinků xxxx xxxx xxxxxxxxxxxx xxxxxxxx u xxxxx xxxxxxxxxxxx zvířat x xxxxxx xxxxxxxxxx jako xxxxxxxxx kontrola xxxxx xxxxxxxxxxxxx v xxxxxx xxxxxxxx x xxxxx x druhé xxxxxxxxx xxxxxxxx, x to x celkovém vzorku 100 xxxxxxxx xx xxxxx xx jedno xxxxx. Xxxxx je xxxxxxxxx pouze mitosa, xxxxxxx v 1000 xxxxxxx xx zvíře xx xxx být xxxxxxxx xxxxxxxxx index.
2.2 XXXXXXXXX X XXXXXXXXXXXX XXXXXXXX
Xxx xxxxxxxxx xxxxxxxxxxx xxxxxxxx xxxxxxxx xxxxxxx xxxxxxxx, xxxx. xxxxxx xxxxx buněk x xxxxxxxxxxxxxx xxxxxxxxx v xxxxxxxxxx na dávce xxxx jasný xxxxxx xxxxx buněk x xxxxxxxxx xxx xxxxxxx x xxxxxxx xxxxxx x x xxxxxxxx xxxxxxxx odběru. Nejdříve xx měla xxx xxxxxxx xxxxxxxxxx xxxxxxxxx xxxxxxxx. Při xxxxxxxxx xxxxxxxx xxxxxxx xxxxx xxx xxxxxxx xxxx xxxxxxx prostředek xxxxxxxxxxx xxxxxx (8). Statistická xxxxxxxxxx by xxxxxx xxx xxxxxxx xxxxxxxxx xxxxxxxx xxx xxxxxxxxx xxxxxxx. Xxxxxxxxxx xxxxxxxx xx xxxx xxx xxxxxxxxx xxxxxx xxxxxxxxx, xxxxxxx x úpravami xxxxxxxxxxxxxxxx podmínek.
Zkoušená xxxxx, xxxxx výsledky xxxxxxxxx xxxx xxxxxxx xxxxxxxx, xx x tomto xxxxxxx xxxxxxxx xx xxxxxxxxxxx.
Xxxxxx většina experimentů xxxxxxxx xxxxx xxxxxxxxx xxxx xxxxxxxxx výsledky, x ojedinělých xxxxxxxxx xxxxxxxx soubor xxxxx xxxxxxxx xxxxxxx xxxxx x aktivitě xxxxxxxx xxxxx. Xxxxxxxx xxxxx xxxxxx xxxxxxxxxx nebo xxxxxx bez xxxxxx xx to, kolikrát xx experiment xxxxxxxx.
Xxxxxxxxx xxxxxxxx zkoušky na xxxxxxxxxxxx xxxxxxx xx xxxxxxxxxxxxxxx savců xx xxxx znamenají, že xxxxxxxx xxxxx xxxxxxxx x xxxxxxxxxxxx buňkách xxxxxxxxxxx xxxxx xxxxxxxxxx xxxxxxxxxxxx aberace. Xxxxxxxxx xxxxxxxx znamenají, xx xxxxxxxx látka za xxxxxxxx xxxxxxx neindukuje x xxxxxxxxxxxx xxxxxxx xxxxxxxxxxx xxxxx xxxxxxxxxxxx xxxxxxx.
Xxxx by být xxxxxxxxxxx xxxxxxxxxxxxxxx, x xxxxx xx xxxxxxxx xxxxx xxxx xxxx xxxxxxxxxx dostanou xx xxxxxx tkáně.
3. XXXXXX
XXXXXXXX X XXXXXXX
Xxxxxxxx x xxxxxxx musí xxxxxxxxx xxxx xxxxxxxxx:
Xxxxxxxxxxxx/xxxxxxxxx:
- xxxxxxxxxx xxxxx vehikula,
- xxxxxxxxxxx x stálost zkoušené xxxxx v xxxxxxxxxxxx/xxxxxxxx, xx-xx xxxxx.
Xxxxxxxxx xxxxxxx:
- xxxxxxx xxxx/xxxx,
- počet x stáří xxxxxx,
- xxxxx, podmínky xxxxx, xxxxxx atd.,
- individuální xxxxxxxx xxxxxx na xxxxxxx xxxxxxx, včetně xxxxxxx tělesné xxxxxxxxx, xxxxxxx hodnoty x xxxxxxxxxx xxxxxxxx xxx xxxxxx xxxxxxx.
Xxxxxxxx podmínky:
- xxxxx xx xxxxxx xxx xxxxxxxx rozsahu, xxxxx xxxx xxxxxxxxx,
- xxxxxxxxxx xxxxxxxxx xxxxxx xxxxx,
- xxxxxxxxxx způsobu xxxxxxxx,
- xxxxx x xxxxxxxx xxxxxxxx látky,
- xxxxx o xxxxxxxx xxxxxxxx xxxxx,
- xxxxxxxxxx xxx xxxxxxxx,
- xxxxxxxx xxxxxxxx xxxx koncentrací xxxxxxxx xxxxx x xxxxxx xxxx xxxx (xxx) xx xxxxxxxxxxxx xxxxx (mg/kg tělesné xxxxxxxxx/xxx),
- xxxxxxxx xxxxx x xxxxxxx xxxxxx x xxxx,
- xxxxxxxx xxxxx xxxxxxx xxxxxxxx x odběru,
- metody xxxxxxxxx xxxxxxxx,
- xxxxxxxxxxxx xxxxx zastavující xxxxxxxx, xxxx xxxxxxxxxxx a xxxxx xxxxxxxx,
- metody xxxxxxxx xxxxxxxxx,
- xxxxxxxx xxxxxxxxx xxxxxxx,
- počet xxxxxxxxxxxxx xxxxx xx xxxxx xxxxx,
- kritéria xxxxxxxxxxx xxxxxx xx xxxxxxxxx, negativní nebo xxxxxxxxxxx.
Xxxxxxxx:
- xxxxxx xxxxxxxx,
- xxxxxxxxx xxxxx,
- xxxxx xxxxxxxxxxxxx x xxxxxx xxxxxxxx x xxxxx x druhé metafázi xxxxxx,
- xxx x xxxxx xxxxxxx xxxxxxx xxxxxxxxxx xxx xxxxx xxxxx,
- xxxxxxx xxxxx xxxxxxx xx skupině,
- xxxxx buněk x xxxxxxxxx ve xxxxxxx,
- xxxxx xxxxxxxx xxxxxxxxx xxxxxxxx xx dávce,
- xxxxxxxx xxxxxxxxxxx xxxxxxx,
- xxxxx o xxxxxxxx xxxxxxxxx xxxxxxxx,
- dosavadní xxxxx x xxxxxxxxx xxxxxxxx s rozpětími, xxxxxxxxx xxxxxxxxx x xxxxxxxxxxxx xxxxxxxxxx,
- xxxxx x souběžné pozitivní xxxxxxxx,
- xxxxx ploidie, xxxxx xxxx xxxxxxxxxx.
Xxxxxx xxxxxxxx.
Xxxxxx.
4. XXXXXXXXXX
1) Xxxxx, X. D., (1986), Xxxxxxxxxxx Xxxxxxxxx xx Xxxxx Xxxxxxxxxxxxx xx Xxxxxxxx Xxxxxxxx Related xx xxxxx Xxxx-Xxxxx Xxxxxxxxxxxxxx, xx: Xxxxxxx Xxxxxxxxxx of Xxxxxxxxxxxxx Xxxxxxxxx, Xxxx X: Xxxxxxx Xxxxxxx and Xxxxxxx Mutagenesis, Xxxxx, X., Xxxxxxx, B., Xxxxxxxxx, J. (eds) Xxxx, Xxx Xxxx, 477-484.
2) Xxxxx, X. X., (1984), Cytogenetic xxxxx in Xxxxxxx, xx: Mutagenicity Xxxxxxx: x Xxxxxxxxx Xxxxxxxx, (xx.) X. Venitt, X. X. Parry, XXX Xxxxx, Oxford, Xxxxxxxxxx XX, 275-306.
3) Xxxxx, E. P., Xxxxxxx, X., Xxxx, X. X. (1964), Xx Air-drying Xxxxxx xxx Meiotic Xxxxxxxxxxxx xxxx Xxxxxxxxx Testes, Xxxxxxxxxxxx Xxxx Xxxxxxxx, 3, 289-294.
4) Richold, X., Xxxxx, X., Xxxxxxxx, A., Xxxxxxxxx, X. X., Henderson, X. (1990), In xxxx Xxxxxxxxxxx Assays, xx: D. J. Xxxxxxxx (ed.), Xxxxx Xxxxxxxxxxxx Tests, XXXXX Xxxxxxxxxxx Xxxxxxxxxx. XXXXX Xxxxxxxxxxxx xx Xxxxxxxxxx xxx Xxxxxxxxxxxx Xxxxxxx. Xxxxxx. Xxxx I xxxxxxx, Cambridge Xxxxxxxxxx Xxxxx, Xxxxxxxxx, New Xxxx, Xxxx Xxxxxxx, Xxxxxxxxx, Xxxxxx, 115-141.
5) Xxxxxxxx, X., Kikuchi, X. (1978), A Xxx Xxxxxx xxx Xxxxxxxxxxx xx Xxxxxxxxx Xxxxxxxxxxxxxx Chromozomes, Mutatation Xxx., 52, 207-209.
6) Xxxxx, X. X., Xxxxxx X. X., Xxxxxxx, J., Xxxxx, X., Generoso, X., Xxxxxxxxxxxx, F., Xxxxxxx, X., Xxxxxx X. (1994), International Xxxxxxxx xx Xxxxxxxxxxxxxxx xx Xxxxxxxxxxxx Test Procedures. Xxxxxxx Xxxxxx xx xxx Xxxxxxx Xxxxx xx Xxxxxxxxx Xxxx Xxxx Tests, Mutatation Xxx., 312, 313-318.
7) Xxxxxxx, X. J., Xxxxx, J. X., Xxxxxx, X. X., Xxxxxx, X. X., Xxx, J., Esdaile, X. X., Xxxxxxxxx, X. X., Hodson-Walker, X., Xxxxxx, X. X., Kirkland, D. X., Xxxxxxx, X. (1992), Xxxxxx xx Xxxxxxx Toxicology Xxxxxxx/XX Xxxxxxxxxxxxx Mutagen Society Xxxxxxx Xxxxx: Dose Xxxxxxx in In xxxx Xxxxxxxxxxxx Assays, Xxxxxxxxxxx, 7, 313-319.
8) Xxxxxx, X. X., Xxxxxxxx, D., Xxxxxxxx, X., Amphlett, X. X., Xxxxx, X., Xxxxxxxx, R., Richold, X., Xxxxxxxx, X. X., Xxxxxx J. X. K. (1989), Xxxxxxxxxxx Xxxxxxxx xx Xx vivo Xxxxxxxxxxx Xxxxxx, in: D. X. Kirkland (xx.), Xxxxxxxxxxx Evaluation xx Xxxxxxxxxxxx Xxxx Xxxx. XXXXX Xxxxxxxxxxxx xx Xxxxxxxxxx for Mutagenicity Xxxxxxx, Xxxxxx, Xxxx XXX. Xxxxxxxxx University Xxxxx, Xxxxxxxxx, Xxx Xxxx, Port Xxxxxxx, Xxxxxxxxx, Sydney, 184-232."
XXXXXXX 4X
"X.39 ZKOUŠKA XX NEPLÁNOVANOU SYNTÉZU XXX (UDS) X XXXXXXXXX BUŇKÁCH XXXXX XX VIVO
1. XXXXXX
Xxxx xxxxxx xx xxxxxxxx xxxxxx OECD TG 486 — Zkouška xx xxxxxxxxxxxx xxxxxxx XXX (XXX) x xxxxxxxxx buňkách savců xx xxxx (1997).
1.1 XXXX
Xxxxxx zkoušky na xxxxxxxxxxxx xxxxxxx DNA (XXX) v xxxxxxxxx xxxxxxx xxxxx in xxxx xx xxxxxxxxxxxxx xxxxxxxx xxxxx, xxxxx xxxxxxxx xxxxxxxx DNA x xxxxxxxxx xxxxxxx xxxxxxxxxxxx xxxxxx (1, 2, 3, 4).
Xxxx xxxxxxx xx vivo xxxxxxxxx xxxxxx vyšetření xxxxxxxxxxxxx účinků chemických xxxxx v xxxxxxx. Xxxxxxxxxxx xxx xx xxxxxxxxxx xxxxxxxxx XXX x xxxxxxxx xxxxxxxx x xxxxxxxxx buňkách. Xxxxx jsou xxxxxxx xxxxxxx xxxxxx, xxx xxxx xxxxxxxxxxx sloučeniny xxxxxxxxxxxxxx. Jsou xxxx xxxxxxx xxxxxx xxx xxxxxxxxx míry poškození XXX in xxxx.
Xxxxxxxx xxxxxxxx xxxxx x xxx, že se xxxxxxxx xxxxx xxxxxxxxx xx xxxxxx xxxxx, xxxx xxxxxx xxxx xxxxxxx xxxxxx.
Xxxxxx xxxxxxxxxxx xxxxxxx XXX (XXX) xx zhodnotí xxxxxxxxxx xxxxxxxxxxx xxxxxxxxx xxxxxxxxxx xx buněk, které xxxxxxxx plánovanou syntézou XXX (X-xxxx). Nejrozšířenější xxxxxxxxx je xxxxxxxxxxxxxxxxx xxxxxxxxx xxxxxxxxxxx thymidinu xxxxxxxxx tritiem (3X-XxX). Xxx xxxxxxx xx XXX in xxxx xx přednostně xxxxxxxxx xxxxx potkana. Xxxx xxxxx než xxxxx xxxxx být rovněž xxxxxxx, xxxxxx xxxx xxxxxxxxx xxxx xxxxxx.
Xxxxxxx xxxxxxxx UDS xxxxxx xx xxxxx xxxx XXX xxxxxxxxxxx a xxxxxxxxxxx x místě xxxxxxxxx. Xxxxxxx xx XXX xx xxxx xxxxxx xxxxxxx xxx xxxxxxx xxxxxxxx xxxxxxxx ("xxxx-xxxxx repair") (20 xx 30 xxxx) xxxxxxxxxxxx xxxxxx. Xxxxxx xxxxxx ("short-patch xxxxxx") (xxxxx xx xxx xxxx) jsou naproti xxxx xxxxxxxxxx s xxxxxx xxxxx citlivostí. Xxxxx xxxx xxxxxxxxx xxxxxxxxxxxxx reparace, xxxxxx xxxxxxxx xxxx chybné xxxxxxxxx xxxx DNA xxxxx x xxxxxxxxxx xxxxxxxxx. Xxxxxx odpovědi XXX xxxxxxxxxxx xxxxxx xxxxxxxxx x xxxxxxxx xxxxxxxxxxx xxxxxxx. Xxxxx xx možné, xx xxxxxxx reaguje x XXX, xxx xxxxxxxxx XXX není xxxxxxxx xxxxxxxxxxx xxxxxxxx. Xxxxxxxxxx xxxxxxxxxxxx xxxxxxxxx, xxxxx xxxx zkouška poskytuje x mutagenní xxxxxxxx, xx xxxxxxx potenciální xxxxxxxxxx xxxxxx xxxx, xxxxx je vyšetřován x celém genomu.
Viz xxxx obecný úvod, xxxx X.
1.2 XXXXXXXX
Xxxxxxxxxx xxxxx : xxxxx xxxxx xxx xxxxxxxxxxxxxx xxxxxxxx xxxxxx (XXX), xxxxx než předvolená xxxxxxx xxxxxxxxx laboratoří xxxxxxxxxxx zkoušku.
Čistý xxxxx xxx odpovídajících buněčným xxxxxx (NNG) : xxxxxxxxxxxxx míra XXX xxxxxxxx xxxxx v xxxxxxxxxxxxxxxxx xxxxxxx xx XXX, xxxxxxxxx xxxxxxxxx xxxxxxxxxx xxxxx xxx x xxxxxxxxxxxxxxxxx oblastech (XX) xxxxxxxxxxxxxx xxxxxx xx xxxxx xxx xxxxxxxxxxxxxx xxxxxxxx jádrům (XX): NNG = XX — XX. Xxxxxxx XXX se xxxxxxx xxx xxxxxxxxxx xxxxx, xxxx xxxxxxxx xxx buňky x xxxxxxx, x xxxxxxxxxxx xxxxxxxxx xxx.
Xxxxxxxxxxx syntéza XXX (UDS) : Xxxxxxx reparací DNA xx xxxxxxxxx x xxxxxxxxxx úseku XXX xxxxxxxxxxxx xxxxxx x xxxxxxxxxx xxxxxxxxxxx xxxxxxxxxx xxxxxxx xxxx fyzikálními xxxxxxxx.
1.3 XXXXXXXX ZKUŠEBNÍ XXXXXX
Xxxxxxx na XXX x xxxxxxxxx buňkách xxxxx xx xxxx xxxxxxxx syntézu xxxxxxxx XXX xx xxxxxxxxx x xxxxxxxxxx xxxxx XXX xxxxxxxxxxxx xxxxxx x xxxxxxxxxx indukovaným xxxxxxxxxx xxxxxxx xxxx xxxxxxxxxxx xxxxxxxx. Xxxxxxx xx xxxxxxx založena xx xxxxxxxxxxx 3X-XxX xx XXX xxxxxxxxx xxxxx, xxx xx xxxx xxxxxxx buněk x X-xxxx xxxxxxxxx xxxxx. Xxxxxxxxxxx 3X-XxX xx obvykle xxxxxxxxx xxxxxxxxxxxxxxx, xxxxxxx xxxx xxxxxxxx xxxx xxx xxxxxxx xx vliv X-xxxx buněk xxxx xxxx. kapalná xxxxxxxxxxx xxxxxxxxxxxxx.
1.4 XXXXX XXXXXX
1.4.1 Xxxxxxxxx
1.4.1.1 Xxxxx druhu xxxxxxx
Xxxxx je xxxxxxxx xxxxxx, xxxxxx xxx xxxxxx xxxxxxxx vhodný xxxx xxxxx. Xxxx xx xxx xxxxxxx xxxxx používané laboratorní xxxxx xxxxxxx xxxxxxxx xxxxxxxx xxxxxxxxx xxxxxx. X xxxxxxxx xxxxxxxx xxxxxx xx měla xxx odchylka v xxxxxxxxx xxxxxx xxxxxxxxx x xxxxxx by xxxxxxxxx ± 20 % xxxxxxx hodnoty xxxxxxxxx pro obě xxxxxxx.
1.4.1.2 Podmínky chovu x xxxxxx
Xxxxx xxxxxx xxxxxxxx podle xxxxxxxx xxxxx x části X, xxxxxxx by xxxx xxx dosaženo xxxxxxxx xxxxxxx 50 - 60 %.
1.4.1.3 Xxxxxxxx xxxxxx
Xxxxxx xxxxxxxx xxxxxxx xxxxxxx se xxxxxxxx výběrem rozdělí xx xxxxxxxxx skupinu x xxxxxxx, která xx xxxxxxxx. Xxxxx xx měly být xxxxxxxxxx xxx, xxx xxx xxxx xxxxxx xxxxxx minimalizován. Xxxxxxx xx xxxxxxxxxxx xxxxxxxxxxxx x xxxx započetím xxxxxx se nechají x xxxxxxxxxxxxx xxxxxxxxxx xxxxxxx pět xxx xxxxxxxxxxxxx.
1.4.1.4 Příprava zkoušené xxxxx
Xxxxx xxxxxxxx látky xx měly být xxxx xxxxxxxx xxxxxxxx xxxxxxxxxx xxxx xxxxxxxxxxxx xx xxxxxxxx xxxxxxxxxxxxxx xxxx xxxxxxxxxx a xxxxxxxxx xxxxxxx. Xxxxxxx xxxxxxxx látky xxxxx xxx xxxxxxxx xxxxx xxxx xxxxx xxx xxxx podáním xxxxxxx. Xxxx xx být xxxxxxx xxxxxxx xxxxxxxxxx xxxxxxxx xxxxxxxx xxxxx, xxxxx xxxxx x xxxxxxxx xxxxxxxxxxx možnost xxxxxxxxxx.
1.4.2 Xxxxxxxx podmínky
1.4.2.1 Xxxxxxxxxxxx/xxxxxxxxx
Xxxxxxxxxxxx/xxxxxxxxx by xxxxxx xxx xxx xxxxxxxxx xxxxxxxx xxxxx xxxxxxx xxxxxx a xxxx xx xxx vyloučeno xxxxxxxxx, že reaguje xx xxxxxxxxx látkou. Xxxx-xx použita xxxx xxx xxxxx rozpouštědla/vehikula, xxxx by xxx xxxxxx xxxxxxxx podloženo xxxxx o xxxxxx xxxxxxxxxxxxx. Doporučuje xx xxxxxxxx zvážit xxxxxxx xxxxx xxxxx vodných xxxxxxxxxxxx/xxxxxxx.
1.4.2.2 Xxxxxxxx
Xxxxxxxx xxxxx xxxxxxxxx prováděné xxxxx xxxxxxxxxxx by xxxx xxx xxxxxxxx xxxxxxxxx x xxxxxxxxx (xxxxxxxxxxxx/xxxxxxxxx) xxxxxxxx. X xxxxxxxx xxxxxxxx xxxxxxxx xxxxx xx xxxx xxxxxxx xxxxxxxxx xxxxxxx xxxxxxxxxx xxxxxx proces jako xxxxxxx xx xxxxxxxxx, x xxxxx dojde x xxxxxxxx.
Xxxxxxxxxxx kontrolami xx měly xxx xxxxx, x xxxxx xx známo, xx xxxxxx xxxxxxxx x xxxxxxxxxxx expozičních xxxxxxxxxxxxx xxxx x nárůstu XXX xxxxxxxxxxxxxxx nad xxxxxxx. Xxxxxxxxx kontroly xxxxxxxxxx metabolickou xxxxxxxx xx xxxx xxx xxxxxxx x dávkách xxxxxxxxxxxx mírnou xxxxxxx (4). Xxxxx mohou xxx xxxxxxx xxx, xxx byl xxxxxx xxxxxxxx, xxx xxx xxx odečtu xxxxxxx xxxxx xxxxxx xxxxxxxx xxxxxxxxxxxx preparátu. Xxxxxxxx xxxxx xxx xxxxxxxxx xxxxxxxx:
Xxxx xxxxxx |
Xxxxx |
Xxxxx CAS |
Číslo xxxxx Xxxxxx |
Xxxxx xxxx xxxxxx (2 xx 4 x) |
X-xxxxxxxxxxxxxxxxxxx |
62–75–9 |
200–249–8 |
Xxxxxx doby xxxxxx (12 až 16 h) |
N-(fluoren-2-yl)acetamid (2-XXX) |
53–96–3 |
200–188–6 |
Xxxxx xxx xxxxxxx také xxxx xxxxx xxx xxxxxxxxx kontrolu. Xx xxxxxxxxx, xxx xxxx xxxxxxxxx xxxxxxxxx látka xxxxxxxx xxxxx xxxxxxxx, xxx xxxxxxxx látka.
1.5 XXXXXX
1.5.1 Xxxxx x xxxxxxx xxxxxx
Xxx by xxx xxxxxx dostatečný xxxxx zvířat, xxx xxxx zohledněno xxxxxxxxx xxxxxxxxxx kolísání xxxxxxxx xx xxxxxxx. Každá xxxxxxx xx xx xxxx skládat xxxxxxx xx tří analyzovatelných xxxxxx. Xxxxxxxx jsou xxxxxxxxxxx xxxxxxxxxx xxxxxxxxx xxxxx, xx xxx xxxxxxxxx a xxxxxxxxx xxxxxxxxx xxxxxxx nezbytné xxxxx xxxxx až xxx zvířata.
Jestliže jsou x době xxxxxx x xxxxxxxxx xxxxx xx xxxxxx xx xxxxxxx xxxxxx x xx použití stejného xxxxxxx expozice, xxx xxxxxxxxx, že xxxxxxxxxx xxxx pohlavími xxxxxx x xxxxxxxx, bude xxxxxxxxxxx zkoušení jednoho xxxxxxx, xxxxxxx samců. Xx-xx xxxxxxxx xxxxxxx xxxxxxxxxx xxx určité xxxxxxx, jako xx xxxx xxxxxxxxx x xxxxxxxxx xxxxxxxxxxxxxxx xxxxx, xxxx by být xxxxxxx xxxxxxxxx xx xxxxxxxx xxxxxxxxxxxxxx pohlaví.
1.5.2 Xxxx xxxxxxxx
Xxxxxxxx látky xxxx xxxxxxxxx xxxxxxxx xxxxxxxxxxx.
1.5.3 Xxxxxxxxx
Xx xxxxxxxxxx xxxxxxxx se xxxxxxxxx xxxxxxx xxx xxxxxx xxxxx. Nejvyšší dávka xx xxxxxxxxxx xxxx xxxxx vyvolávající xxxxxx xxxxxx xxxxxxxx, xx xxxxx dávky by xxxxx xxxxx xxxxxxxxx xxx xxxxxxx xxxxxx xxxxxxxxx x xxxxxxxx. Xxxxx xxxxx xx xxxx xxx xxxxxxxxx 50 % xx 25 % vyšší xxxxx.
Xxxxx xx specifickou xxxxxxxxxxx xxxxxxxxx při xxxxxxx xxxxxxxxxxx dávkách (xxxx. xxxxxxx x xxxxxxxx) xxxxxx xxxxxxxxx xxxxxxxxx xxxxx xxxxxxxxx x xxxx xx xxx hodnoceny xxxxxx xx případu. Provádí-li xx xxxxx xxxxxxxxxxx xxxxxxxx xxxxxxxxxx údajů xxxxxx xxx xxxxxxxx xxxxxxx, měla xx xxx provedena xx xxxxxx xxxxxxxxxx, xx xxxxxxx xxxxxx, kmenem, xxxxxxxx x xx xxxxxxxx xxxxxx expozice, xxx se použijí x xxxxxx studii.
Nejvyšší xxxxx xxxx xxx xxxxxxxxxx xxxx xxxx xxxxx vyvolávající známky xxxxxxxx x játrech (xxxx. xxxxxxxxxx xxxxx).
1.5.4 Xxxxxxx xxxxxxx
Xxxxxxxx xxxxxxx x jednou xxxxxx x alespoň 2000 xx/xx xxxxxxx xxxxxxxxx xxxxxxx xxxxxxxxxxx xxxx xx dvou xxxxxxx x xxxxxx dni xxxxxxxxxx žádné xxxxxxxxxxxxx xxxxxxx účinky a xxxx-xx xx základě xxxxx o xxxxxxx, xxxxx mají xxxxxxxx xxxxxxxxx, xxxxxxxxx genotoxicita, xxxxxx xxx úplná xxxxxx xxxxxxxx. Očekávaná xxxxxxxx člověka může xxxxxxxx xxxxxxx xxxxxx x xxxxxxx zkoušce xxxxx úroveň dávky.
1.5.5 Xxxxxxxx xxxxx
Xxxxxxxx látka xx obvykle podává xxxxxxxxxxxxxx, xxxxxxxxx xxxxxx xxxx vhodnou intubační xxxxxxx. Xxxx způsoby xxxxxxxx jsou xxxxx, xxx-xx xx xxxxxxxxx. Xxxxxxxx intraperitoneálně se xxxx nedoporučuje, xxxxx xx xxxxx mohla xxx xxxxxxxxxx zkoušené xxxxx xxxxx a xxxxxx prostřednictvím xxxxxxxxx xxxxxxx. Xxxxxxxxx xxxxx xxxxxxxx, xxxxx může xxx najednou xxxxx xxxxxxxxx xxxxxx xxxx xxxxxxxx, xxxxxx na xxxxxxxxx xxxxxxxxxxx xxxxxxx. Xxxxx xx xxxxx xxxxxxxxx 2 ml/100 x xxxxxxx xxxxxxxxx. Xxxxxxx xxxxxxx xxxxxx, xxx xx xxxxxxx xxxxx, xxxx xxx xxxxxxxxxx. Xx na xxxxxxxx x xxxxxx xxxxx, které xxxxxxx xxx xxxxxxx xxxxxxxxxxxxx xxxxxxxx xxxxxxxx xxxxxx, xx měla xxx xxxxxxxxxxx xxxxxxxxxx xxxxxx xxxxxxxxxxxxxx nastavením xxxxxxxxxxx xxxxxxxxxxx xxxxxxxxxx xxxxx xxx všech úrovních xxxxx.
1.5.6 Xxxxxxxx xxxxxxxxx xxxxx
Xxxxxxx xxxxx xx xxxxxxxxxx x xxxxxxxxxxxx xxxxxx xxxxxxxxx 12 xx 16 xxxxx xx xxxxxx xxxxx. Xxxxxxxxxx xxxxxxxx odebrání xxxxxx (xxxxxx dvě xx čtyři xxxxxx xx xxxxxxxx) xx xxxxxxxx, xxxx-xx xx 12 až 16 xxxxxxxx jasná xxxxxxxxx xxxxxxx. Xxxxx xxxx xxx xxxxxxx xxxx xxxx odběru, xxxx-xx xxxxxxxxxx na základě xxxxxxxxxxxxxxxxx xxxxx.
Xxxxxxxxxx xxxxxxx xxxxxxxxx buněk savců xx zpravidla zakládají xxxxxxx jater xxxxxxxxxxx xx situ x xxxxxx xx, xxx xx čerstvě xxxxxxxxxxx xxxxxxx xxxxx xxxxxxxxx xx xxxxxxx xxxxxxx. Xxxxxxx xxxxx x xxxxxxxxx xxxxxxxx xx xxxx xxxxxxxxx xxxxxxxxxxxxxxx (5) xxxxxxx 50 %.
1.5.7 Stanovení UDS
Čerstvě xxxxxxxxx jaterní xxxxx xxxxx xx obvykle xxxxxxx xxxx, např. xxx xx xxx xxxxx, inkubují x xxxxxx xxxxxxxxxxx 3H-TdR. Xx konci inkubační xxxx by xxxx xxx xxxxxx x xxxxx odstraněno x xxxxx xxxx xxxxx xxx inkubovány s xxxxxx xxxxxxxxxxx xxxxxxxx xxxxxxxxxxx thymidinu, aby xxxx xxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxxxx ("xxxx xxxxx"). Xxxxx xx xxxx xxxxxxx, fixují x xxxxxx. Xxx xxxxx xxxxxxxxx době xxxxxx xxx snížení radioaktivity xxxxxxxx. Preparáty se xxxxxx xx autoradiografické xxxxxx, exponují se x xxxxx (xxxx. x xxxxxx 7 xx 14 dnů), xxxxxxxx xx, xxxxxx x xxxxxxxxx se xxxxxxxxxx zrna xxxxxxx. X každého xxxxxxx xx xxxxxxxx xxx xx xxx xxxxxxxxx.
1.5.8 Xxxxxxx
Xxxxxxxxx by xxxx xxxxxxxxx xxxxxxxxxx xxxxx xxxxxxxxxxxx xxxxxxxxxx buněk, xxx mělo hodnocení XXX výpovědní xxxxxxx. Xxxxxxxxx xx xxx xxxxxxxxxxx prohlédnou xx xxxxxx xxxxxx xxxxxxxxxxxx (xxxx. xx pyknosu, xxxxxxxx úroveň xxxxxxx xxxxxxxxxxxxx xxxxxxxx).
Xxxx xxxxxxxxx xxx xx xxxx xxx xxxxxxxxx kódovány. Xxxxxxxxx se vyšetřuje 100 xxxxx na xxxxx zvíře alespoň xx xxxx xxxxxxxxx; xxxxxxxxx méně xxx 100 xxxxx/xxxxx xx xxxx xxx xxxxxxxxxx. Xxx počítání xxx xx xxxxx x X-xxxx nevyšetřují, ale xxxxx buněk v X-xxxx může být xxxxxxxxxx.
Xxxxxxxx 3H-TdR inkorporovaného xx xxxxx x xxxxxxxxxx xxxxxxxxxxxx xxxxxxxxxx xxxxx xxxxxxxx xxxxxxxxxxx xxx stříbra xx xxxx xxx stanoveno xxxxxxx xxxxxxx.
Xxxxx xxxxx xx stanoví x xxxxx xxx xxxxxxxxxxxxxx xxxxxxxx xxxxŭx (xx) x z prŭměrného xxxxx xxx x xxxxxxxxxxxxxxxxx xxxxxxxxx (cg) xxxxxxxxxxxxxx xxxxŭx. xxxx xxxxxxx xx se xxxxxxx xxx xxxxx xxxxx pro nejsilněji xxxxxxxxx xxxxxx cytoplasmy, xxxx xxŭxxxxx xxxxxxx xxxx xx xxx xxxxxxx vybraných xxxxxxx x blízkosti xxxxxxxxx xxxxxxxxx xxxxx. po xxxxxxxxxxxxx xxXxxxxxxx xxxxx xxx xxxxxxx i xxxx xxxxxxx stanovení xxxxx xxxxx (xxxx. xxxxxxxx xxxxxx buněk) (6).
2. ÚDAJE
2.1 XXXXXXXXXX XXXXXXXX
Xxxx xx xxx xxxxxxx údaje pro xxxxxxxxxx xxxxxxxxx x xxxxxxx. Xxxxx by xxxx xxx dále xxxxxxx ve xxxxx xxxxxxx. Xxxxxxxxx xxxxxxx XX od hodnoty XX xx xxx xxx xxxxxxxx pro xxxxxx xxxxx, xxx xxxxx xxxxx x xxx každou dávku x čas čistý xxxxx zrn xxxxxxxxxxxxxx xxxxxxxx jádrům (XXX). Xxxxxxxx xxxx xxxxxxxx "xxxxxxxxxx" xxxxx, xxxx xx xxx xxxxxxxx xxx xxxxxxxxxx "xxxxxxxxxxxx" xxxxx xxxxxxxxxx x xxxxxxxx na dosavadních xxxx xxxxxxxxxx xxxxxxx x xxxxxxxxxxx xxxxxxxxxx. Xxxxxxxxx výsledky mohou xxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxx. Xxxx-xx xxx xxxxxxx, měly xx xxx xxxxxxxxxxx xxxxx xxxxxxx a xxxxxxxxxx xxxx xxxxxxxxxx studie.
2.2 XXXXXXXXX X INTERPRETACE XXXXXXXX
Xxxx příklady xxxxxxxx xxx xxxxxxxxx xxxx xxxxxxxxx xxxxxxx patří:
pozitivní |
i) |
hodnota XXX xxxx xxx xxxxxxxx úrovní, která xx xxxxxxxxxx xx xxxxxxx xxxxxxxxxxx údajů xxxxxxxxxx; |
xxxx |
xx) |
xxxxxxx NNG je xxxxxxxx xxxxx xxx xxxxxxx xxx xxxxxxxxx xxxxxxxx; |
xxxxxxxxx |
x) |
xxxxxxx NNG leží xx xxxxxxxxx xxxxxxx xxxxxxx xxxx pod xx; |
xxxx |
xx) |
xxxxxxx XXX xxxx xxxxxxxx xxxxx xxx xxxxxxx pro xxxxxxxxx xxxxxxxx. |
Xxxx xx být xxxxxxxxx xxxxxxxxxx relevance xxxxx, xx. měly xx xxx xxxxx x úvahu xxxxxxxxx, xxxx xxxx xxxxxxxxxxx xxxxxx, xxxxx xxxxx x xxxxxxxx a xxxxxxxxxxxx. Xxx hodnocení xxxxxxxx zkoušky mohou xxx xxxxxxx jako xxxxxxx xxxxxxxxxx xxxxxxxxxxx xxxxxx. Xxxxxxxxxxx významnost xx xxxx xxxxxx xxx xxxxxxx určujícím xxxxxxxx xxx xxxxxxxxx xxxxxxx.
Xxxxxx xxxxxxx xxxxxxxxxxx xxxxxxxx xxxxx xxxxxxxxx xxxx xxxxxxxxx xxxxxxxx, x ojedinělých xxxxxxxxx xxxxxxxx soubor xxxxx xxxxxxxx konečný výrok x aktivitě xxxxxxxx xxxxx. Xxxxxxxx xxxxx xxxxxx xxxxxxxxxx xxxx xxxxxx bez xxxxxx xx to, kolikrát xx experiment xxxxxxxx.
Xxxxxxxxx xxxxxxxx zkoušky xx XXX x xxxxxxxxx xxxxxxx xxxxx xx xxxx znamenají, xx xxxxxxxx xxxxx indukuje x xxxxxxxxx xxxxxxx xxxxx in xxxx xxxxxxxxx DNA, xxxxx xxx xxxxxxx neplánovanou xxxxxxxx XXX in xxxxx. Negativní xxxxxxxx xxxxxxxxx, že zkoušená xxxxx xx xxxxxxxx xxxxxxx xxxxxxxxxx xxxxxxxxx XXX, xxxxx xxx xxxxxxxxx xxxxx zkouškou.
Měla xx xxx xxxxxxxxxxx xxxxxxxxxxxxxxx, x xxxxx xx zkoušená xxxxx xxxxxxx xx xxxxxxxx xxxxx popř. xx xxxxxx xxxxx (xxxx. xxxxxxxxx xxxxxxxx).
3. XXXXXX
XXXXXXXX X XXXXXXX
Xxxxxxxx x xxxxxxx musí obsahovat xxxx xxxxxxxxx:
Xxxxxxxxxxxx/xxxxxxxxx:
- xxxxxxxxxx xxxxx xxxxxxxx,
- xxxxxxxxxxx x xxxxxxx zkoušené xxxxx x rozpouštědle/vehikulu, xx-xx známa.
Testovací xxxxxxx:
- xxxxxxx druh/kmen,
- xxxxx, xxxxx x xxxxxxx xxxxxx,
- zdroj, podmínky xxxxx, strava xxx.,
- xxxxxxxxxxxx hmotnost xxxxxx xx xxxxxxx zkoušky, xxxxxx xxxxxxx tělesné xxxxxxxxx, střední xxxxxxx x xxxxxxxxxx odchylky xxx každou skupinu.
Zkušební xxxxxxxx:
- pozitivní a xxxxxxxxx (vehikulum/rozpouštědlo) xxxxxxxx,
- xxxxx xx xxxxxx xxx xxxxxxxx rozsahu, xxxxx xxxx xxxxxxxxx,
- xxxxxxxxxx zvolených úrovní xxxxx,
- údaje o xxxxxxxx zkoušené látky,
- xxxxx x xxxxxxxx xxxxxxxx xxxxx,
- xxxxxxxxxx xxxxxxx podávání,
- popřípadě xxxxxx xxxxxxx, zda xx zkoušená xxxxx xxxxxxx xx xxxxxxxx xxxxx xxxx xx xxxxxx tkáně,
- případně xxxxxxxx xxxx koncentrací xxxxxxxx látky x xxxxxx nebo vodě (xxx) xx xxxxxxxxxxxx xxxxx (xx/xx xxxxxxx xxxxxxxxx/xxx),
- xxxxxxxx xxxxx x xxxxxxx xxxxxx x xxxx,
- podrobný xxxxx rozvrhu xxxxxxxx x xxxxxx,
- metody xxxxxxxxx xxxxxxxx,
- xxxxxx xxxxxxxx x xxxxxxxxx xxxxxxxxx xxxxx,
- xxxxxxx xxxxxxxxxxxxxxxxx xxxxxxxx,
- xxxxx xxxxxxxxx x počet xxxxxxxxxxx buněk,
- xxxxxxxx xxxxxxxxx,
- xxxxxxxx xxxxxxxxxxx xxxxxx xx pozitivní, xxxxxxxxx xxxx dvojznačnou.
Výsledky:
- xxxxxxx hodnoty počtu xxx xxxxxxxxxxxxxx xxxxxxxx xxxxxx x počtu xxx odpovídajících cytoplasmě, x xxxxx xxxxx xxx, xxxxxxxxxx pro xxxxxxxxx, xxxxxxx x xxxxxxx,
- xxxxx xxxxxxxx xxxxxxxxx xxxxxxxx xx xxxxx,
- xxxxxxxx statistické xxxxxxxxx,
- xxxxxx xxxxxxxx,
- xxxxx o xxxxxxxx xxxxxxxxx (xxxxxxxxxxxx/xxxxxxxxx) x xxxxxxxxx xxxxxxxx,
- xxxxxxxxx xxxxx x xxxxxxxxx (xxxxxxxxxxxx/xxxxxxxxx) x pozitivní xxxxxxxx x xxxxxxxxx, xxxxxxxxx xxxxxxxxx x xxxxxxxxxxxx odchylkami,
- xxxxx xxxxx "xxxxxxxxxxxx" xxxxx, xx-xx xxxxxxxx,
- xxxxx xxxxx x S-fázi, xx-xx xxxxxxxx,
- xxxxxxxxxxxxxxx xxxxx.
Xxxxxx xxxxxxxx.
Xxxxxx.
4. XXXXXXXXXX
1) Xxxxx, X. Lefevre, X. X., Burlinson, X., Xxxxxx, X. X. (1985), An Xxxxxxxxxx of the Xx xxxx Rat. Xxxxxxxxxx XXX Xxxxxx Xxxxx, Xxxxxxxxxx Xxx., 156, 1-18.
2) Butterworth, X. X., Xxxxx, X., Xxxxxxxx, X., Xxxxxxxx, X., Mirsalis, X., Probst, X., Xxxxxxxx, X. (1987), X Xxxxxxxx and Xxxxx xxx the Xx xxxx Xxx Xxxxxxxxxx DNA Xxxxxx Xxxxx, Mutatation Xxx., 189, 123-133.
3) Xxxxxxxx, X. X., Xxxxxx, X., Ashby, J., Xxxxxxx, X. X., Xxxxxxxxx, X., Benford, X. X., Xxxx, X. W., Xxxxxxxx, X. de G. (1993), Xx xxxx Xxx Liver XXX Xxxxx, in: Xxxxxxxx X. X., Fox X., (eds), Supplementary Xxxxxxxxxxxx Xxxxx: XXXX Xxxxxxxxxxx Procedures. XXXXX Xxxxxxxxxxxx xx Guidelines xxx Xxxxxxxxxxxx Xxxxxxx. Xxxxxx. Xxxx XX xxxxxxx, Cambridge Xxxxxxxxxx Xxxxx, Xxxxxxxxx, Xxx Xxxx, Xxxx Xxxxxxx, Xxxxxxxxx, Xxxxxx, 52-77.
4) Xxxxx, X., Xxxx, X. W., Andrac, X., Xxxxxxxxx. X., Xxxxxxxxx, B., Doolittle, X. X., Xxxxxxxx, X., Hertner, T., XxXxxxx, X. X., Xxxx, X. (1993), Xxxxxxxxxxxxxxx xxx xxx Xxxxxxxxxxx xx UDS Xxxxx In xxxxx xxx In xxxx, Xxxxx. Xxx., 312, 263-285.
5) Xxxxx, X., Xxxxxxx, X., Efstathiou, X., Xxxxxxxxxxxx-Xxxxxx, X. (1993), Assessment of xxx Relation Xxxxxxx xxx Xxxxxxx Xxxxxxxxx xxx the Xxxxxxxxxx xx Xxxxxxx Xxxxxxxx Xxx Xxxxxxxxxxx Xxxx xxx the In xxxx/Xx vitro XXX Xxxxxx Assay (XXX), Xxxxxxxxxx Xxx., 291, 21-27.
6) Xxxxxxxx, X. X., Xxxxx, C. X., Xxxxxxxxxxx, X. X. (1982), Detection xx Xxxxxxxxx Carcinogens xx the Xx xxxx/Xx xxxxx Xxxxxxxxxx XXX Xxxxxx Xxxxx, Xxxxxxx.Xxxxxxx. 4, 553-562."
PŘÍLOHA 5
XXXXXX POŽADAVKY XX XXXXXXXXXXX X XXXXXXXXXX XXXXXXXXXXXX LÁTEK X XXXXXXXXX
Xxx xxxxxxxx Xxxxxx 2001/59/XX, Xx. xxxx. X 332, 28. 12. 2000, x. 81.
XXXXXXX 6
"
XXXXXXX IX
ČÁST X
xxxxxxxx xxxxxxxx xx xxxxxxx xxxxxxxx xxxxx xxxxxxxx xxxxx
Xxxxx xxxxxxxxxx xx. 22 odst. 1 xxxx. e) xxxx směrnice, musí xxx obaly o xxxxxxxxx xxxxxx xxxxxxxxxx xxxxx, x nimiž xx spojeno xxxxxx xxx xxxxxxxxxx (Xn; X 65) x xxxxx xxxx klasifikovány x xxxxxxxx xxxxx xxxx 3.2.3 přílohy XX xxxx směrnice, x xxxxxxxx xxxxx xxxxxxxxx xx trh xx xxxxx xxxxxxxx xxxx v xxxxxxxx xxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxxxx, xxxxxxxx uzávěry xxxxxxxx xxxxx xxxxxxxx xxxxx.
1. Xxxxxxxxx xxxxxxxxxxxx obaly
Uzávěry xxxxxx proti xxxxxxxx xxxxx xxxxxxx xx xxxxxxxxx uzavíratelných obalech xxxx splňovat xxxxxxxxx xxxxx ISO 8317 (xxxxxx xx dne 1. xxxxxxxx 1989) "Xxxxx xxxxxx xxxxx — Požadavky xx xxxxxxxxx xxxxxxxxxxxx xxxxx x metody xxxxxx xxxxxxxx" xxxxxxxx Xxxxxxxxxxx xxxxxxxxxx pro normalizaci (XXX).
2. Opakovaně neuzavíratelné xxxxx
Xxxxxxx odolné xxxxx xxxxxxxx xxxxx použité xx xxxxxxxxx xxxxxxxxxxxxxxxx xxxxxxx xxxx xxxxxxxx xxxxxxxxx xxxxx XXX XX 862 (xxxxxx x xxxxxx 1997) "Xxxxx — Obaly xxxxxx xxxxx — Xxxxxxxxx a xxxxxxxx xxxxxxx pro xxxxxxxxx xxxxxxxxxxxxxx obaly xxxxxx xxx xxxxxxxxxxxxxxx výrobků" xxxxxxxx Xxxxxxxxx xxxxxxx xxx xxxxxxxxxxx (XXX).
3. Xxxxxxxx
1. Prokázání xxxxx x xxxx uvedenými xxxxxxx mohou xxxxxxxxxx xxxxx xxxxxxxxxx, xxxxx xxxxxxx xxxxxxxx xxxxx xxxx EN 45000.
2. Xxxxxxxxxx případy
Je-li zřejmé, xx xxxx xx xxxxxxxxxx xxxxxxxx pro xxxx, xxxxx xx xxxxxxx xxxxxx x xxxxxx bez xxxxxx xxxxxxxx, xxxxxx xxx xxxxxxx provedena.
Ve všech xxxxxxxxx xxxxxxxxx a xxxxx existují xxxxxxxxx xxxxxx k xxxxxxxx x xxxxxxxxxxx uzávěru xxx dítě, xxxx xxxxxxxxxxxx xxxxx požadovat, xxx osoba xxxxxxxxx xx xxxxxxx xxxxxxx xx xxx xxxxxxxxxx xxxxxxxxxx vydaný xxxxxxxxxx xxxxx xxxx. 3 xxxx 1 xxxxxxxxxxxx, xx buď
- xxx xxxxxxx xx takový, xx jej není xxxxxxxx zkoušet xxxxx xxxx xxxxxxxxx norem XXX x XXX,
xxxx
- xx uzávěr xxx xxxxxxx x xxx xxxxxxx xxxxxxxxxxx podle xxxx xxxxxxxxx xxxxx.
XXXX X
Xxxxxxxx xxxxxxxx xx xxxxxxxxxxxx xxxxxxx
Xxxxxxxxx specifikace xxx hmatatelné xxxxxxxx xxxx xxx x xxxxxxx s normou XX XXX 11683 (xxxxxx x roku 1997) "Xxxxx — Xxxxxxxxxx xxxxxxxx xxxx xxxxxxxxxx — Požadavky".
"